CA2567835A1 - Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease - Google Patents
Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease Download PDFInfo
- Publication number
- CA2567835A1 CA2567835A1 CA002567835A CA2567835A CA2567835A1 CA 2567835 A1 CA2567835 A1 CA 2567835A1 CA 002567835 A CA002567835 A CA 002567835A CA 2567835 A CA2567835 A CA 2567835A CA 2567835 A1 CA2567835 A1 CA 2567835A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- group
- hydrogen
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 66
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 33
- 201000010099 disease Diseases 0.000 title claims abstract description 20
- 229940124530 sulfonamide Drugs 0.000 title claims description 25
- 150000003456 sulfonamides Chemical class 0.000 title claims description 11
- 239000003112 inhibitor Substances 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 245
- 238000000034 method Methods 0.000 claims abstract description 91
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 239000000651 prodrug Substances 0.000 claims abstract description 17
- 229940002612 prodrug Drugs 0.000 claims abstract description 17
- 150000002148 esters Chemical class 0.000 claims abstract description 13
- 150000001408 amides Chemical class 0.000 claims abstract description 11
- -1 phosphorothioate diester Chemical class 0.000 claims description 225
- 125000000217 alkyl group Chemical group 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 103
- 239000001257 hydrogen Substances 0.000 claims description 103
- 125000001072 heteroaryl group Chemical group 0.000 claims description 69
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 125000003545 alkoxy group Chemical group 0.000 claims description 47
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 40
- 239000002253 acid Substances 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000004414 alkyl thio group Chemical group 0.000 claims description 33
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 33
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 32
- 125000004468 heterocyclylthio group Chemical group 0.000 claims description 32
- 229910052717 sulfur Inorganic materials 0.000 claims description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 125000002252 acyl group Chemical group 0.000 claims description 28
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 27
- 239000011593 sulfur Substances 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 18
- 125000005110 aryl thio group Chemical group 0.000 claims description 18
- 125000004104 aryloxy group Chemical group 0.000 claims description 18
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 17
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 16
- 125000005354 acylalkyl group Chemical group 0.000 claims description 16
- 125000004423 acyloxy group Chemical group 0.000 claims description 16
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 16
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims description 16
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 16
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 16
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 16
- 125000005121 aminocarbonylalkoxy group Chemical group 0.000 claims description 16
- 125000003435 aroyl group Chemical group 0.000 claims description 16
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 16
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 16
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 16
- 125000005164 aryl thioalkyl group Chemical group 0.000 claims description 16
- 125000001589 carboacyl group Chemical group 0.000 claims description 16
- 230000003197 catalytic effect Effects 0.000 claims description 16
- 125000005159 cyanoalkoxy group Chemical group 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 16
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 16
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 16
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 16
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 16
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 16
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 16
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 16
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 16
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 16
- 125000004442 acylamino group Chemical group 0.000 claims description 15
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 15
- 125000004659 aryl alkyl thio group Chemical group 0.000 claims description 15
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 15
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 14
- 125000005001 aminoaryl group Chemical group 0.000 claims description 14
- 125000001769 aryl amino group Chemical group 0.000 claims description 14
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 14
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 13
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000007970 thio esters Chemical class 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 49
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 20
- 208000035475 disorder Diseases 0.000 abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 12
- 208000020084 Bone disease Diseases 0.000 abstract description 7
- 206010016654 Fibrosis Diseases 0.000 abstract description 5
- 208000007502 anemia Diseases 0.000 abstract description 5
- 230000033115 angiogenesis Effects 0.000 abstract description 5
- 230000004761 fibrosis Effects 0.000 abstract description 5
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 5
- 208000015114 central nervous system disease Diseases 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 230000000451 tissue damage Effects 0.000 abstract description 4
- 231100000827 tissue damage Toxicity 0.000 abstract description 4
- 208000002903 Thalassemia Diseases 0.000 abstract description 3
- 150000001728 carbonyl compounds Chemical class 0.000 abstract description 3
- 230000004968 inflammatory condition Effects 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 52
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
- 238000002360 preparation method Methods 0.000 description 49
- 238000005160 1H NMR spectroscopy Methods 0.000 description 46
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 46
- 210000004027 cell Anatomy 0.000 description 41
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- 101150041968 CDC13 gene Proteins 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 125000005843 halogen group Chemical group 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 125000003367 polycyclic group Chemical group 0.000 description 14
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 150000003573 thiols Chemical class 0.000 description 12
- 108010033040 Histones Proteins 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 230000003915 cell function Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 150000001356 alkyl thiols Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 102000006947 Histones Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical group 0.000 description 4
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- DZPSCKPPDNJMAC-UHFFFAOYSA-N n-(4-acetylphenyl)-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(C(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 DZPSCKPPDNJMAC-UHFFFAOYSA-N 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 3
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- DTIDOUTWNLYXKH-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] furan-2-carbothioate Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CSC(=O)C=2OC=CC=2)C=C1 DTIDOUTWNLYXKH-UHFFFAOYSA-N 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 125000005152 trihalomethanesulfonyl group Chemical group 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 2
- HZFREMCDKZXYSS-UHFFFAOYSA-N 2-chloro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=CC=C1Cl HZFREMCDKZXYSS-UHFFFAOYSA-N 0.000 description 2
- GLEIEZOOQYAMPZ-UHFFFAOYSA-N 3,4-dichloro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 GLEIEZOOQYAMPZ-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- AJTJTGIYKMAXOG-UHFFFAOYSA-N 4-chloro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 AJTJTGIYKMAXOG-UHFFFAOYSA-N 0.000 description 2
- LGKNOYCTWRIFAW-UHFFFAOYSA-N 4-fluoro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CS)C=C1 LGKNOYCTWRIFAW-UHFFFAOYSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 102000007371 Ataxin-3 Human genes 0.000 description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241000080590 Niso Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 238000003287 bathing Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- ALPHPMUHYJTBGK-UHFFFAOYSA-N n-[2-(2-sulfanylacetyl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)CS ALPHPMUHYJTBGK-UHFFFAOYSA-N 0.000 description 2
- ZVZHZPDLGWUZFZ-UHFFFAOYSA-N n-[4-(2-bromoacetyl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CBr)C=C1 ZVZHZPDLGWUZFZ-UHFFFAOYSA-N 0.000 description 2
- SQGCPDKCCZFBTB-UHFFFAOYSA-N n-[4-(2-sulfanylacetyl)phenyl]-3,4-bis(trifluoromethoxy)benzenesulfonamide Chemical compound C1=C(OC(F)(F)F)C(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CS)C=C1 SQGCPDKCCZFBTB-UHFFFAOYSA-N 0.000 description 2
- CPORCCFHIOUPDV-UHFFFAOYSA-N n-[4-(2-sulfanylacetyl)phenyl]-4-(trifluoromethyl)benzenesulfonamide Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CS)C=C1 CPORCCFHIOUPDV-UHFFFAOYSA-N 0.000 description 2
- XJSYPDKYVGQYJN-UHFFFAOYSA-N n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=CC=C1 XJSYPDKYVGQYJN-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- AYVZOGZJPBNUGL-UHFFFAOYSA-N s-[2-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-2-oxoethyl] ethanethioate Chemical compound C1CC2=CC(C(=O)CSC(=O)C)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 AYVZOGZJPBNUGL-UHFFFAOYSA-N 0.000 description 2
- XNFDKPQPBARMAS-UHFFFAOYSA-N s-[2-[1-(benzenesulfonyl)indol-5-yl]-2-oxoethyl] ethanethioate Chemical compound C1=CC2=CC(C(=O)CSC(=O)C)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 XNFDKPQPBARMAS-UHFFFAOYSA-N 0.000 description 2
- ABKTYZYEEOXJRU-UHFFFAOYSA-N s-[2-[2-[(3,4-dichlorophenyl)sulfonylamino]-4-methyl-1,3-thiazol-5-yl]-2-oxoethyl] ethanethioate Chemical compound CC1=C(C(=O)CSC(=O)C)SC(NS(=O)(=O)C=2C=C(Cl)C(Cl)=CC=2)=N1 ABKTYZYEEOXJRU-UHFFFAOYSA-N 0.000 description 2
- DUURQYSOFJYUIO-UHFFFAOYSA-N s-[2-[2-[[3,4-bis(trifluoromethoxy)phenyl]sulfonylamino]-4-methyl-1,3-thiazol-5-yl]-2-oxoethyl] ethanethioate Chemical compound CC1=C(C(=O)CSC(=O)C)SC(NS(=O)(=O)C=2C=C(OC(F)(F)F)C(OC(F)(F)F)=CC=2)=N1 DUURQYSOFJYUIO-UHFFFAOYSA-N 0.000 description 2
- JVJXECCTMVMOOU-UHFFFAOYSA-N s-[2-[2-chloro-4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=C(Cl)C(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 JVJXECCTMVMOOU-UHFFFAOYSA-N 0.000 description 2
- OUDMGLGIFRINIS-UHFFFAOYSA-N s-[2-[2-fluoro-4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=C(F)C(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 OUDMGLGIFRINIS-UHFFFAOYSA-N 0.000 description 2
- WIKSIDLIOVPREK-UHFFFAOYSA-N s-[2-[4-(ethylsulfonylamino)phenyl]-2-oxoethyl] ethanethioate Chemical compound CCS(=O)(=O)NC1=CC=C(C(=O)CSC(C)=O)C=C1 WIKSIDLIOVPREK-UHFFFAOYSA-N 0.000 description 2
- YMZSWWDGISDUHP-UHFFFAOYSA-N s-[2-[4-[(4-methoxyphenyl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CSC(C)=O)C=C1 YMZSWWDGISDUHP-UHFFFAOYSA-N 0.000 description 2
- JLCSWZSZKHXXJU-UHFFFAOYSA-N s-[2-[4-[(4-methylphenyl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(C)C=C1 JLCSWZSZKHXXJU-UHFFFAOYSA-N 0.000 description 2
- XTMZURQRKWPPHT-UHFFFAOYSA-N s-[2-[4-[methyl-[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C=1C=C(OC(F)(F)F)C=CC=1S(=O)(=O)N(C)C1=CC=C(C(=O)CSC(C)=O)C=C1 XTMZURQRKWPPHT-UHFFFAOYSA-N 0.000 description 2
- DDFVLITVOZVAEE-UHFFFAOYSA-N s-[2-[6-[(3-methoxyphenyl)sulfonylamino]pyridin-3-yl]-2-oxoethyl] ethanethioate Chemical compound COC1=CC=CC(S(=O)(=O)NC=2N=CC(=CC=2)C(=O)CSC(C)=O)=C1 DDFVLITVOZVAEE-UHFFFAOYSA-N 0.000 description 2
- BZPLMALSQAHOPF-UHFFFAOYSA-N s-[2-oxo-2-[4-(propan-2-ylsulfonylamino)phenyl]ethyl] ethanethioate Chemical compound CC(C)S(=O)(=O)NC1=CC=C(C(=O)CSC(C)=O)C=C1 BZPLMALSQAHOPF-UHFFFAOYSA-N 0.000 description 2
- XEYFFMBMIXENGF-UHFFFAOYSA-N s-[2-oxo-2-[4-(pyridin-2-ylsulfonylamino)phenyl]ethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=CC=N1 XEYFFMBMIXENGF-UHFFFAOYSA-N 0.000 description 2
- WKLYMDSNAYUMTB-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] benzenecarbothioate Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CSC(=O)C=2C=CC=CC=2)C=C1 WKLYMDSNAYUMTB-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- JNBRDOQHPXUXLY-UHFFFAOYSA-N (2,5-difluorophenyl)hydrazine Chemical compound NNC1=CC(F)=CC=C1F JNBRDOQHPXUXLY-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 0 *C(*)(C(N*N)=O)NO Chemical compound *C(*)(C(N*N)=O)NO 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- GYMZRGMAWRJZPV-UHFFFAOYSA-N 1-(2,3-dihydro-1h-indol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2NCCC2=C1 GYMZRGMAWRJZPV-UHFFFAOYSA-N 0.000 description 1
- OCWKYVHYDKRJST-UHFFFAOYSA-N 1-[1-(benzenesulfonyl)-2,3-dihydroindol-5-yl]-2-bromoethanone Chemical compound C1CC2=CC(C(=O)CBr)=CC=C2N1S(=O)(=O)C1=CC=CC=C1 OCWKYVHYDKRJST-UHFFFAOYSA-N 0.000 description 1
- OPRRCDJJCJBNGD-UHFFFAOYSA-N 1-[4-(diethylamino)phenyl]-2-sulfanylethanone Chemical compound CCN(CC)C1=CC=C(C(=O)CS)C=C1 OPRRCDJJCJBNGD-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- BSHACVGLKPQEEK-UHFFFAOYSA-N 2,4-dichloro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C=C1Cl BSHACVGLKPQEEK-UHFFFAOYSA-N 0.000 description 1
- FDLFHVFMNMQECH-UHFFFAOYSA-N 2-(2-nitrophenoxy)sulfonylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1S(=O)(=O)OC1=CC=CC=C1[N+]([O-])=O FDLFHVFMNMQECH-UHFFFAOYSA-N 0.000 description 1
- WUEHSFSWKSCHCK-UHFFFAOYSA-N 2-(4-ethylpiperazin-1-ium-1-yl)acetate Chemical compound CCN1CCN(CC(O)=O)CC1 WUEHSFSWKSCHCK-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- PRSYVZJLSVZHID-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethanethioic s-acid Chemical compound CC(C)(C)OC(=O)NCC(O)=S PRSYVZJLSVZHID-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- VZWIUEPUGFSPEC-UHFFFAOYSA-N 2-fluoro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound FC1=CC=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CS)C=C1 VZWIUEPUGFSPEC-UHFFFAOYSA-N 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- YRMKGZCBAKCWAF-UHFFFAOYSA-N 2-methoxy-2-phenylbutanoic acid Chemical compound CCC(OC)(C(O)=O)C1=CC=CC=C1 YRMKGZCBAKCWAF-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- BLLOSURJQUCKOK-UHFFFAOYSA-N 3-chloro-n-[4-(2-sulfanylacetyl)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)CS)=CC=C1NS(=O)(=O)C1=CC=CC(Cl)=C1 BLLOSURJQUCKOK-UHFFFAOYSA-N 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 1
- XEVAYBHGIONDGY-UHFFFAOYSA-N 4-(2-bromoacetyl)-n-[4-(trifluoromethoxy)phenyl]benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1NS(=O)(=O)C1=CC=C(C(=O)CBr)C=C1 XEVAYBHGIONDGY-UHFFFAOYSA-N 0.000 description 1
- DTXBFNZDMFXQSN-UHFFFAOYSA-N 4-(dimethylamino)benzenecarbothioic s-acid Chemical compound CN(C)C1=CC=C(C(O)=S)C=C1 DTXBFNZDMFXQSN-UHFFFAOYSA-N 0.000 description 1
- XUJFOSLZQITUOI-UHFFFAOYSA-N 4-(trifluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)(F)F)C=C1 XUJFOSLZQITUOI-UHFFFAOYSA-N 0.000 description 1
- ZKRLRHHSWPBAEO-UHFFFAOYSA-N 4-acetyl-n-[4-(trifluoromethoxy)phenyl]benzenesulfonamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(OC(F)(F)F)C=C1 ZKRLRHHSWPBAEO-UHFFFAOYSA-N 0.000 description 1
- FXVDNCRTKXMSEZ-UHFFFAOYSA-N 4-acetylbenzenesulfonyl chloride Chemical compound CC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 FXVDNCRTKXMSEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000020853 Inedia Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000036831 Moderate mental retardation Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 1
- SGXDXUYKISDCAZ-UHFFFAOYSA-N N,N-diethylglycine Chemical compound CCN(CC)CC(O)=O SGXDXUYKISDCAZ-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 125000005631 S-sulfonamido group Chemical group 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ZHUOWEBVIBXORG-UHFFFAOYSA-N [2-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl]sulfanylcarbonylphenyl] acetate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)SCC(=O)C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 ZHUOWEBVIBXORG-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000004339 autoimmune neuropathy Diseases 0.000 description 1
- 208000006424 autoimmune oophoritis Diseases 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- HDFRDWFLWVCOGP-UHFFFAOYSA-N carbonothioic O,S-acid Chemical compound OC(S)=O HDFRDWFLWVCOGP-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006195 histone acetylation Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001261 isocyanato group Chemical group *N=C=O 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- CVAOBPOFXDPIBX-UHFFFAOYSA-N n-[3-(2-sulfanylacetyl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=CC(C(=O)CS)=C1 CVAOBPOFXDPIBX-UHFFFAOYSA-N 0.000 description 1
- FLODEGQEWIPAAM-UHFFFAOYSA-N n-[4-(2-sulfanylacetyl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CS)C=C1 FLODEGQEWIPAAM-UHFFFAOYSA-N 0.000 description 1
- WHJDACVZYNGIFE-UHFFFAOYSA-N n-[4-[2-(1-methylpyridin-1-ium-2-yl)sulfanylacetyl]phenyl]-4-(trifluoromethoxy)benzenesulfonamide;bromide Chemical compound [Br-].C[N+]1=CC=CC=C1SCC(=O)C(C=C1)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 WHJDACVZYNGIFE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- WOLHAJCCVHQNGD-UHFFFAOYSA-N o-[2-[4-[(3,5-dimethylphenyl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(C(=O)COC(=S)C)=CC=C1NS(=O)(=O)C1=CC(C)=CC(C)=C1 WOLHAJCCVHQNGD-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000004717 pyruvic acids Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- FRWGQFATKAWTPV-UHFFFAOYSA-N s-[2-[3-fluoro-4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound FC1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 FRWGQFATKAWTPV-UHFFFAOYSA-N 0.000 description 1
- YEEIAJYMZMWZQX-UHFFFAOYSA-N s-[2-[4-[(1,2-dimethylimidazol-4-yl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CN(C)C(C)=N1 YEEIAJYMZMWZQX-UHFFFAOYSA-N 0.000 description 1
- BXNCCGKZGQVQOM-UHFFFAOYSA-N s-[2-[4-[(3-methoxyphenyl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound COC1=CC=CC(S(=O)(=O)NC=2C=CC(=CC=2)C(=O)CSC(C)=O)=C1 BXNCCGKZGQVQOM-UHFFFAOYSA-N 0.000 description 1
- WZHYEONTFAXPMR-UHFFFAOYSA-N s-[2-[4-[(4-fluoro-2-methylphenyl)sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(F)C=C1C WZHYEONTFAXPMR-UHFFFAOYSA-N 0.000 description 1
- HPCQHGFCIDVOKJ-UHFFFAOYSA-N s-[2-[4-[[4-chloro-3-(trifluoromethyl)phenyl]sulfonylamino]phenyl]-2-oxoethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 HPCQHGFCIDVOKJ-UHFFFAOYSA-N 0.000 description 1
- FBLGAYMSDHFHFP-UHFFFAOYSA-N s-[2-oxo-2-(1-pyridin-2-ylsulfonyl-2,3-dihydroindol-5-yl)ethyl] ethanethioate Chemical compound C1CC2=CC(C(=O)CSC(=O)C)=CC=C2N1S(=O)(=O)C1=CC=CC=N1 FBLGAYMSDHFHFP-UHFFFAOYSA-N 0.000 description 1
- HUAPZKKSJHWVSW-UHFFFAOYSA-N s-[2-oxo-2-[4-(pyridin-3-ylsulfonylamino)phenyl]ethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=CN=C1 HUAPZKKSJHWVSW-UHFFFAOYSA-N 0.000 description 1
- FMFZKQQSFJLLRT-UHFFFAOYSA-N s-[2-oxo-2-[4-[[3-(trifluoromethyl)phenyl]sulfonylamino]phenyl]ethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1NS(=O)(=O)C1=CC=CC(C(F)(F)F)=C1 FMFZKQQSFJLLRT-UHFFFAOYSA-N 0.000 description 1
- BKMWKPSIAMDBIH-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfamoyl]phenyl]ethyl] ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C(OC(F)(F)F)C=C1 BKMWKPSIAMDBIH-UHFFFAOYSA-N 0.000 description 1
- HOQOMYSTOIZKPV-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethanethioate Chemical compound C1=CC(C(=O)CSC(=O)CNC(=O)OC(C)(C)C)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 HOQOMYSTOIZKPV-UHFFFAOYSA-N 0.000 description 1
- SVFIVIIDLRLLCB-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] pentanethioate Chemical compound C1=CC(C(=O)CSC(=O)CCCC)=CC=C1NS(=O)(=O)C1=CC=C(OC(F)(F)F)C=C1 SVFIVIIDLRLLCB-UHFFFAOYSA-N 0.000 description 1
- MURKQYIWEVFLGY-UHFFFAOYSA-N s-[2-oxo-2-[4-[[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] pyridine-2-carbothioate Chemical compound C1=CC(OC(F)(F)F)=CC=C1S(=O)(=O)NC1=CC=C(C(=O)CSC(=O)C=2N=CC=CC=2)C=C1 MURKQYIWEVFLGY-UHFFFAOYSA-N 0.000 description 1
- AXRFZJREUUFPQH-UHFFFAOYSA-N s-[2-oxo-2-[4-[propan-2-yl-[4-(trifluoromethoxy)phenyl]sulfonylamino]phenyl]ethyl] ethanethioate Chemical compound C=1C=C(OC(F)(F)F)C=CC=1S(=O)(=O)N(C(C)C)C1=CC=C(C(=O)CSC(C)=O)C=C1 AXRFZJREUUFPQH-UHFFFAOYSA-N 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- CYFJIBWZIQDUSZ-UHFFFAOYSA-N thioglycine Chemical compound NCC(S)=O CYFJIBWZIQDUSZ-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- PRXNKYBFWAWBNZ-UHFFFAOYSA-N trimethylphenylammonium tribromide Chemical compound Br[Br-]Br.C[N+](C)(C)C1=CC=CC=C1 PRXNKYBFWAWBNZ-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
- C07C329/02—Monothiocarbonic acids; Derivatives thereof
- C07C329/04—Esters of monothiocarbonic acids
- C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
- C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1653—Esters of thiophosphoric acids with arylalkanols
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Disclosed herein are carbonyl compounds of having the structural formula (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
Description
NOVEL SULFONAMIDES AS INHIBITORS OF HISTONE DEACETYLASE FOR
THE TREATMENT OF DISEASE
RELATED DOCUMENTS
The present application claims priority to the following applications: U.S.
Patent Application No.: 60/635,019 filed December 9, 2004; U.S. Patent Application No.:
10/865,743 filed June 10, 2004 and PCT/US2004/018502 filed June 10, 2004 which are incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0001] The present invention is directed to carbonyl compounds as inhibitors of histone deacetylase (HDAC). These compounds are useful in treating disease states including cancers, autoiininune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis plays a role in pathogenesis.
BACKGROUND OF THE INVENTION
THE TREATMENT OF DISEASE
RELATED DOCUMENTS
The present application claims priority to the following applications: U.S.
Patent Application No.: 60/635,019 filed December 9, 2004; U.S. Patent Application No.:
10/865,743 filed June 10, 2004 and PCT/US2004/018502 filed June 10, 2004 which are incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0001] The present invention is directed to carbonyl compounds as inhibitors of histone deacetylase (HDAC). These compounds are useful in treating disease states including cancers, autoiininune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis plays a role in pathogenesis.
BACKGROUND OF THE INVENTION
[0002] Histone proteins organize DNA into nucleosomes, which are regular repeating structures of chromatin. The acetylation status of histones alters chromatin structure, which, in turn, is involved in gene expression. Two classes of enzymes can affect the acetylation of histones - histone acetyltransferases (HATs) and histone deacetylases (HDACs). A number of HDAC inlzibitors have been characterized. However, to date no effective candidate for cancer therapy has been identified. Therefore, there is a need in the art to discover HDAC inhibitors that have effective anti-tumor activity.
SUMMARY OF THE INVENTION
[00031 Disclosed herein are carbonyl compounds having structural formula (I) or related formulate as described herein:
__~G4 G3-G2-G s Rl R2 (I) related fonnulae as described herein, including their pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein GI is an optionally substituted phenyl or optionally substituted or 6 meinbered heteroaryl, G2 is an N-sulfonainide moiety having structure (II) or an S-sulfonamide moiety having structure (III);
\ j S
N
K3 (II) R4 (III);
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, wherein Rl and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen. and perhaloalkyl, or R1 and R2 taken together fonn optionally substituted cycloalkyl, wherein R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl; or a structural element known to confer aqueous solubility, e.g. N-piperazinylethyl, N-morpholinylethyl, 1,3-dihydroxy-2N -propanoyl etc., G4 is chosen from the group consisting of optionally substituted acyl, wherein G4 taken in combination with sulfur forms a thioester, optionally substituted thiol, wherein G4 taken in combination wit11 sulfur forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in cornbination with sulfur, forms a phosphorothioate diester or phosphorothioate; and eacll R5 is independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl.
[0004] The invention provides phannaceutical coinpositions comprising a compound having structural formula (I) or a related formula, which are capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
[0005] The invention also provides methods and compositinos for treating diseases in mainmals using coinpounds of the invention, including but not limited to, treating cancers, autoimmune diseases, tissue dainage, central nervous systein disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalasseinias, inflainmatory conditions, cardiovascular conditions, and disorders in which angiogenesis plays a role in pathogenesis.
[0006] The invention further provides imthods of inhibiting the catalytic activity and cellular function of histone deacetylase (HDAC).
SUMMARY OF THE INVENTION
[00031 Disclosed herein are carbonyl compounds having structural formula (I) or related formulate as described herein:
__~G4 G3-G2-G s Rl R2 (I) related fonnulae as described herein, including their pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein GI is an optionally substituted phenyl or optionally substituted or 6 meinbered heteroaryl, G2 is an N-sulfonainide moiety having structure (II) or an S-sulfonamide moiety having structure (III);
\ j S
N
K3 (II) R4 (III);
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, wherein Rl and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen. and perhaloalkyl, or R1 and R2 taken together fonn optionally substituted cycloalkyl, wherein R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl; or a structural element known to confer aqueous solubility, e.g. N-piperazinylethyl, N-morpholinylethyl, 1,3-dihydroxy-2N -propanoyl etc., G4 is chosen from the group consisting of optionally substituted acyl, wherein G4 taken in combination with sulfur forms a thioester, optionally substituted thiol, wherein G4 taken in combination wit11 sulfur forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in cornbination with sulfur, forms a phosphorothioate diester or phosphorothioate; and eacll R5 is independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl.
[0004] The invention provides phannaceutical coinpositions comprising a compound having structural formula (I) or a related formula, which are capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
[0005] The invention also provides methods and compositinos for treating diseases in mainmals using coinpounds of the invention, including but not limited to, treating cancers, autoimmune diseases, tissue dainage, central nervous systein disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalasseinias, inflainmatory conditions, cardiovascular conditions, and disorders in which angiogenesis plays a role in pathogenesis.
[0006] The invention further provides imthods of inhibiting the catalytic activity and cellular function of histone deacetylase (HDAC).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Definition of Terms [0007] The term "pharmaceutically acceptable salt" refers to a fonnulation of a compound that does not cause significant irritation to an organisin to which it is administered and does not abrogate the biological activity and properties of the compound.
Pharmaceutical salts can be obtained by reacting a coinpound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
[0008] The terms "physiologically acceptable" and "physiologically compatible"
refers to excipients, products, or hydrolysis products of disclosed molecular embodiments of the invention. By way of example, protected thiol prodrug embodiments may release acids upoii hydrolysis of the protected thiol. Physiologically acceptable excipients and acids are those that do not abrogate the biological activity or properties of the compound, and are nontoxic. "Physiologically acceptable" and "pharmaceutically acceptable" may be coextensive terms.
[0009] The tenn "ester" refers to a chemical moiety with formula -(R)õCOOR', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1. Any amine, hydroxy, or carboxyl side chain on the compounds of the present invention can be esterified. The procedures and specific groups to be used to achieve makes such esters are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3'd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
[0010] An "amide" is a chemical moiety with formula -(R)õC(O)NHR' or -(R),1 NHC(O)R', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded througll a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1. An amide may be an ainino acid or a peptide molecule attached to a molecule of the present invention, thereby forming a prodrug.
[0011] Any amine, hydroxy, or carboxyl side chain on the coinpounds of the present invention can be esterified or anlidified. The procedures and specific groups to be used to achieve this end is known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
[0012] A "prodrug" refers to an ageint that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility over the parent drug. An example, without limitation, of a prodrug would be a coinpound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. Yet another example of a prodrug are protected thiol compounds.
Thiols bearing hydrolyzable protecting groups can unmask protected SH groups prior to or siinultaneous to use. As shown below, the moiety -C(O)-RE of a thioester may be hydrolyzed to yield a thiol and a pharmaceutically acceptable acid HO-C(O)-RE.
O O
---- SH HO"'~RE
~S,,-I~ RE + H20 )0 [0013] The term "thiol protecting group" refers to thiols bearing hydrolyzable protecting groups that can unrnask protected SH groups prior to or simultaneous to use.
Preferred thiol protecting groups include but are not limited to thiol esters which release pharmaceutically acceptable acids along with an active thiol moiety. Such phaimaceutically acceptable acids are generally nontoxic and do not abbrogate the biological activity of the active thiol moiety. Exainples of pharmaceutically acceptable acids include, but are not limited to: N,N-diethylglycine; 4-ethylpiperazino acetic acid; ethyl 2-methoxy-2-phenylacetic acid; N,N-dimethylglycine; (nitrophenoxysulfonyl)benzoic acid; acetic acid;
maleic acid;
fumaric acid; benzoic acid; tartraric acid; natural amino acids (like glutamate, aspartate, cyclic ainino acids such proline); D-amino acids; butyric acid; fatty acids like palmitic acid, stearic acid, oleate; pipecolic acid; phosphonic acid; phosphoric acid;
pivalate (trimethylacetic acid); succinic acid; cinnamic acid; anthranilic acid;
salicylic acid; lactic acid; and pyruvic acids.
[0014] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon group.
The alkyl moiety may be a "saturated alkyl" group, which means that it does not contain any alkene or alkyne moieties. The alkyl moiety may also be an "unsaturated alkyl"
moiety, which means that it contains at least one alkene or alkyne moiety. An "alkene"
moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an "alkyne" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.
[0015] The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range sucll as "1 to 20" refers to each integer in the given range; e.g., "1 to 20 carbon atoms" means that the alkyl group may consist of I carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no nuinerical range is designated). The alkyl group may also be a mediuin size alkyl having 1 to 10 carbon atoms.
The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds of the invention may be designated as "C1-CS alkyl" or similar designations.
By way of exalnple only, "C1-C4 alkyl" indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
[0016] The alkyl group may be substituted or unsubstituted. When substituted, any group(s) besides hydrogen can be the substitutent group(s). When substituted, the substituent group(s) is(are) one or more group(s) individually and independently selected from the following non-limiting illustrative list: alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxy, alkoxy, aryloxy, 0, S, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, 0-carbamyl, N-carbamyl, 0-thiocarbamyl, N-thiocarbamyl, C-ainido, N-ainido, S-sulfonainido, N-sulfonainido, C-carboxy, 0-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and ainino, including mono- and di-substituted amino groups, and the protected derivatives thereof. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Each substituent group may be further substituted.
[0017] Unless otlierwise indicated, when a group is described as "optionally substituted," it is meant that the group may be substituted with one or more substituents selected from the following non-limiting illustrative list: hydroxy, alkyl, alkoxy, aryloxy, cycloalkyl, aryl, carbocyclic cycloalkyl, carbocyclic aryl, heteroaryl, heterocycloalkyl, 0, S, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, 0-carbamyl, N-carbamyl, 0-thiocarbamyl, N-thiocarbainyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, 0-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and di-substituted amino groups, and protected derivatives thereof. Protecting groups that may form the protective derivatives of the substituents recited above are known to those of skill in the art and may be found in references such as Greene and Wuts, above. Each optional substituent may be further optionally substituted. Optionally substituted groups may be unsubstituted.
[0018] The term "halo" or, alternatively, "halogen" means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo. The terms "haloalkyl,"
"haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures, that are substituted with one or more halo groups or with combinations thereof.
The terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
[0019] The terin "hetero" in such terms as "heteroalkyl," "heteroalkenyl,"
"heteroalkynyl," "heterocycloalkyl," and "heteroaryl" refers to groups in which one or more of the backbone atoms is selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
[0020] Cyclic alkyl moeities contain one or more covalently closed ring structures. Cyclic alkyl moeities can have a single ring (inonocyclic) or two or more rings (polycyclic or multicyclic). Polycyclic groups include fused polycyclic groups wherein rings share adjacent pairs of backbone atoms, and linked cyclic groups wherein the rings are separate but linked. In fused polycyclic groups, rings may share adjacent carbon atoms, or may share non-carbon atoms such as N. Linked polycyclic groups may be coiuiected by a bond or a linker. Polycyclic groups can be linked by an optionally substituted alkyl moeity including but not limited to saturated alkyl linkers, or unsaturated alkyl linlcers such as alkylene (e.g., methylene, ethylene, or propylene) or alkynylene linlcers.
Definition of Terms [0007] The term "pharmaceutically acceptable salt" refers to a fonnulation of a compound that does not cause significant irritation to an organisin to which it is administered and does not abrogate the biological activity and properties of the compound.
Pharmaceutical salts can be obtained by reacting a coinpound of the invention with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
Pharmaceutical salts can also be obtained by reacting a compound of the invention with a base to form a salt such as an ammonium salt, an alkali metal salt, such as a sodium or a potassium salt, an alkaline earth metal salt, such as a calcium or a magnesium salt, a salt of organic bases such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and salts with amino acids such as arginine, lysine, and the like.
[0008] The terms "physiologically acceptable" and "physiologically compatible"
refers to excipients, products, or hydrolysis products of disclosed molecular embodiments of the invention. By way of example, protected thiol prodrug embodiments may release acids upoii hydrolysis of the protected thiol. Physiologically acceptable excipients and acids are those that do not abrogate the biological activity or properties of the compound, and are nontoxic. "Physiologically acceptable" and "pharmaceutically acceptable" may be coextensive terms.
[0009] The tenn "ester" refers to a chemical moiety with formula -(R)õCOOR', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1. Any amine, hydroxy, or carboxyl side chain on the compounds of the present invention can be esterified. The procedures and specific groups to be used to achieve makes such esters are known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3'd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
[0010] An "amide" is a chemical moiety with formula -(R)õC(O)NHR' or -(R),1 NHC(O)R', where R and R' are independently selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl (bonded througll a ring carbon) and heteroalicyclic (bonded through a ring carbon), and where n is 0 or 1. An amide may be an ainino acid or a peptide molecule attached to a molecule of the present invention, thereby forming a prodrug.
[0011] Any amine, hydroxy, or carboxyl side chain on the coinpounds of the present invention can be esterified or anlidified. The procedures and specific groups to be used to achieve this end is known to those of skill in the art and can readily be found in reference sources such as Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein in its entirety.
[0012] A "prodrug" refers to an ageint that is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, for instance, be bioavailable by oral administration whereas the parent is not. The prodrug may also have improved solubility over the parent drug. An example, without limitation, of a prodrug would be a coinpound of the present invention which is administered as an ester (the "prodrug") to facilitate transmittal across a cell membrane where water solubility is detrimental to mobility but which then is metabolically hydrolyzed to the carboxylic acid, the active entity, once inside the cell where water-solubility is beneficial. A further example of a prodrug might be a short peptide (polyaminoacid) bonded to an acid group where the peptide is metabolized to reveal the active moiety. Yet another example of a prodrug are protected thiol compounds.
Thiols bearing hydrolyzable protecting groups can unmask protected SH groups prior to or siinultaneous to use. As shown below, the moiety -C(O)-RE of a thioester may be hydrolyzed to yield a thiol and a pharmaceutically acceptable acid HO-C(O)-RE.
O O
---- SH HO"'~RE
~S,,-I~ RE + H20 )0 [0013] The term "thiol protecting group" refers to thiols bearing hydrolyzable protecting groups that can unrnask protected SH groups prior to or simultaneous to use.
Preferred thiol protecting groups include but are not limited to thiol esters which release pharmaceutically acceptable acids along with an active thiol moiety. Such phaimaceutically acceptable acids are generally nontoxic and do not abbrogate the biological activity of the active thiol moiety. Exainples of pharmaceutically acceptable acids include, but are not limited to: N,N-diethylglycine; 4-ethylpiperazino acetic acid; ethyl 2-methoxy-2-phenylacetic acid; N,N-dimethylglycine; (nitrophenoxysulfonyl)benzoic acid; acetic acid;
maleic acid;
fumaric acid; benzoic acid; tartraric acid; natural amino acids (like glutamate, aspartate, cyclic ainino acids such proline); D-amino acids; butyric acid; fatty acids like palmitic acid, stearic acid, oleate; pipecolic acid; phosphonic acid; phosphoric acid;
pivalate (trimethylacetic acid); succinic acid; cinnamic acid; anthranilic acid;
salicylic acid; lactic acid; and pyruvic acids.
[0014] As used herein, the term "alkyl" refers to an aliphatic hydrocarbon group.
The alkyl moiety may be a "saturated alkyl" group, which means that it does not contain any alkene or alkyne moieties. The alkyl moiety may also be an "unsaturated alkyl"
moiety, which means that it contains at least one alkene or alkyne moiety. An "alkene"
moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon double bond, and an "alkyne" moiety refers to a group consisting of at least two carbon atoms and at least one carbon-carbon triple bond. The alkyl moiety, whether saturated or unsaturated, may be branched, straight chain, or cyclic.
[0015] The alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range sucll as "1 to 20" refers to each integer in the given range; e.g., "1 to 20 carbon atoms" means that the alkyl group may consist of I carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl" where no nuinerical range is designated). The alkyl group may also be a mediuin size alkyl having 1 to 10 carbon atoms.
The alkyl group could also be a lower alkyl having 1 to 4 carbon atoms. The alkyl group of the compounds of the invention may be designated as "C1-CS alkyl" or similar designations.
By way of exalnple only, "C1-C4 alkyl" indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
[0016] The alkyl group may be substituted or unsubstituted. When substituted, any group(s) besides hydrogen can be the substitutent group(s). When substituted, the substituent group(s) is(are) one or more group(s) individually and independently selected from the following non-limiting illustrative list: alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, hydroxy, alkoxy, aryloxy, 0, S, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, 0-carbamyl, N-carbamyl, 0-thiocarbamyl, N-thiocarbamyl, C-ainido, N-ainido, S-sulfonainido, N-sulfonainido, C-carboxy, 0-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and ainino, including mono- and di-substituted amino groups, and the protected derivatives thereof. Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. Each substituent group may be further substituted.
[0017] Unless otlierwise indicated, when a group is described as "optionally substituted," it is meant that the group may be substituted with one or more substituents selected from the following non-limiting illustrative list: hydroxy, alkyl, alkoxy, aryloxy, cycloalkyl, aryl, carbocyclic cycloalkyl, carbocyclic aryl, heteroaryl, heterocycloalkyl, 0, S, mercapto, alkylthio, arylthio, cyano, halo, carbonyl, thiocarbonyl, 0-carbamyl, N-carbamyl, 0-thiocarbamyl, N-thiocarbainyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido, C-carboxy, 0-carboxy, isocyanato, thiocyanato, isothiocyanato, nitro, silyl, trihalomethanesulfonyl, and amino, including mono- and di-substituted amino groups, and protected derivatives thereof. Protecting groups that may form the protective derivatives of the substituents recited above are known to those of skill in the art and may be found in references such as Greene and Wuts, above. Each optional substituent may be further optionally substituted. Optionally substituted groups may be unsubstituted.
[0018] The term "halo" or, alternatively, "halogen" means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo. The terms "haloalkyl,"
"haloalkenyl," "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy structures, that are substituted with one or more halo groups or with combinations thereof.
The terms "fluoroalkyl" and "fluoroalkoxy" include haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
[0019] The terin "hetero" in such terms as "heteroalkyl," "heteroalkenyl,"
"heteroalkynyl," "heterocycloalkyl," and "heteroaryl" refers to groups in which one or more of the backbone atoms is selected from an atom other than carbon, e.g., oxygen, nitrogen, sulfur, phosphorus or combinations thereof.
[0020] Cyclic alkyl moeities contain one or more covalently closed ring structures. Cyclic alkyl moeities can have a single ring (inonocyclic) or two or more rings (polycyclic or multicyclic). Polycyclic groups include fused polycyclic groups wherein rings share adjacent pairs of backbone atoms, and linked cyclic groups wherein the rings are separate but linked. In fused polycyclic groups, rings may share adjacent carbon atoms, or may share non-carbon atoms such as N. Linked polycyclic groups may be coiuiected by a bond or a linker. Polycyclic groups can be linked by an optionally substituted alkyl moeity including but not limited to saturated alkyl linkers, or unsaturated alkyl linlcers such as alkylene (e.g., methylene, ethylene, or propylene) or alkynylene linlcers.
[0021] The term "carbocyclic" refers to a compound which contains one or more covalently closed ring structures, wherein the atoms fonning the backbone of the ring are all carbon atoms.
[0022] The tenn "heterocyclic" refers to a compound with contains one or more covalently closed ring structures, wherein at least one ring backbone contains at least one atom which is different from carbon. Generally, heterocyclic groups can contain one to four heteroatoms, each selected from 0, S and N, wherein each ring has from 4 to 10 atoms in the ring. Geiierally, heterocyclic rings do not contain two adjacent 0 or S atoms.
An exalnple of a 4-membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5-membered heterocyclic group is thiazolyl. An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10-membered heterocyclic group is quinolinyl.
[0023] The term "cycloalkyl" refers to an aliphatic cyclic alkyl moeity wherein the ring is either completely saturated, partially unsaturated, or fully unsaturated, wherein if there is unsaturation, the conjugation of the pi-electrons in the ring do not give rise to aromaticity. The term "cycloalkyl" may refer to a monocyclic or polycyclic group.
Cycloalkyl groups may be fused or linked to other cyclic alkyl moeities. A
cycloalkyl group may be optionally substituted. Preferred cycloalkyl groups include groups having from tliree to twelve ring atoms, more preferably from 5 to 10 ring atoms. The term "carbocyclic cycloalkyl" refers to a monocyclic or polycyclic cycloalkyl group which contains only carbon and hydrogen. The term "heterocycloalkyl" refers to ainonocyclic or polycyclic cycloalkyl group wherein at least one ring backbone contains at least one atom which is different from carbon. Illustrative examples of carbocyclic cycloalkyl groups include the following moieties:
A-, E>, >EO, 0, 0, (> o'c,,o co, and the like.
[0024] A heterocycloalkyl group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur. Heterocycloalkyl groups may be fused with one or more aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
Heterocycloalkyl groups may be linked with one or more aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Examples of heterocycloalkyl (non-aromatic heterocyclic groups) are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, iinidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl.
Illustrative examples of heterocycloalkyl groups include:
~~5~ N
Cs, NN N O O O
0' CN N O O S N
O
~ N-N
o N I0 ( N/\O
ON N c N
H
O
N-S=O CT
N N N N a O
, N .~' O
[0022] The tenn "heterocyclic" refers to a compound with contains one or more covalently closed ring structures, wherein at least one ring backbone contains at least one atom which is different from carbon. Generally, heterocyclic groups can contain one to four heteroatoms, each selected from 0, S and N, wherein each ring has from 4 to 10 atoms in the ring. Geiierally, heterocyclic rings do not contain two adjacent 0 or S atoms.
An exalnple of a 4-membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5-membered heterocyclic group is thiazolyl. An example of a 6-membered heterocyclic group is pyridyl, and an example of a 10-membered heterocyclic group is quinolinyl.
[0023] The term "cycloalkyl" refers to an aliphatic cyclic alkyl moeity wherein the ring is either completely saturated, partially unsaturated, or fully unsaturated, wherein if there is unsaturation, the conjugation of the pi-electrons in the ring do not give rise to aromaticity. The term "cycloalkyl" may refer to a monocyclic or polycyclic group.
Cycloalkyl groups may be fused or linked to other cyclic alkyl moeities. A
cycloalkyl group may be optionally substituted. Preferred cycloalkyl groups include groups having from tliree to twelve ring atoms, more preferably from 5 to 10 ring atoms. The term "carbocyclic cycloalkyl" refers to a monocyclic or polycyclic cycloalkyl group which contains only carbon and hydrogen. The term "heterocycloalkyl" refers to ainonocyclic or polycyclic cycloalkyl group wherein at least one ring backbone contains at least one atom which is different from carbon. Illustrative examples of carbocyclic cycloalkyl groups include the following moieties:
A-, E>, >EO, 0, 0, (> o'c,,o co, and the like.
[0024] A heterocycloalkyl group refers to a cycloalkyl group that includes at least one heteroatom selected from nitrogen, oxygen and sulfur. Heterocycloalkyl groups may be fused with one or more aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
Heterocycloalkyl groups may be linked with one or more aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Examples of heterocycloalkyl (non-aromatic heterocyclic groups) are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, iinidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl.
Illustrative examples of heterocycloalkyl groups include:
~~5~ N
Cs, NN N O O O
0' CN N O O S N
O
~ N-N
o N I0 ( N/\O
ON N c N
H
O
N-S=O CT
N N N N a O
, N .~' O
N N N N
~~~ N
N N and the like.
[0025] The terms "aryl" or "aromatic" refer to a group which has at least one ring having a conjugated pi electron system, Aryl groups can be carbocylic aryl groups or heteroaryl groups. The term "carbocyclic aryl" refers to a group (e.g., phenyl) in which all ring backbone atoms are carbon. The terms "heteroaryl" or "heteroaromatic"
refer to an aryl (aromatic) group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. Aryl groups may be optionally substituted. Aryl groups may be monocyclic or polycyclic. Polycyclic aryl groups may be fused or linked. Polycyclic aryl groups can be fused or linked to aryl groups or cycloalkyl groups.
[0026] Examples of heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.
Polycyclic heteroaryl groups may be attached througll carbon ring backbone atoms, or may be attached througll ring backbone heteroatoms, especially N, depending on structure of the group. For instance, a group derived from pyrrole may be pyrrol-l-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be iinidazol-l-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). Polycyclic heteroaryl groups include benzo-fused ring systeins and ring systems substituted with one or two oxo (=0) moieties such as pyrrolidin-2-one.
[0027] Illustrative examples of heteroaryl groups include the following moieties:
N S N
>, OO( ~N// N
N CN CN
N\ / ~N N) N ~I~ N /N
N~ N
N ~,i S
a:), N' N' and the like.
[0028] The substituent "R" appea.ring by itself and without a number designation refers to a substituent selected from the group consisting of optionally substituted alkyl, including optionally substituted alkenyl or alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl (bonded through a ring carbon) and optionally substituted hetercycloalkyl (bonded through a ring carbon).
[0029] An "O-carboxy" group refers to a RC(=O)O- group, where R is as defined herein.
[0030] A "C-carboxy" group refers to a -C(=O)OR groups where R is as defined herein.
[0031] An "acyl" group refers to a -C(=O)R group.
[0032] An "acetyl" group refers to a-C(=O)CH3, group.
[0033] A"trihalomethanesulfonyl" group refers to a X3CS(=O)2- group where X
is a halogen.
[0034] A "cyano" group refers to a -CN group.
[0035] An "isocyanato" group refers to a -NCO group.
[0036] A "thiocyanato" group refers to a -CNS group.
[0037] An "isothiocyanato" group refers to a -NCS group.
[0038] A "sulfinyl" group refers to a-S(=O)-R group, with R as defined herein.
[0039] A"S-sulfonainido" group refers to a-S(=O)2NR, group, with R as defined herein.
[0040] A "N-sulfonamido" group refers to a RS(=O)2NH- group with R as defined herein.
[0041] A"trihaloinethanesulfonamido" group refers to a X3CS(=0)2NR- group with X and R as defined herein.
[0042] An "O-carbamyl" group refers to a -OC(=O)-NR, group-with R as defined herein.
[0043] An "N-carbamyl" group refers to a ROC(=O)NH- group, with R as defined herein.
[0044] An "O-thiocarbamyl" group refers to a -OC(=S)-NR, group with R as defined herein.
[0045] An "N-thiocarbamyl" group refers to an ROC(-S)NH- group, with R as defined herein.
[0046] A "C-amido" group refers to a -C(=O)-NR2 group with R as defined herein.
[0047] An "N-amido" group refers to a RC(=O)NH- group, with R as defined herein.
[0048] The term partially halogenated alkyl refers to an alkyl group having both hydrogen and halogen substituents, [0049] The term "perhaloalkyl" refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
[0050] The term "lower perfluoroalkoxy" refers to a radical -O-(CX2),iCX3 where X is any halogen, preferable F or Cl, and n is 1-5.
[0051] When two substituents taken together along with the two ring carbons to wl7ich they are attached form a ring, it is meant that the following structure:
is, for example, representative of a structure such as the following:
~
[0052] In the above exatnple, Rl and R2, taken together along with the two ring carbons to which they are attached, form a six-membered aroinatic ring.
Solubility is a thermodynamic parameter and plays an important role in the determination of a drug's bioavailability. Since a drug inust be soluble in the gastrointestinal fluid to be orally active, the rate and extent of dissolution depend critically upon intrinsic water solubility (neutral species solubility) ( Dressman, J.; Amindo, G. L.,;
Reppas, C.; Shah.
V. P. Pharm. Res., 1998, 15, 11.) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting have been described (Lipinski C. A. et al. 1997 Adv. Drug Deliv. Rev. 23, 3-25)Adv. Drug Deliv.
Rev. 23, 3-25 ).
Traditional analytical methods define solubility as the concentration of material in solution at equilibrium with its solid fonn. In this method a compound is extensively shaken in the buffer of choice, filtered through a micropore membrane, and the concentration of dissolved compound in the filtrate determined. This approach results in a thermodynamic solubility assessment. For discovery, it is beneficial to measure kinetic solubility in which a compound DMSO solution is added to aqueous buffer. Several high throughput approaches for solubility have been described, e.g. turbidimetric method (Bevan, C. and Lloyd, R. S. Anal.
Chem. 2000 72, 1781-1787), nephelometric method (Avdeef, A. (2001) High througllput measurements of solubility profiles. In Pharmacokinetic Optimization in D ug Research;
Biological, Physicochemical, And Computational Strategies (Testa, B. et al., eds), pp. 305-326, Verlag Helvitica Chimica Actaand). Measurement of solubility at multiple pH levels (pH 1-8), is more useful that a single pH, since many drug candidates contain ionizable groups. A solubility-pH profile provides the pH gradient of the gastrointestinal tract.
Accurate understanding of a compound's solubility is also necessary to not only prepare and dispense formulations, but also to evaluate new chemical series and provide feedback to drive synthetic optimization. Structural series of compounds are synthesized with the aim of iinproving solubility by the addition of various chemical moieties. Sti-uctural elements known to confer aqueous solubility on otherwise insoluble molecular entities include but are not limited to N-piperazinylethyl, N-morpholinylethyl, 1,3-dihydroxy-2N -propanoyl moieties. Common solubilizing groups often incorporated in synthetic approaches to improve solubility of molecules include ainine functionality, such as dimethylainino, diethylamino, piperazinyl, N-methyl-N-isopropylainino, morpholino, pyrrolidino moieties, or groups bearing aliphatic alcohol functionality, such as that found in ethanolamine or glycerol.
In certain einbodiments of the invention, a structural element known to confer aqueous solubility is incorporated in a compound of the invention. Such structural elements are preferably attached to synthetically accessible regions of the coinpound.
In certain einbodiments, such structural elements are attached to or incorporate synthetically available N atoms in amine or amide or sulfonamide moieties of the compound. In certain embodiments a solubilizing group is attached to or incorporates a N atom and is chosen from the group consisting of dimethylamino, diethylamino, piperazinyl, N-methyl-N-isopropylamino, morpholino, pyrrolidino moieties, or groups bearing aliphatic alcohol functionality, such as that found in ethanolamine or glycerol.
Compounds of the invention The invention provides compounds having structural fonnula (I), s G3"G2-G1 \G4 Rl R2 (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,wherein G1 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or G1 and R3 taken together form an optionallysubstituted heterocycloalkyl, G2 is an N-sulfonamide moiety having structure (II), an S-sulfonarnide moiety having structure (III), or an amide of the fonn -NR3C(O)- or -C(O)NR3-:
\\S/ S
"-R3 (II) R4 (III);
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, Rl and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen and perhaloalkyl, or Rl and R2 taken together form optionally substituted cycloalkyl, R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl, or a structural element known to confer aqueous solubility, including but not limited to N-piperazinylethyl, N-morpholinylethyl, or 1,3-dihydroxy-2N-propanoyl, or R3 and R4 taken togetller form an optionally substituted heterocycloalkyl, and G4 is chosen from the group consisting of optionally substituted acyl, wherein G4 taken in combination with sulfur forins a thioester, optionally substituted thiol, wherein G4 taken in combination with sulfur forms a disulfide, and structure (IV) P\ oR5 yO-R5 IV
wherein G4, taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate.
In certain embodiments of compounds having Structure (I) as described above, G1 is an optionally substituted phenyl having structure (IV) or (V):
X~ O X~ O
~\ S,G4 S, X2~ ;_ R1 R2 2 ~
G3-G2 (IV) X2 (V) wherein Xl and X2 are eacll independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
In certain elnbodiments, compounds have the structure of Forinula (1), wherein G1 is an optionally substituted phenyl having structure (IV) or (V) and G2 is N-sulfonainide moiety having structure (VI) or (VII);
X, O
S, X2~ G4 X O
R1 R2 ~~ S'G
\
O O, NR3 OO I/~ 4 G3 N R, R2 (VI) (VII) In certain embodiments, compounds have the structure of Formula (1), wherein Gz is an optionally substituted phenyl having structure (IV) or (V) and G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 comprises is an optionally substituted phenyl of structure (VIII) or (IX) X, O
X2 P-"' R \G4 O~, NR3 X / i X
3 l\ \ 5 X4 (VIII) X, O
S, SN , .\ R, R2 X4 X5 (IX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, liydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxanido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, halo alkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylainino, aminothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1), wherein GI is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), G3 comprises is an optionally substituted phenyl of structure (VIII) or (IX), and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in coinbination with sulfur, forms a phosphorothioate.
diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected froin hydrogen, halogen, hydroxyl, lower alkyl, lower perizaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular einbodiments include:
S~/
~~~~ ~ ~~/,0 II
S.H / 0 C'N 0 ~cr H
Me0 0S~ S 1 0 1 ~S~ SII
H H
Me0) / CIaCi ~ S\~-op R\ ip I j1 S.N 0 S.N / 0 I/ H I/ H
OO SY OO I~ SY
S. O F3C S' 0 H H
oso SY Oso icr"--- SY
j~ H Me0~~ H0 %\ ~
F
O
\ S'N ID,-~,SyQN
01 /0 Sy ~S~
N
~ / H
OSO HI~ SY OSO H/ Sy C O C
I
R"P SY 0\\,p S-Ir C SN~ 0 Me0 ~ S.N J(D
H I H
Ci \%
O O
OõO I\ SY O0 O sY
I\ S'H / 0 H 0 '\!/
F CI
O O
CI OSO J/ S0 F co OSO I/ S0 H I H
a,, SY S~
SO 0 ~S~
'N ~ O
H I / H
F
O O
\ S \ \ S~
OS~ O OSO I/ O
O S SY
SO 0 OSO I \ / CI 0 SY J&SyNH
S N r 0 OS~ / 0 H
F3CO ~ F3CO
O
R\ iP jqr"" S O Y
~oj:~ \ SN I/ H F O
O
~
pS. O H~ ~ 0 F3CO I)", O O
R'lp ~
S. H/ 0 O O
H~OMe S.H O
I/
O /
S ~~
OO
S.N 0 O~
H
O
1)", In certain embodiments, compounds have the structure of Formula (1), wherein Gt is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 comprises an 5 or, 6 membered heteroaromatic optionally substituted by X3, X4, X5, wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl; N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkeilyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxainido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylainino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aininoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl. In par-ticular embodiments, G3 is selected can be any of the following:
N-~
O~J N
N N H
HN N 1i S~i <\O J ~NN
N O
N~i ~N ~N~i N
N ININ N:NJ
H
N N . N
N N
N N % N-N, ri -N~ N N~ L//N N
N~
I rN N
~ J
In further embodiments, G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substiiuted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent known to confer aqueous solubility. Particular embodiments include:
O O
OO S,~r OO STr ~ O S SN O
O\N~ H N:C' H
O O
o~H 0 0S0 S0 N ' 0 ~ --~s N, N
H
O O
O \01 I\ I S 101 N \SHN N S' N
~ ,O
O HO O
Jo--~ 5\ S
O HN ~OI O\S/N
Cl- ~O N O
k,N N
O ~Nr O
\ / I S~ ~ S o/
O\ ~N \ O O\ ,N
a~l o I ~O
O HO
O
jo-,~ S1~ ~ ~ ~ S1~(~
OHN 0 O\N\ 0 ~ S
O O
N N
O
S S",/
~ O 101 ~ HN O IHN
\N II s S~ \O
\O
O'N
O p HN S-k" HN
O S,O N
~ ~ INI~N
N
/
~-N
/ O
41irs-k, N . N HN ~O 0 S~ O 0 , N"~ N /
In certain embodiments, compounds have the structure of Forinula (1), wherein G1 is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 is an optionally substituted alkyl. In further embodiments, G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; R1 and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular embodiments include:
O
sy oSo \
H
O
S
OSO
\ S~
O O
,N
O O
O O
1 S0 ~~ ~
~S. N O N \ O
~' ~O ' ~-O
~ ~ II
HN \ S~ N
In certain einbodiments , compounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI) as shown below.
X, X2 X, 0 R4 \~/ R~ R2 Rq ri\ s\G4 G3 N~S~ S'G4 G" N,S~ % R~ R2 O~ ~0 3 /s ~
0 (X) 0 0 X2 (XI) In further embodiments, G3 is an optionally substituted phenyl of structure (XII) or (XIII) X, ~ 2 X, 0 R2 R4 S, R4 ' R, N~S S~G4 \ N~S" R1 R2 X3 00 0 X3 l' O 0 X2 /
X4 X5 (XII) X4 X5 (XIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylallcoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxainide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylainidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aininothiocarbonylamino, aminothiocarbonylaminoalkyl. In further embodiments, G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and XI and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent known to confer aqueous solubility. Particular embodiments include:
O
S
N\ Y
~ ~ oso O O
SY SY
OS O OS ~ ~ O
HN ~O I ~HN ~O
/
~
F
N"~s joj ~ ~HN ~p I ~p F ~ H3CO 0 0 S,,r )1tSOS O /s IOI
~ \ ' \O ~ \ NO
HO
OH
O\ p p\ 0 ~O \ HN~SO \ N SO
~O
O 0 Os Os ~ I
HN O O HN ~p O
~
O N
~ p p os ~ I S~ s I~ HN ~O O I~ HN ~O
O
CI ~ ~
Og g'~~ p ~
, ~
~?'**' N O 0 rz,~""THN O O
/
~ P 1 ~ cv-~
N,O O N N,SO O S
r S\ ~ r SY
O ~ O
NISO
HWSO CCF
F
SY Sy O O O~ O
\ HN'S10 \ HN'SO
~ r I .r CI
CI
SY r-Sy ~S O \ ~S \ ~ O
a H N I N
CI CI
CI
0, 0 0 HN
S O O F
p , ~ ~ o~ ~ I 0 NO S~ N.SO
F r r CI
HN'p HNO
O
CI C!
In certain embodiments wherein compounds have Structure (I) as described above, Gt is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonainide moiety having structure (X) or (XI), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, Xs as shown below:
N~
o~J N
N N H
<\O--~j' N -N HN N 5 N O
I N1~ ~N1~ ~N~i N
INI~ N,,~,- N NN
H
N
N ~ LS~ ~/ . / N ~//
N N /
N r N-N, ~ N N N N
wherein X3, X4 and X5 are each indepeildently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxainidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylainino, aminoalkyl, , dialkylaminoalkyl, aininoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylarnino, aminothiocarbonylaininoalkyl.
In certain embodiments of the compounds described in the preceding paragraph, wherein compounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, X5 as described in the preceding paragraph, G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected fiom hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular einbodiments include:
O O
O \ 0 O \ S~
N HN' N N~S\
O O
\ ~
HO Sj 0S O }~S \ I TO
N \ NHO N0 ' N N
O O
SY N io Sy ~ O ~O
I \ N \O N
Nr~
O O
HO
O\ SY ~~ )cr&sY0 ~S O
N r NH ~ ' N N~
~N
~ C' O
S'Ir S O HN
N~NH~O c O O
~
-N /
/ O ~ O
9\ ~
' ~ S
NISO S N NH S\
~O
/OD ~ 0 N %~ 0 \N N
/ I O HO a O
,5~ \ S.S~ S~
N~
HNN O O O
N- N(~
In certain embodiments wherein coinpounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI),G3 can be an optionally substituted alkyl.
In further embodiments, G4 can be an optionally substituted acyl of the formula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, foirns a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element kiiown to confer aqueous solubility. Particular embodiments include:
O ~ O
HO
/ SY -'N SY
~S I O z 0S O
N ~p N
O O
S~
0 S 0 O\ 0 N' ~HN'%
O
O O
--,,HN O O ~NO
O
In certain einbodiments of compounds having Structure (I) as described above, Gl is a or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV);
O
S, 5or6 G4 Membered R1 R2 Heteroaromatic ring X, (XIV) wherein Xi and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
In certain embodiments, coxnpounds have the structure of Fonnula (1) above, Gl is a 5 or 6 meinbered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), and G2 is a sulfonainide having an N-sulfonamide moiety of structure (XV) or an S-sulfonamide moeity of structure (XVI) O O
S, S~
5 or 6 G4 5 or 6 G4 Membered R, R2 Membered R, R2 Heteroaromatic Heteroaromatic 0~ 0 ring R4 ring N, X' (XV) X, (XVI) In certain einbodiments, coinpounds have the structure of Fonnula (1) above, G, is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonainide (XVI), and G3 is an optionally substituted phenyl of structure (XVII):
S, 5 or 6 G4 Membered R, R2 Heteroaromatic X 0 0 ring N
C ~ R3 X2 X, X4 X5 (XVII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylainino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylainino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyllaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkyltllio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
In certain einbodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), and G3 is an optionally substituted phenyl of structure (XVII), and X3, X4 and X5 are selected as described in the preceding paragraph, G4 can be an optionally substituted acyl of the formula -C(O)RE , wherein RE is any phalmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or --P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In these embodiments, G1 can be any of:
O1~
N NJ
H
~O J'' ~N N
N O \J ~
~Nl~ IIN~~' NNN N~
~ NJ N:N~
H
N .
N N ~J N
N N
N N N-N, N N N~ N N
Particular embodiments include:
O O
S S~,/ N~
0 HN~\N IOI ~\ HN O
O ~ \ O
~
O
HN~N 0 \ S O S
O~~ HN ~ 0 NI ~
0 0 ~ N O
~
H3CO N~
I
O O
O~ NS ~ O S S
~HN 1 101 O O
CI ~
O O
NS /S S
~\ ~N- ~N ~ O HN"\N K 0 I\ S,.o O I\ o ~
a In certain embodiments, coinpounds have the structure of Fonnula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), G2 is an N-sulfonainide moiety having structure (XV) or S-sulfonamide (XVI), and G3 can be a 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XVIII) S, or 6 G4 Membered R, R2 Heteroaromatic X3 O~ O ring S~N
X4 X5 (XVIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perllaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxainidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylalnino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylainino, aminocarbonylalkoxy, amino carbonylamino, aminothiocarbonylainino, or aminothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), and G3 is can be a 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XVIII), with X3, X4 and X5 selected as described in the preceding paragraph, G4 can be an optionally substituted acyl of the fonnula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in coinbination with sulfur, forins a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; R1 and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perlialoalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In these einbodiments, G3 can be :
/S' 01 N~ 'NJ H
</N N H N N, S~i N O ~
03- N " II N~/ ~N'' N
N NN NN
H
.
N ~ ~S~ N 'N N
N"N/ i N
N~
LN~ N N~ N
Particular embodiments include:
O
O N S"r S
~ HN~ I O ~ HN O
N N~ ~
O I N O
O O
O S~ S S~
QS~O N~N ~ 101 O SHN I , ~N ~ O:1 <\
O'N N
In certain embodiments, compounds have the structure of Formula (1) above, G1 is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), and G2 is an N-sulfonamide moiety having structure (XV), wherein G3 comprises an optionally substituted alkyl.
S, 5or6 C'4 Membered R, R2 Heteroaromatic 0~ s~
3 ring G ~S1N
X1 (XV) In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV), G3 coinprises an optionally substituted alkyl, and G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, aii optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination witl7 sulfur, fonns a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and X, and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In certain einbodiments, Gl can be:
O/~'~
N N H
N N
''O J'~ \ N HN'i 5~--' N O
02' N ' I'N~~" IIN\~ NI' N,,,J N~N N, ~
N
H
N S~ N N
N N
LN,,- N N
N~
N N~
Particular embodiments include:
O N\ Sy SY
HN~ :~' ~~ HN 0 O N yg O
+ S S g~
ONN ~ N ~ 101 \O b In certain embodiments, compounds have the structure of Formula (1) above, G, is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonainide (XVI), and G3 is an optionally substituted phenyl of structure (XIX):
S, 5 or 6 04 Membered R, R2 Heteroaromatic R4 ring N, S
Xg X2 X4 X5 xI (XIX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxainido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylainino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylainino, alkylthio, arylainino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkyltllio, alkylsulfinyl, arylsulfinyl, diallcylamino, aininoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, aminothiocarbonylaminoalkyl.
In certain embodiments, coinpounds have the structure of Formula (1) above, Gl is a 5 or 6 meinbered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), G3 is an optionally substituted phenyl of structure (XIX) as described in the preceding paragraph, and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, fonns a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wlierein G4 taken in coinbination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together fonn optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In further embodiments, Gj can be:
S~
N Ni~ O~'~
N HN'N1-~
N O \--~j 021- N ~ IIN NNN N
N J NN
H
N-S, ~/N
N N
N N
LN~ ~ N
N N~
N N
(N
'~~~J
N~N/
Particular embodiments include:
O O
S S N S
O'S~\ ~ 0 O
HN~ ~O N 0 \ HN~SO
F~ /
~
OCH3 oS ~~ Sy 0\ O ~ Slir HN O ~ HN'SpJ'\\N 0 ~ i S
y S
-\~ ~'' HN \S' N 0 N, S\ 1 ~ S~
I \ O
CI ~ ~
0S-N I' o'S Sy N 'O O'N 0 a HN'SO N O
In certain embodiments, compounds have the structure of Formula (1) above, G1 is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is a S-sulfonamide (XVI), and G3 is a 5 or 6 membered optionally substituted heteroaromatic of structure (XVIII), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, XS of structure (XX) S, or 6 C'4 Membered RI R2 Heteroaromatic X3 R4 ring S
O~ ~\O X2 X~
X4 X5 (XX) wherein X3, X4 and X5 are each independently cl7osen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylainino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxainido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkyltliio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylainido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylainino, aininoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or arninothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is a S-sulfonamide (XVI), and G3 is a 5 or 6 membered optionally substituted heteroaromatic of structure (XVIII), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, X5 of structure (XX), and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in coinbination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate;
R, and R2 are eacll independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In further einbodiments, Gl and G3 can each be independently selected from:
O~~J N
N N H
~O <N ~ HN
N O
C2J N ~ IINII N\/ N
N NN N;N~
H
S -S N-S, N
N N N N~ N
N r N-N, ~N NN~ LIJN N~
%/>
\N
Particular embodiments include:
O
N\ S O
' /
O o\S S S ~"
N~NH ~
O I~ N' ~O O
\,N N~
O O
S
O'S /S I O S /O I S~ 11 O N yN N N H~N O
~, ~ ~ o N C
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an S-sulfonamide (XVI), and G3 is an optionally substituted alkyl.
O
5 or 6 S\G4 Membered R, R2 Heteroaromatic R4 ring N, X, (XVI) In certain embodiments, coinpounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an S-sulfonamide (XVI), G3 is an optionally substituted alkyl, and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 talcen in coinbination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 talcen in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or RI and R2 taken together fonn optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent loiown to confer aqueous solubility. In further embodiments, Gl can be:
p~~~
NJ N O~
H
~J ~N N HN S
N O
I N1~ N N N N ~N I~
~ INIJ ~ N.NJ
H
S NS, N
N N -N~ N
NN N'N, N N N N N~
(N
N-, N
Particular einbodiments include:
N S O
~ o~\ O \0~~ S~
N p p O
S
~S~S 0 lir ~\ ~S~O Dr S Il N N3 N' ~\ p N p In one einbodilnent, a compound having the structure of Fonnula (1), has the structure consisting of:
O
F3CO/ S~
~ ( ~NH 0 OSO
[0053] In another aspect, the invention relates to a compound selected from the goup consisting of the compounds set forth in the examples, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof:
Exemplary compounds and pharinaceutically acceptable esters or prodrugs thereof the invention include, but are not limited to, disulfide dimers, mercaptans, and thioesters of coinpounds of Formula (I).
Uses of compounds of the invention [0054] In accordance with one aspect, the present invention provides compounds of Formula (I), where each compound is capable of inhibiting the catalytic activity of histone deacetylase (HDAC). In another aspect, the present invention provides phannaceutical compositions comprising compounds of Formula (I), capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
[0055] In accordance with another aspect, the present invention provides compounds of Formula (I), capable of inhibiting the cellular function of HDAC.
In anotller aspect, the present invention provides phannaceutical compositions comprising compounds of Forlnula (I), capable of inhibiting the cellular function of histone deacetylase (HDAC).
[0056] In accordance with yet another aspect of the invention, the present invention provides methods and compositions for treating certain diseases or disease states.
Methods and compositions are provided for using compounds of the invention for treating diseases or disease states including, but not limited to, cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, and disorders in which angiogenesis play a role in pathogenesis, [0057] In accordance with one aspect, methods and compositions of the invention are used for treating cancer. In some embodiments, but without limitation, the tenn cancer refers to and is selected from disorders such as colon cancer, breast cancer, ovarian cancer, lung cancer and prostrate cancer, tumor invasion, tumor growth, tumor metastasis, and cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stoinach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, bone, connective tissue, skin, cervix uteri, corpus endornetriurn, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and endocrine gland. The term "cancer" also encompasses Hodgkin's disease, non-Hodgkin's lymphoinas, inultiple myeloma and hematopoietic malignancies including leukemias (Cluonlc Lymphocytic Leukeinia) and lymphomas including lymphocytic, granulocytic and monocytic.
Additional types of cancers which may be treated using the coinpounds and methods of the invention include, but are not limited to, adrenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, blastoglioma, chondrosarcoma, choriocarcinoma, chordoma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoina, endotheliosarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancers, glioblastoma multifonne, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, hepatoma, Kaposi's sarcoma, large cell carcinoma, cancer of the larynx, leiomyosarcoina, leukeinias, liposarcoma, lyinphatic system cancer, lymphomas, lyinphangiosarcoma, lymphangioendotheliosarcoma, medullary thyroid carcinoma, medulloblastoma, meningioma mesothelioma, myelomas, inyxosarcoma neuroblastoma, neurofibrosarcoina, oligodendroglioma, osteogenic sarcoma, epithelial ovarian cancer, papillary carcinoma, papillary adenocarcinomas, parathyroid tumours, pheochromocytoma, pinealoma, plasmacytomas, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancers, melanoma, small cell lung carcinoma, squainous cell carcinoma, sweat gland carcinoma, synovioma, thyroid cancer, uveal melanoma, and Wilm's tuinor.
[00581 In accordance with another aspect, methods and compositions of the invention are used for preventing neoplasias including, but not limited to, brain cancer, bone cancer, a leukemia, a lymphoma, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophogeal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body. The neoplasia can be selected from gastrointestinal cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers.
[0059] In accordance with another aspect, metllods and compositions of the invention are used for treating autoimmune diseases including, but not limited to:
autoimmune disease that targets the nervous system, e.g., inultiple sclerosis, myasthenia gravis, autoimmune neuropathies such as Guillain-Barre syndrome, autoimmune uveitis;
autoimmune disease that targets the gastrointestinal system, e.g., Crohn's disease, ulcerative colitis, primary biliary cirrhosis; autoimmune hepatitis; autoimmune disease that targets the blood, e.g., autoimmune heinolytic anemia, pernicious anemia, autoimmune thrombocytopenia; autoimmune disease that targets endocrine glands, e.g., Type 1 or immune-mediated diabetes mellitus, Grave's disease, Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disease of the adrenal gland; autoimmune disease that targets blood vessels, e.g., temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, Behcet's disease; autoimmune disease that targets multiple organs including the musculoskeletal systein, e.g., rheumatoid arthritis, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, Sjogren's syndrome; autoimmune disease that targets skin, e.g., psoriasis, dermatitis herpetiformis, pemphigus vulgaris, or vitiligo.
[0060] In accordance with another aspect, methods and compositions of the invention are used for treating disease states characterized by tissue damage, where the disease states include, but are not limited to, vascular diseases, inigraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheuinatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like.
[0061] In accordance with another aspect, methods and coinpositions of the invention are used for treating the fibrosis which occurs with radiation therapy.
[0062] In accordance with another aspect, methods and compositions of the invention are used for treating subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, the present coinpounds and methods can be used to prevent polyps from forming in patients at risk of FAP.
[0063] In accordance with another aspect, methods and compositions of the invention are used for treating anemias or thalassemias including, without limitation, sickle cell anemia.
[0064] In accordance with another aspect, methods and coinpositions of the invention are used for treating a cardiovascular condition, e.g., cardiac hypertrophy and heart failure.
[0065] In accordance with another aspect, methods and coinpositions of the invention are used for treating diseases related to an inflainmatory condition including, but not limited to, rheumatoid arthritis (RA), inflainmatory bowel disease (IBD), ulcerative colitis and psoriasis.
[0066] In accordance with another aspect, methods and compositions of the invention are used for treating certain central nervous system disorders including, but not limited to, Parkinson's disease, Alzheimer's disease, Alzheimer's dementia, and central nervous system damage resulting fiom stroke, ischeinia and trauma.
[0067] In accordance with another aspect, methods and compositions of the invention are used for treating a neurological or polyglutamine-repeat disorder including, but not limited to, Huntington's disease, Spinocerebellar ataxia 1(SCA 1), Machado-Joseph disease (MJD)/Spinocerebella ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyian atrophy (DRPLA).
[0068] In accordance with another aspect, methods and compositions of the invention are used for treating neurodegenerative disorders in which HDAC
iiihlbltlon is useful include nerve degeneration or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in cases of central nervous system (CNS) trauma (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia e.g. pre-senile dementia, and AIDS-related dementia, cachexia, Sydenham's chorea, Huntington's disease, Amyotrophic Lateral Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, depression or other symptoins associated with Premenstrual Syndrome (PMS), anxiety and septic shock.
[0069] In accordance with another aspect, methods and compositions of the invention are used for treating bone diseases, including bone disorders involving osteoclasts and chonrocytes. Without wishing to be limited by this tlleory, it is noted that HDAC activity regulates the process of osteoclastogenesis and chondrocyte differentiation, such that inhibitors of HDAC are also useful in the treatment of all bone disorders involving osteoclasts and chondrocytes.
[0070] In accordance with another aspect, methods and coinpositions of the invention are used for treating ophthalmic diseases and other diseases in which angiogenesis plays a role in pathogeneis, such as glaucoma, retinal ganglion degeneration,occular ischemia, retinitis, retinopathies, uveitis, ocular photophobia, and of inflammation and pain associated with acute injury to the eye tissue.
[0071] Methods and compositions of the invention are used for treating human and non-huinan subjects. Methods and compositions of the invention are suitable for veterinary uses in treating companion animals, exotic animals and farm animals, including mammals, rodents, and the like. In particular embodiments, inethods and compositions of the invention are used for treating horses, dogs,and cats.
[0072] The terms "treat" or "treating" or "therapy" as used herein refer to (1) reducing the rate of progress of a disease, or, in case of cancer reducing the size of the tumor;
(2) inhibiting to some extent furtlier progress of the disease, which in case of cancer may mean slowing to some extent, or preferably stopping, tumor metastasis or tumor growth;
and/or, (3) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the disease. Thus, the term "therapeutically effective amount"
as used herein refers to that amount of the compound being administered which will provide therapy or affect treatment.
[0073J In accordance with certain aspects of the invention, the compounds of the present invention act as anti-tumor compounds and/or inhibit the growth of a tumor, i.e., they are tumor-growtll-iiiliibiting compounds. The tenns "anti-tumor" a.nd "tumor-growth-inhibiting," when modifying the term "coinpound," and the terms "inhibiting"
and "reducing", when modifying the terms "compound" and/or "tumor," mean that the presence of the subject compound is correlated with at least the slowing of the rate of growth of the tuinor. More preferably, the terms "anti-tumor," "tumor-growth-inhibiting,"
"inhibiting," and "reducing" refer to a correlation between the presence of the subject compound and at least the temporary cessation of tumor growtli. The terms "anti-tuinor," "tumor-growth-inhibiting," "inhibiting," and "reducing" also refer to, a correlation between the presence of the compound(s) of the invention and at least the temporary reduction in the mass of the tumor. It is understood that the effectiveness of compounds of the invention as anti-tumor, or tumor-inhibiting, agents may be contribute to their effectiveness in treating cancer, but that the compound of the invention may also act through other mechanisms to exert measured effects on cancer.
[0074] The term "cellular function" refers to the function of HDAC in the cell.
The term "HDAC function" is generally understood to refer to interaction of HDAC with a natural binding partner, and is particularly understood to refer to catalytic activity. The "cellular function" of HDAC is understood to refer not only to the catalyic activity of HDAC
in a cell, but also to the cellular effects of HDAC catalytic activity on the function of the cell.
The term "catalytic activity", in the context of the invention, defines the rate at wllich HDAC
deacetylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of time.
Deacetylation of a substrate occurs at the active-site of HDAC. The active-site is normally a cavity in which the substrate binds to HDAC and is deacetylated.
[0075] The term "substrate" as used herein refers to a molecule deacetylated by HDAC. The substrate is preferably a peptide and more preferably a protein. In some embodiments, the protein is a histone, whereas in other embodiments, the protein is not a histone.
[0076] The term "inhibit" refers to decreasing the cellular function of HDAC.
It is understood that coarnpounds of the present invention may inhibit the cellular function of HDAC by various direct or indirect mechanisms, in particular by direct or indirect inhibition of the catalytic activityof HDAC. The term "activates" refers to increasing the cellular function of HDAC.
[0077] The tenn "modulates" refers to altering the function of HDAC by increasing or decreasing the probability that a complex forms between HDAC and a natural binding partner. A modulator may increase the probability that such a coinplex forms between HDAC and the natural binding partner, or may increase or decrease the probability that a complex forms between HDAC and the natural binding partner depending on the concentration of the compound exposed to HDAC, or may decrease the probability that a complex forms between HDAC and the natural binding partner. A modulator may activate the catalytic activity of HDAC, or may activate or inhibit the catalytic activity of HDAC
depending on the concentration of the compound exposed to HDAC, or may inhibit the catalytic activity of HDAC.
[0078] The term "complex" refers to an assembly of at least two molecules bound to one another. The term "natural binding partner" refers to polypeptides that bind to HDAC
in cells. A change in the interaction between HDAC and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of HDAC/natural binding partner complex.
[0079] The term "contacting" as used herein refers to mixing a solution comprising a compound of the invention with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as dimethylsulfoxide (DMSO), which facilitates the uptake of the compound or compounds into the cells of the metllods. The solution comprising the compound of the invention may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based device or syringe-based device.
[0080] The term "monitoring" refers to observing the effect of adding the compound to the cells of the method. The effect can be manifested in a change in cell phenotype, cell proliferation, HDAC catalytic activity, substrate protein acetylation levels, gene expression changes, or in the interaction between HDAC and a natural binding partner.
[0081] The term "effect" describes a change or an absence of a change in cell phenotype or cell proliferation. "Effect" can also describe a change or an absence of a change in the catalytic activity of HDAC. "Effect" can also describe a change or an absence of a change in an interaction between HDAC and a natural binding partner.
[0082] The term "cell phenotype" refers to the outward appearance of a cell or tissue or the function of the cell or tissue. Examples of cell phenotype are cell size (reduction or enlargement), cell proliferation (increased or decreased numbers of cells), cell differentiation (a change or absence of a change in cell shape), cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (e.g., glucose uptake).
Changes or the absence of changes in cell phenotype are readily measured by techniques known in the art.
The present compounds are usefule for identifying a carbonyl coinpounds that modulates the cellular function of HDAC, comprising the steps of:
a) contacting cells expressing HDAC with the disclosed compounds of and b) measuring an effect of the coinpound or composition.
Optionally the effect is inhibition of the catalytic activity of HDAC. Further the inethods of coinprises measuring histone hyperacetylation. Additionally the effect is a change in cell phenotype and/or the effect is a change in cell proliferation.
Furtlier the disclosed compounds can be used for the manufacture of a medicainent for use in the treatment of a condition mediated by HDAC activity.
A. Pharmaceutical Compositions [0083] The present invention also relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt, solvate, amide, ester, or prodrug thereof, as described herein. and a pharmaceutically acceptable carrier, diluent, or excipient, or a combination thereof.
[0084] The term "pharmaceutical coinposition" refers to a mixture of a coinpound of the invention with other chemical components, such as carriers, diluents or excipients.
The pharmaceutical composition facilitates administration of the compound to an organism.
Multiple techniques of adininistering a compound exist in the art including, but not limited to: intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
[0085] The term "carrier" refers to relatively nontoxic chemical compounds or agents. Such carriers may facilitate the incorporation of a coinpound into cells or tissues.
For exainple, hulnan serum albuinin (HSA) is a coinmonly utilized canier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.
[0086] The term "diluent" refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (providing pH control) are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline. It is a buffer found naturally in the blood systein, Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
[0087] The compounds described herein can be administered to a human patient per se, or in phartnaceutical coinpositions where they are mixed with other active ingredients, as in coinbination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," 20th ed. Edited by Alfonso Gennaro, 2000.
1) Routes Of Administration [0088] Suitable routes of administration include local or systemic routes of administration including, but not limited to, topical, transdermal, oral, rectal, transinucosal, pulmonary, ophthalmic, intestinal, parenteral, intramuscular, subcutaneous, intravenous, intramedullary, intrathecal, direct intraventricular, iiitraperitoneal, intranasal, or intraocular delivery. In certain embodiments, compounds of the invention are adininistered topically, e,g in an ointment, patch, nasal spray, or eye drops/ointinent. In certain embodiments, compounds of the invention are delivered by intestinal, parenteral, intramuscular, subcutaneous, intravenous, intramedullary, intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
[0089] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot or sustained release formulation. Furthennore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.
2) Composition/Formulation [0090] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0091] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Phannaceutical Sciences, above.
[0092] For intravenous injections, the agents of the invention may be formulated in aqueous solutions, preferably in phannaceutically compatible buffers such as Hanlcs's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be perineated are used in the forinulation. Such penetrants are generally known in the art. For other parenteral injections, the agents of the invention may be fomlulated in aqueous or nonaqueous solutions, preferably with pharmaceutically compatible buffers or excipients. Such excipients are generally known in the art.
[0093] For oral administration, the compounds can be formulated readily by combining the active compounds with pharinaceutically acceptable carriers or excipients well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with one or more compound of the invention, optionally grinding the resulting mixture, and processing the niixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for exainple, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethyl cellulose; or others such as:
polyvinylpyrrolidone (PVP or povidone) or calciurn phosphate. If desired, disintegrating agents may be added, such as the cross-linked croscannellose sodium, polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0094] Dragee cores are provided witll suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or piginents may be added to the tablets or dragee coatings for identification or to characterize different combinations of active coinpound doses.
[0095] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All forinulations for oral adininistration should be in dosages suitable for such administration.
[0096] For buccal or sublingual administration, the coinpositions inay take the form of tablets, lozenges, or gels forinulated in conventional manner.
[0097] For administration by inhalation, the coinpounds for use according to the present invention are conveniently delivered in the fonn of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be fonnulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
[0098] The compounds may be forinulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage fonn, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such fonns as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain fornnulatory agents such as suspending, stabilizing and/or dispersing agents.
[0099] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble forni. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxyinethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[00100] Alternatively, the active ingredient niay be in powder form for constitution wit11 a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[00101] The compounds may also be formulated in rectal coinpositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
[00102] In addition to the formulations described previously, the coinpounds may also be formulated as a depot preparation. Such long acting forinulations may be administered by iinplantation (for example subcutaneously or intrainuscularly) or by intrainuscular injection. Thus, for example, the coinpounds may be formulated with suitable polylneric or hydrophobic materials (for example as an einulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[00103] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent systein may be a 10%
ethanol, 10%
polyethylene glycol 300, 10% polyethylene glycol 40 castor oil (PEG-40 castor oil) with 70%
aqueous solution. This cosolvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systeinic administration. Naturally, the proportions of a cosolvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components may be varied: for exainple, other low-toxicity nonpolar surfactants may be used instead of PEG-40 castor oil, the fraction size of polyethylene glycol 300 may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides maybe included in the aqueous solution.
[00104] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as N-inethylpyrrolidone also may be employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
[00105] Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not liinited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free acid or base forms.
GENERAL SYNTHETIC METHODS FOR PREPARING COMPOUNDS
Molecular einbodiments of the present invention can be synthesized using standard synthetic techniques known to those of skill in the art. Compounds of the present invention can be synthesized using the general synthetic procedures set forth in Scheines I-III.
General procedure for sulfonamide (a): Scheme I
Q a ~~~~ Q
-Ir R35HN R45 0 R31 / S\ I NQ O
SI-I
b ~S\N a S~R3z ~ c Y.O~Q)r-~.-Br R31 ~ 1 ~ 0 R31 R
Reagents: (a) R31SO2CI, Et3N, THF; (b) PTT, THF; (c) KSCOR32, MeOH
General procedure for sulfonamide (b): Scheme II
Q
Rg4SO2Cl + \ ~ a R34/S\N / R~
\ ~ O
0 i b nN~ S O~~ / ~Br O
0 ( x- c /S\ \ (a R34'~ \N \ E Rs4 i ~ R35 d O
O O / ~ R3z \'e~ 0-'0y-SH e R jS~N 34 O R
I
Reagents: (a) pyridine, THF; (b) PTT, THF; (c) N-methyl 2-thiopyridone, EtOH;
(d) NaOH, water; (e) acid chloride, hunig's base, DCM
General Procedure for reverse sulfonamide :
Scheme III
a R34R33N\S ~ I Q
CI~S 0 SIII-1 O~ \O
b 0 S~R32 c Br y R34R33N YQ
\ \ \ \
$f li-3 SI I I-2 Reagents: (a) Amine (R34R33N), THF, pyr; (b) THF, PTT; (c) MeOH, KSC(O)R32 General Procedure for Ring-Fused Sulfonamides Scheme IV
pO 0 :Cr S"CI a N ~ S~ O
H
b O C
SY Br N 0 c SO f / \ O
(a) Pyridine, THF; (b) PTT, THF; (c) KSC(O)CH3, MeOH
Scheme V illustrates the general syntliesis of disulfide embodiments of the present invention.
Scheme V
Rt O R1 O
Rz /~ Br a RZ / S11 --~ I
Rs \ Re R3 ~ R 0 Ra R4 b Rl O
RZ ~ S
R3 ~ I R5 Ry Reagents: (a) KSC(O)CH3, MeOH; (b) NaOH, MeOH
Scheme VI depicts an alternative general scheme for the synthesis of thiol (mercaptan) and disulfide embodiments of the present invention Scheme VI
Ri 0 R, O
R2 a Rp / Br R3 I RS R. ~ I Rs Ry R2 = ~b ::i'ii"- c Rq d Ri 0 R3 ~ I R5 Rq Reagents: (a) PTT, THF; (b) N-methyl 2-thiopyridone, EtOH;
(c) NaOH, water; (d) MeOH, water.
EXAMPLES
[00106] The examples below are non-limiting and are merely representative of various aspects of the invention.
Example 1 o / S
\ ~s/~N \ ~ y F, CFsO I
Thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound tlliobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl}ester was synthesized according to Scheme I.
Step 1 \ ii S"N
\ H
I /
N-(4-Acetyl-phenyl)-4-trifluoromethoxy-benzenesulfonamide (SI-2): 4'-Amino acetophenone (0.375 g, 2.78 mmol) was dissolved in THF (5 ml) before pyridine (0.674 ml, 8.34 minol) was added, leaving a yellow solution. 4-trifluorometlioxy benzenesulfonylchloride (0.871 g, 3.34 minol) was then added dropwise with stirring. After strirring for 2h, THF and pyridine were removed. The desired sulfonamide (0.848 g, 2.36 minol, 85 %) was recrystallized from ethyl acetate and hexanes. 'H-NMR: (400 MHz, CDC13) 7.89 (m, 4H), 7.29 (d, IH), 7.16 (d, 2H), 6.88 (s, 1H), 2.55 (s, 3H).
LC-MS (ES+):
360 [MH]+ in/e.
Step 2 O
Br \ N
~
/ H
N-[4-(2-Bromo-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SI-3):
The ketone from stepl (0.32 g, 0.868 mmol) was dissolved in THF (9 ml), and phenyltrilnethylammonium tribromide (PTT) (0.368 g, 0.868 mmol) was added as a solid leaving an orange solution which began to deposit a white solid immediately.
Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (90% desired mono-brominated material by LC-MS, 5% starting inaterial, 5 % dibrominated) suitable for the next step. LC-MS
(ES-): 436, 43 8 m/e.
Step 3 o I
s \
v ~ \ \S~N 0 ~ H
Thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: oc-Bromoketone (SI-3) (0.3 g, 0.68 mmol) was dissolved in anliydrous THF (5 ml), and thiobenzoic acid (104 mg, 0.75 mmol) was added followed inunediately by potassium carbonate (104 rng, 0.75 mmol). The reaction was stirred for 2 hours. The THF
was evaporated and the residue was taken up in DCM and filtered. After evaporation of the DCM the product was purified by flash chromatography (7:3 EtOAC: hexanes).
Removal of the solvent afforded 57 mg product (0.11 mmols, 16%) as a white solid. 'H-NMR:
(400 MHz, DMSO): 8.00 (t, 3H), 7.98 (d, 2H), 7.61 (t, 2H), 7.50 (t, 2H), 7.32 (d, 2H), 7.22 (d, 2H), 4.52 (s, 2H); LC-MS (ES+): 496 [MH] + m/e.
Example 2 / S \ N
o Y
~N \ 0 I \
/ y Thionicotinic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Exainple 2 was synfihesized according to the procedure outlined in Example 1.
'H-NMR: (400 MHz, CDC13): 9.11 (s, 1H), 8.86 (d, 1H), 8.30 (d, 1H), 8,00 (d, 2H), 7.98 (d, 2H), 7.44 (t, 1H), 7.33 (d, 2H), 7.28 (d, 2H), 4.60 (s, 2H); LC-MS (ES+): 498 m/e.
Example 3 \V' lol / H
CF3O ~ \
Pentanethioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylainino)-phenyl]-ethyl} ester (SI-4) (0.5 g, 1.15 mmol) was dissolved in anhydrous DMF
(5 ml).
Lithium hydroxide (28 mg, 1.15 mmol) was added and the solution was sonicated until homogeneous and heated to 90 C for 4 hours, The solution was allowed to cool to room temperature and valeryl chloride (150 ing, 1.27 mmol) was added and the mixture stirred for 16 hours. The solution was partioned between 20 ml each water and EtOAc. The organic layer was washed with water, then brine and dried over Na2SO4. The solution was then filtered, stripped of solevent and the product purified by flash chromatography (100% DCM), The solvent was evaporated to afford 107 mg (0.22 mmol, 19%) product as a clear oil, 1H-NMR: (400 MHz, DMSO): 8.07 (d, 2H), 7.60 (d, 2H), 7.40 (d, 2H), 7.25 (d, 2H), 2.40 (s, 2H), 2.10 (t, 2H), 1.42 (t, 2H) 1,11 (t, 2H), 0.90 (t, 3H); LC-MS (ES+): 476 [M]+m/e.
Example 4 QLSO H
Furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester was synthesized according to Scheme II.
Step 1 \/
S~N
\ H
I
N-(4-Acetyl-phenyl)-4-trifluoromethoxy-benzenesulfonamide (SII-1): 4'-Amino acetophenone (0.375 g, 2.78 inmol) was dissolved in THF (5 ml) before pyridine (0.674 ml, 8.34 mmol) was added, leaving a yellow solution. 4-trifluoromethoxy benzenesulfonylehloride (0.871 g, 3.34 mmol) was then added dropwise with stirring. After removal of THF and pyridine, the desired sulfonamide (0.848 g, 2.36 mmol, 85 %) was recrystallized from ethyl acetate and hexanes. 1H-NMR: (400 MHz, CDCl3) 7.89 (m, 4H), 7.29 (d, 1H), 7.16 (d, 2H), 6.88 (s, 1H), 2.55 (s, 3H). LC-MS (ES+): 360 [MH]+m/e.
Sten 2 Br 0i I
S" N
I~ y N-[4-(2-Bromo-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SII-2):
The ketone from step 1(0.32 g, 0.868 nunol) was dissolved in THF (9 ml), and phenyltrimethylainmonium tribroinide (PTT) (0.368 g, 0.868 mmol) was added as a solid leaving an orange solution which began to deposit a white solid iinmediately.
Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (90% desired mono-brominated material by LC-MS, 5% starting material, 5 % dibrominated) suitable for the next step. LC-MS
(ES-): 436, 43 8 m/e.
Step 3 / s\ ~
N ~N'v/'1J
\ \S/~ H
I/ X' 1-Methyl-2-{2-oxo-2-[4-(4-trifluoromethoxybenzene- sulphonylamino) phenyl]ethylsulfanyl}-pyridinium bromide (SII-3): The bromoketone from step 2 (0.141 g crude material, 0.322 mmol) was dissolved in ethanol (2 ml) before N-methyl thiopyridone (0.040 g, 0.322 mmol) was added as a solid. The resulting yellow solution was then heated to reflux overnight. Evaporation of the volatiles leaves a residue (75 % by NMR, 0.116 g, 0.240 mmol) suitable for the next step, however, the product may be recrystallized from ethanol if desired. 'H-NMR: (400 MHz, DMSO-d6) 11.21 (s, 1H), 8.90 (d, IH), 8.18 (t, 1H), 8.03 (m, 5H), 7.90 (t, 1H), 7.80 (d, 2H), 7.15 (d, 2H), 5.33 (s, 2H), 4.24 (s, 3H). LC-MS (ES+): 483 [M]+ m/e.
Step 4 SH
\V/
I / H
S\N
N-[4-(2-Mercapto-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SII-4):
SII-3 (4.35 g, 7,72 mmol) was suspended in water (1.7 1) before 2 M NaOH (7.25 ml) was added. Solid NaOH (1 g) was then added, and the resulting mixture was then heated to reflux overnight, producing a red solution. The solution was then acidified to a pH
of 1 and extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a red oil.
Throughout the work-up, the alpha-mercapto ketone readily oxidizes to the coiresponding disulfide, which was purified by preparative HPLC (0.582 g, 0.75 mmol, 10 %).
1H-NMR:
(400 MHz, DMSO-d6) 11.09 (bs, 2H), 7.97 (d, 4H), 7.85 (d, 4H), 7.57 (d, 4H), 7.22 (d, 4H), 4.29 (s, 4H). LC-MS (ES+): 781 [MH]+ m/e.
Step 5 I'~ y ~
H
Furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: To thiol SII-4 (0.5 g, 1.33 mmol) in 5 ml degassed anhydrous DCM (5 ml) was added 2-furoyl chloride (190 mg, 1.46 mmol) followed by DIEA (0.19 g, 1.46 mmol). The reaction was stirred for 4 hours and the solvent was evaporated.
The product was first purified by flash chromatography (4:6 EtOAc:hexanes), then recrystallized from EtOAc and finally triturated with DCM to afford 31 mg (0.064 mmol, 5%) product as a white solid. 'H-NMR: (400 MHz, CDC13): 8.00 (d, 2H), 7.94 (d, 2H), 7.64 (d, 1H), 7.35 (d, 2H), 7.29 (d, 1H), 7.22 (d, 2H), 6.60 (t, 1H), 4.50 (s, 2H); LC-MS (ES+): 486 [MH]+
m/e.
Example 5 o S
\ \8~N I 0 I / H
1-(4-Diethylamino-phenyl)-2-mercapto-ethanone was syntllesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13):
7.96 (d, 2H), 7.93 (d, 2H), 7.35 (d, 2H), 7.21 (d, 2H), 4.27 (s, 2H); LC-MS (ES+): 476 [MH]+ m/e, Example 6 s \
I \ S'T 0 0Y
/
/ H o Acetic acid 2-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethylsulfanylcarbonyl}-phenyl ester was synthesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13): 7.99 (d, 2H), 7.95 (d, 2H), 7.60 (t, IH), 7.30 (d, 2H), 7.12 (d, 2H), 7.09 (d, 2H), 4.47 (s, 2H), 2.37 (s, 3H); LC-MS
(ES+): 555 [MH] + m/e.
Example 7 O / ~ N\
4I~ ~ SN O
CF30 I~
4-Dimethylamino-thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl ester was synthesized according to the procedure described in the preparation of Example 4. 1H-NMR: (400 MHz, DMSO): 11.10 (s, 1H), 8.01 (d, 2H), 7.99 (d, 2H), 7.78 (d, 2H), 7.60 (d, 2H), 7.28 (d, 2H), 6.78 (d, 2H), 4.35 (s, 2H), 3.02 (s, 6H); LC-MS (ES+): 539 [MH]+ mle.
Example 8 sYo"
~S"N 0 Thiocarbonic acid 0-methyl ester S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13): 7.96 (d, 2H), 7,92 (d, 2H), 7.38 (d, 2H), 7.21 (d, 2H), 4.37 (s, 2H), 3.83 (s, 3H); LC-MS (ES+):
448 [MH]+ in/e.
Example 9 /I S ~N
\ \S/\N \
I H
CF3O" v Pyridine-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Picolinic acid (0.25 g, 2.04 mmol) was dissolved in anhydrous, degassed DCM (5 ml), HATU (775 mg, 2.04 mmol) was added followed by DIEA (0.53 g, 4.1 mmol). The mixture was stirred for 20 min and N-[4-(2-Mercapto-acetyl)-phenyl]-4-trifluoroinethoxy-benzenesulfonamide SII-4 (0.725 g, 1.85 mmol) was added in 5 ml anhydrous, degassed DCM and the mixture was stirred for 16 hours. The reaction was filtered and the solvent evaporated. The product was purified by flash chromatography (1:1 EtOAc:hexanes) to afford 125 mg (0.25 mmol, 14%) product as a white solid. 'H-NMR:
(400 MHz, DMSO): 11.12 (s, 1H), 8.89 (d, 1H), 8.03 (t, 1H), 8.01 (d, 2H), 8.00 (d, 2H), 7.90 (d, 1H), 7.78 (t, 1H), 7.60 (d, 2H), 7.14 (d, 2H), 4.60 (s, 2H); LC-MS (ES+):
497 [MH]} in/e.
Example 10 H
~S\N \ 0 I / H
Tert-Butoxycarbonylamino-thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound tert-Butoxycarbonylamino-thioacetic acid S- {2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylainino)-phenyl]-ethyl}ester was synthesized according to the procedures described in the preparation of Example 9. 1H-NMR: (400 MHz, CDC13): 7.94 (d, 2H), 7.88 (d, 2H), 7.31 (d, 2H), 7.21 (d, 2H), 5.24 (bs, 1H), 4.36 (s, 2H), 4.14 (s, 2H), 1.48 (s, 9H); LC-MS (ES-): 448 [MH]" - Boc m/e (major fragment, no parent ion observed).
Example 11 / H
Amino-thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylaniino)-phenyl]-ethyl} ester: N-Boc thioester from Example 12 (110 mg, 0.2 mmol) was dissolved in anhydrous DCM (1 ml) and TFA (1 ml) was added. The mixture was stirred for minutes and the volatiles removed in vacuo. Recrystallization from EtOAc-hexanes afforded 70 mg product (0.15 mmol, 75%) as an off white solid. 'H-NMR: (400 MHz, DMSO):
~~~ N
N N and the like.
[0025] The terms "aryl" or "aromatic" refer to a group which has at least one ring having a conjugated pi electron system, Aryl groups can be carbocylic aryl groups or heteroaryl groups. The term "carbocyclic aryl" refers to a group (e.g., phenyl) in which all ring backbone atoms are carbon. The terms "heteroaryl" or "heteroaromatic"
refer to an aryl (aromatic) group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. Aryl groups may be optionally substituted. Aryl groups may be monocyclic or polycyclic. Polycyclic aryl groups may be fused or linked. Polycyclic aryl groups can be fused or linked to aryl groups or cycloalkyl groups.
[0026] Examples of heteroaryl groups include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.
Polycyclic heteroaryl groups may be attached througll carbon ring backbone atoms, or may be attached througll ring backbone heteroatoms, especially N, depending on structure of the group. For instance, a group derived from pyrrole may be pyrrol-l-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be iinidazol-l-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C-attached). Polycyclic heteroaryl groups include benzo-fused ring systeins and ring systems substituted with one or two oxo (=0) moieties such as pyrrolidin-2-one.
[0027] Illustrative examples of heteroaryl groups include the following moieties:
N S N
>, OO( ~N// N
N CN CN
N\ / ~N N) N ~I~ N /N
N~ N
N ~,i S
a:), N' N' and the like.
[0028] The substituent "R" appea.ring by itself and without a number designation refers to a substituent selected from the group consisting of optionally substituted alkyl, including optionally substituted alkenyl or alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl (bonded through a ring carbon) and optionally substituted hetercycloalkyl (bonded through a ring carbon).
[0029] An "O-carboxy" group refers to a RC(=O)O- group, where R is as defined herein.
[0030] A "C-carboxy" group refers to a -C(=O)OR groups where R is as defined herein.
[0031] An "acyl" group refers to a -C(=O)R group.
[0032] An "acetyl" group refers to a-C(=O)CH3, group.
[0033] A"trihalomethanesulfonyl" group refers to a X3CS(=O)2- group where X
is a halogen.
[0034] A "cyano" group refers to a -CN group.
[0035] An "isocyanato" group refers to a -NCO group.
[0036] A "thiocyanato" group refers to a -CNS group.
[0037] An "isothiocyanato" group refers to a -NCS group.
[0038] A "sulfinyl" group refers to a-S(=O)-R group, with R as defined herein.
[0039] A"S-sulfonainido" group refers to a-S(=O)2NR, group, with R as defined herein.
[0040] A "N-sulfonamido" group refers to a RS(=O)2NH- group with R as defined herein.
[0041] A"trihaloinethanesulfonamido" group refers to a X3CS(=0)2NR- group with X and R as defined herein.
[0042] An "O-carbamyl" group refers to a -OC(=O)-NR, group-with R as defined herein.
[0043] An "N-carbamyl" group refers to a ROC(=O)NH- group, with R as defined herein.
[0044] An "O-thiocarbamyl" group refers to a -OC(=S)-NR, group with R as defined herein.
[0045] An "N-thiocarbamyl" group refers to an ROC(-S)NH- group, with R as defined herein.
[0046] A "C-amido" group refers to a -C(=O)-NR2 group with R as defined herein.
[0047] An "N-amido" group refers to a RC(=O)NH- group, with R as defined herein.
[0048] The term partially halogenated alkyl refers to an alkyl group having both hydrogen and halogen substituents, [0049] The term "perhaloalkyl" refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
[0050] The term "lower perfluoroalkoxy" refers to a radical -O-(CX2),iCX3 where X is any halogen, preferable F or Cl, and n is 1-5.
[0051] When two substituents taken together along with the two ring carbons to wl7ich they are attached form a ring, it is meant that the following structure:
is, for example, representative of a structure such as the following:
~
[0052] In the above exatnple, Rl and R2, taken together along with the two ring carbons to which they are attached, form a six-membered aroinatic ring.
Solubility is a thermodynamic parameter and plays an important role in the determination of a drug's bioavailability. Since a drug inust be soluble in the gastrointestinal fluid to be orally active, the rate and extent of dissolution depend critically upon intrinsic water solubility (neutral species solubility) ( Dressman, J.; Amindo, G. L.,;
Reppas, C.; Shah.
V. P. Pharm. Res., 1998, 15, 11.) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting have been described (Lipinski C. A. et al. 1997 Adv. Drug Deliv. Rev. 23, 3-25)Adv. Drug Deliv.
Rev. 23, 3-25 ).
Traditional analytical methods define solubility as the concentration of material in solution at equilibrium with its solid fonn. In this method a compound is extensively shaken in the buffer of choice, filtered through a micropore membrane, and the concentration of dissolved compound in the filtrate determined. This approach results in a thermodynamic solubility assessment. For discovery, it is beneficial to measure kinetic solubility in which a compound DMSO solution is added to aqueous buffer. Several high throughput approaches for solubility have been described, e.g. turbidimetric method (Bevan, C. and Lloyd, R. S. Anal.
Chem. 2000 72, 1781-1787), nephelometric method (Avdeef, A. (2001) High througllput measurements of solubility profiles. In Pharmacokinetic Optimization in D ug Research;
Biological, Physicochemical, And Computational Strategies (Testa, B. et al., eds), pp. 305-326, Verlag Helvitica Chimica Actaand). Measurement of solubility at multiple pH levels (pH 1-8), is more useful that a single pH, since many drug candidates contain ionizable groups. A solubility-pH profile provides the pH gradient of the gastrointestinal tract.
Accurate understanding of a compound's solubility is also necessary to not only prepare and dispense formulations, but also to evaluate new chemical series and provide feedback to drive synthetic optimization. Structural series of compounds are synthesized with the aim of iinproving solubility by the addition of various chemical moieties. Sti-uctural elements known to confer aqueous solubility on otherwise insoluble molecular entities include but are not limited to N-piperazinylethyl, N-morpholinylethyl, 1,3-dihydroxy-2N -propanoyl moieties. Common solubilizing groups often incorporated in synthetic approaches to improve solubility of molecules include ainine functionality, such as dimethylainino, diethylamino, piperazinyl, N-methyl-N-isopropylainino, morpholino, pyrrolidino moieties, or groups bearing aliphatic alcohol functionality, such as that found in ethanolamine or glycerol.
In certain einbodiments of the invention, a structural element known to confer aqueous solubility is incorporated in a compound of the invention. Such structural elements are preferably attached to synthetically accessible regions of the coinpound.
In certain einbodiments, such structural elements are attached to or incorporate synthetically available N atoms in amine or amide or sulfonamide moieties of the compound. In certain embodiments a solubilizing group is attached to or incorporates a N atom and is chosen from the group consisting of dimethylamino, diethylamino, piperazinyl, N-methyl-N-isopropylamino, morpholino, pyrrolidino moieties, or groups bearing aliphatic alcohol functionality, such as that found in ethanolamine or glycerol.
Compounds of the invention The invention provides compounds having structural fonnula (I), s G3"G2-G1 \G4 Rl R2 (I) or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof,wherein G1 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or G1 and R3 taken together form an optionallysubstituted heterocycloalkyl, G2 is an N-sulfonamide moiety having structure (II), an S-sulfonarnide moiety having structure (III), or an amide of the fonn -NR3C(O)- or -C(O)NR3-:
\\S/ S
"-R3 (II) R4 (III);
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, Rl and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen and perhaloalkyl, or Rl and R2 taken together form optionally substituted cycloalkyl, R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl, or a structural element known to confer aqueous solubility, including but not limited to N-piperazinylethyl, N-morpholinylethyl, or 1,3-dihydroxy-2N-propanoyl, or R3 and R4 taken togetller form an optionally substituted heterocycloalkyl, and G4 is chosen from the group consisting of optionally substituted acyl, wherein G4 taken in combination with sulfur forins a thioester, optionally substituted thiol, wherein G4 taken in combination with sulfur forms a disulfide, and structure (IV) P\ oR5 yO-R5 IV
wherein G4, taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate.
In certain embodiments of compounds having Structure (I) as described above, G1 is an optionally substituted phenyl having structure (IV) or (V):
X~ O X~ O
~\ S,G4 S, X2~ ;_ R1 R2 2 ~
G3-G2 (IV) X2 (V) wherein Xl and X2 are eacll independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
In certain elnbodiments, compounds have the structure of Forinula (1), wherein G1 is an optionally substituted phenyl having structure (IV) or (V) and G2 is N-sulfonainide moiety having structure (VI) or (VII);
X, O
S, X2~ G4 X O
R1 R2 ~~ S'G
\
O O, NR3 OO I/~ 4 G3 N R, R2 (VI) (VII) In certain embodiments, compounds have the structure of Formula (1), wherein Gz is an optionally substituted phenyl having structure (IV) or (V) and G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 comprises is an optionally substituted phenyl of structure (VIII) or (IX) X, O
X2 P-"' R \G4 O~, NR3 X / i X
3 l\ \ 5 X4 (VIII) X, O
S, SN , .\ R, R2 X4 X5 (IX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, liydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxanido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, halo alkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylainino, aminothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1), wherein GI is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), G3 comprises is an optionally substituted phenyl of structure (VIII) or (IX), and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in coinbination with sulfur, forms a phosphorothioate.
diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected froin hydrogen, halogen, hydroxyl, lower alkyl, lower perizaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular einbodiments include:
S~/
~~~~ ~ ~~/,0 II
S.H / 0 C'N 0 ~cr H
Me0 0S~ S 1 0 1 ~S~ SII
H H
Me0) / CIaCi ~ S\~-op R\ ip I j1 S.N 0 S.N / 0 I/ H I/ H
OO SY OO I~ SY
S. O F3C S' 0 H H
oso SY Oso icr"--- SY
j~ H Me0~~ H0 %\ ~
F
O
\ S'N ID,-~,SyQN
01 /0 Sy ~S~
N
~ / H
OSO HI~ SY OSO H/ Sy C O C
I
R"P SY 0\\,p S-Ir C SN~ 0 Me0 ~ S.N J(D
H I H
Ci \%
O O
OõO I\ SY O0 O sY
I\ S'H / 0 H 0 '\!/
F CI
O O
CI OSO J/ S0 F co OSO I/ S0 H I H
a,, SY S~
SO 0 ~S~
'N ~ O
H I / H
F
O O
\ S \ \ S~
OS~ O OSO I/ O
O S SY
SO 0 OSO I \ / CI 0 SY J&SyNH
S N r 0 OS~ / 0 H
F3CO ~ F3CO
O
R\ iP jqr"" S O Y
~oj:~ \ SN I/ H F O
O
~
pS. O H~ ~ 0 F3CO I)", O O
R'lp ~
S. H/ 0 O O
H~OMe S.H O
I/
O /
S ~~
OO
S.N 0 O~
H
O
1)", In certain embodiments, compounds have the structure of Formula (1), wherein Gt is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 comprises an 5 or, 6 membered heteroaromatic optionally substituted by X3, X4, X5, wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl; N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkeilyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxainido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylainino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aininoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl. In par-ticular embodiments, G3 is selected can be any of the following:
N-~
O~J N
N N H
HN N 1i S~i <\O J ~NN
N O
N~i ~N ~N~i N
N ININ N:NJ
H
N N . N
N N
N N % N-N, ri -N~ N N~ L//N N
N~
I rN N
~ J
In further embodiments, G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substiiuted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent known to confer aqueous solubility. Particular embodiments include:
O O
OO S,~r OO STr ~ O S SN O
O\N~ H N:C' H
O O
o~H 0 0S0 S0 N ' 0 ~ --~s N, N
H
O O
O \01 I\ I S 101 N \SHN N S' N
~ ,O
O HO O
Jo--~ 5\ S
O HN ~OI O\S/N
Cl- ~O N O
k,N N
O ~Nr O
\ / I S~ ~ S o/
O\ ~N \ O O\ ,N
a~l o I ~O
O HO
O
jo-,~ S1~ ~ ~ ~ S1~(~
OHN 0 O\N\ 0 ~ S
O O
N N
O
S S",/
~ O 101 ~ HN O IHN
\N II s S~ \O
\O
O'N
O p HN S-k" HN
O S,O N
~ ~ INI~N
N
/
~-N
/ O
41irs-k, N . N HN ~O 0 S~ O 0 , N"~ N /
In certain embodiments, compounds have the structure of Forinula (1), wherein G1 is an optionally substituted phenyl having structure (IV) or (V), G2 is N-sulfonamide moiety having structure (VI) or (VII), and G3 is an optionally substituted alkyl. In further embodiments, G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; R1 and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular embodiments include:
O
sy oSo \
H
O
S
OSO
\ S~
O O
,N
O O
O O
1 S0 ~~ ~
~S. N O N \ O
~' ~O ' ~-O
~ ~ II
HN \ S~ N
In certain einbodiments , compounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI) as shown below.
X, X2 X, 0 R4 \~/ R~ R2 Rq ri\ s\G4 G3 N~S~ S'G4 G" N,S~ % R~ R2 O~ ~0 3 /s ~
0 (X) 0 0 X2 (XI) In further embodiments, G3 is an optionally substituted phenyl of structure (XII) or (XIII) X, ~ 2 X, 0 R2 R4 S, R4 ' R, N~S S~G4 \ N~S" R1 R2 X3 00 0 X3 l' O 0 X2 /
X4 X5 (XII) X4 X5 (XIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylallcoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxainide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylainidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aininothiocarbonylamino, aminothiocarbonylaminoalkyl. In further embodiments, G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and XI and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent known to confer aqueous solubility. Particular embodiments include:
O
S
N\ Y
~ ~ oso O O
SY SY
OS O OS ~ ~ O
HN ~O I ~HN ~O
/
~
F
N"~s joj ~ ~HN ~p I ~p F ~ H3CO 0 0 S,,r )1tSOS O /s IOI
~ \ ' \O ~ \ NO
HO
OH
O\ p p\ 0 ~O \ HN~SO \ N SO
~O
O 0 Os Os ~ I
HN O O HN ~p O
~
O N
~ p p os ~ I S~ s I~ HN ~O O I~ HN ~O
O
CI ~ ~
Og g'~~ p ~
, ~
~?'**' N O 0 rz,~""THN O O
/
~ P 1 ~ cv-~
N,O O N N,SO O S
r S\ ~ r SY
O ~ O
NISO
HWSO CCF
F
SY Sy O O O~ O
\ HN'S10 \ HN'SO
~ r I .r CI
CI
SY r-Sy ~S O \ ~S \ ~ O
a H N I N
CI CI
CI
0, 0 0 HN
S O O F
p , ~ ~ o~ ~ I 0 NO S~ N.SO
F r r CI
HN'p HNO
O
CI C!
In certain embodiments wherein compounds have Structure (I) as described above, Gt is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonainide moiety having structure (X) or (XI), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, Xs as shown below:
N~
o~J N
N N H
<\O--~j' N -N HN N 5 N O
I N1~ ~N1~ ~N~i N
INI~ N,,~,- N NN
H
N
N ~ LS~ ~/ . / N ~//
N N /
N r N-N, ~ N N N N
wherein X3, X4 and X5 are each indepeildently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxainidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylainino, aminoalkyl, , dialkylaminoalkyl, aininoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylarnino, aminothiocarbonylaininoalkyl.
In certain embodiments of the compounds described in the preceding paragraph, wherein compounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, X5 as described in the preceding paragraph, G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid; Rl and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected fiom hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. Particular einbodiments include:
O O
O \ 0 O \ S~
N HN' N N~S\
O O
\ ~
HO Sj 0S O }~S \ I TO
N \ NHO N0 ' N N
O O
SY N io Sy ~ O ~O
I \ N \O N
Nr~
O O
HO
O\ SY ~~ )cr&sY0 ~S O
N r NH ~ ' N N~
~N
~ C' O
S'Ir S O HN
N~NH~O c O O
~
-N /
/ O ~ O
9\ ~
' ~ S
NISO S N NH S\
~O
/OD ~ 0 N %~ 0 \N N
/ I O HO a O
,5~ \ S.S~ S~
N~
HNN O O O
N- N(~
In certain embodiments wherein coinpounds have Structure (I) as described above, Gl is an optionally substituted phenyl having structure (IV) or (V),and G2 is S-sulfonamide moiety having structure (X) or (XI),G3 can be an optionally substituted alkyl.
In further embodiments, G4 can be an optionally substituted acyl of the formula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, foirns a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element kiiown to confer aqueous solubility. Particular embodiments include:
O ~ O
HO
/ SY -'N SY
~S I O z 0S O
N ~p N
O O
S~
0 S 0 O\ 0 N' ~HN'%
O
O O
--,,HN O O ~NO
O
In certain einbodiments of compounds having Structure (I) as described above, Gl is a or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV);
O
S, 5or6 G4 Membered R1 R2 Heteroaromatic ring X, (XIV) wherein Xi and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
In certain embodiments, coxnpounds have the structure of Fonnula (1) above, Gl is a 5 or 6 meinbered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), and G2 is a sulfonainide having an N-sulfonamide moiety of structure (XV) or an S-sulfonamide moeity of structure (XVI) O O
S, S~
5 or 6 G4 5 or 6 G4 Membered R, R2 Membered R, R2 Heteroaromatic Heteroaromatic 0~ 0 ring R4 ring N, X' (XV) X, (XVI) In certain einbodiments, coinpounds have the structure of Fonnula (1) above, G, is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonainide (XVI), and G3 is an optionally substituted phenyl of structure (XVII):
S, 5 or 6 G4 Membered R, R2 Heteroaromatic X 0 0 ring N
C ~ R3 X2 X, X4 X5 (XVII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylainino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylainino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyllaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkyltllio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
In certain einbodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), and G3 is an optionally substituted phenyl of structure (XVII), and X3, X4 and X5 are selected as described in the preceding paragraph, G4 can be an optionally substituted acyl of the formula -C(O)RE , wherein RE is any phalmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or --P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In these embodiments, G1 can be any of:
O1~
N NJ
H
~O J'' ~N N
N O \J ~
~Nl~ IIN~~' NNN N~
~ NJ N:N~
H
N .
N N ~J N
N N
N N N-N, N N N~ N N
Particular embodiments include:
O O
S S~,/ N~
0 HN~\N IOI ~\ HN O
O ~ \ O
~
O
HN~N 0 \ S O S
O~~ HN ~ 0 NI ~
0 0 ~ N O
~
H3CO N~
I
O O
O~ NS ~ O S S
~HN 1 101 O O
CI ~
O O
NS /S S
~\ ~N- ~N ~ O HN"\N K 0 I\ S,.o O I\ o ~
a In certain embodiments, coinpounds have the structure of Fonnula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), G2 is an N-sulfonainide moiety having structure (XV) or S-sulfonamide (XVI), and G3 can be a 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XVIII) S, or 6 G4 Membered R, R2 Heteroaromatic X3 O~ O ring S~N
X4 X5 (XVIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perllaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxainidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylalnino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylainino, aminocarbonylalkoxy, amino carbonylamino, aminothiocarbonylainino, or aminothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), and G3 is can be a 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XVIII), with X3, X4 and X5 selected as described in the preceding paragraph, G4 can be an optionally substituted acyl of the fonnula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in coinbination with sulfur, forins a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; R1 and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perlialoalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In these einbodiments, G3 can be :
/S' 01 N~ 'NJ H
</N N H N N, S~i N O ~
03- N " II N~/ ~N'' N
N NN NN
H
.
N ~ ~S~ N 'N N
N"N/ i N
N~
LN~ N N~ N
Particular embodiments include:
O
O N S"r S
~ HN~ I O ~ HN O
N N~ ~
O I N O
O O
O S~ S S~
QS~O N~N ~ 101 O SHN I , ~N ~ O:1 <\
O'N N
In certain embodiments, compounds have the structure of Formula (1) above, G1 is a 5 or 6 membered heteroaromatic optionally substituted by Xi, X2 of structure (XIV), and G2 is an N-sulfonamide moiety having structure (XV), wherein G3 comprises an optionally substituted alkyl.
S, 5or6 C'4 Membered R, R2 Heteroaromatic 0~ s~
3 ring G ~S1N
X1 (XV) In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV), G3 coinprises an optionally substituted alkyl, and G4 is an optionally substituted acyl of the forinula -C(O)RE , wherein RE
is any pharmaceutically acceptable acid, aii optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination witl7 sulfur, fonns a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and X, and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R3 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In certain einbodiments, Gl can be:
O/~'~
N N H
N N
''O J'~ \ N HN'i 5~--' N O
02' N ' I'N~~" IIN\~ NI' N,,,J N~N N, ~
N
H
N S~ N N
N N
LN,,- N N
N~
N N~
Particular embodiments include:
O N\ Sy SY
HN~ :~' ~~ HN 0 O N yg O
+ S S g~
ONN ~ N ~ 101 \O b In certain embodiments, compounds have the structure of Formula (1) above, G, is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonainide (XVI), and G3 is an optionally substituted phenyl of structure (XIX):
S, 5 or 6 04 Membered R, R2 Heteroaromatic R4 ring N, S
Xg X2 X4 X5 xI (XIX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxainido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylainino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylainino, alkylthio, arylainino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkyltllio, alkylsulfinyl, arylsulfinyl, diallcylamino, aininoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, aminothiocarbonylaminoalkyl.
In certain embodiments, coinpounds have the structure of Formula (1) above, Gl is a 5 or 6 meinbered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an N-sulfonamide moiety having structure (XV) or S-sulfonamide (XVI), G3 is an optionally substituted phenyl of structure (XIX) as described in the preceding paragraph, and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in combination with sulfur, fonns a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wlierein G4 taken in coinbination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or Rl and R2 taken together fonn optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In further embodiments, Gj can be:
S~
N Ni~ O~'~
N HN'N1-~
N O \--~j 021- N ~ IIN NNN N
N J NN
H
N-S, ~/N
N N
N N
LN~ ~ N
N N~
N N
(N
'~~~J
N~N/
Particular embodiments include:
O O
S S N S
O'S~\ ~ 0 O
HN~ ~O N 0 \ HN~SO
F~ /
~
OCH3 oS ~~ Sy 0\ O ~ Slir HN O ~ HN'SpJ'\\N 0 ~ i S
y S
-\~ ~'' HN \S' N 0 N, S\ 1 ~ S~
I \ O
CI ~ ~
0S-N I' o'S Sy N 'O O'N 0 a HN'SO N O
In certain embodiments, compounds have the structure of Formula (1) above, G1 is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is a S-sulfonamide (XVI), and G3 is a 5 or 6 membered optionally substituted heteroaromatic of structure (XVIII), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, XS of structure (XX) S, or 6 C'4 Membered RI R2 Heteroaromatic X3 R4 ring S
O~ ~\O X2 X~
X4 X5 (XX) wherein X3, X4 and X5 are each independently cl7osen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylainino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxainido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkyltliio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylainido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylainino, aininoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or arninothiocarbonylaminoalkyl.
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is a S-sulfonamide (XVI), and G3 is a 5 or 6 membered optionally substituted heteroaromatic of structure (XVIII), G3 can be a 5 or 6 meinbered heteroaromatic optionally substituted by X3, X4, X5 of structure (XX), and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 taken in coinbination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate;
R, and R2 are eacll independently hydrogen, lower alkyl or Rl and R2 taken together form optionally substituted cycloalkyl; and Xl and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility. In further einbodiments, Gl and G3 can each be independently selected from:
O~~J N
N N H
~O <N ~ HN
N O
C2J N ~ IINII N\/ N
N NN N;N~
H
S -S N-S, N
N N N N~ N
N r N-N, ~N NN~ LIJN N~
%/>
\N
Particular embodiments include:
O
N\ S O
' /
O o\S S S ~"
N~NH ~
O I~ N' ~O O
\,N N~
O O
S
O'S /S I O S /O I S~ 11 O N yN N N H~N O
~, ~ ~ o N C
In certain embodiments, compounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an S-sulfonamide (XVI), and G3 is an optionally substituted alkyl.
O
5 or 6 S\G4 Membered R, R2 Heteroaromatic R4 ring N, X, (XVI) In certain embodiments, coinpounds have the structure of Formula (1) above, Gl is a 5 or 6 membered heteroaromatic optionally substituted by Xl, X2 of structure (XIV), G2 is an S-sulfonamide (XVI), G3 is an optionally substituted alkyl, and G4 is an optionally substituted acyl of the formula -C(O)RE , wherein RE is any pharmaceutically acceptable acid, an optionally substituted alkylthiol, wherein G4 talcen in coinbination with sulfur, forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 talcen in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; Rl and R2 are each independently hydrogen, lower alkyl or RI and R2 taken together fonn optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy. R4 can be hydrogen, optionally substituted lower alkyl, or a structural eleinent loiown to confer aqueous solubility. In further embodiments, Gl can be:
p~~~
NJ N O~
H
~J ~N N HN S
N O
I N1~ N N N N ~N I~
~ INIJ ~ N.NJ
H
S NS, N
N N -N~ N
NN N'N, N N N N N~
(N
N-, N
Particular einbodiments include:
N S O
~ o~\ O \0~~ S~
N p p O
S
~S~S 0 lir ~\ ~S~O Dr S Il N N3 N' ~\ p N p In one einbodilnent, a compound having the structure of Fonnula (1), has the structure consisting of:
O
F3CO/ S~
~ ( ~NH 0 OSO
[0053] In another aspect, the invention relates to a compound selected from the goup consisting of the compounds set forth in the examples, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof:
Exemplary compounds and pharinaceutically acceptable esters or prodrugs thereof the invention include, but are not limited to, disulfide dimers, mercaptans, and thioesters of coinpounds of Formula (I).
Uses of compounds of the invention [0054] In accordance with one aspect, the present invention provides compounds of Formula (I), where each compound is capable of inhibiting the catalytic activity of histone deacetylase (HDAC). In another aspect, the present invention provides phannaceutical compositions comprising compounds of Formula (I), capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
[0055] In accordance with another aspect, the present invention provides compounds of Formula (I), capable of inhibiting the cellular function of HDAC.
In anotller aspect, the present invention provides phannaceutical compositions comprising compounds of Forlnula (I), capable of inhibiting the cellular function of histone deacetylase (HDAC).
[0056] In accordance with yet another aspect of the invention, the present invention provides methods and compositions for treating certain diseases or disease states.
Methods and compositions are provided for using compounds of the invention for treating diseases or disease states including, but not limited to, cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, and disorders in which angiogenesis play a role in pathogenesis, [0057] In accordance with one aspect, methods and compositions of the invention are used for treating cancer. In some embodiments, but without limitation, the tenn cancer refers to and is selected from disorders such as colon cancer, breast cancer, ovarian cancer, lung cancer and prostrate cancer, tumor invasion, tumor growth, tumor metastasis, and cancers of the oral cavity and pharynx (lip, tongue, mouth, pharynx), esophagus, stoinach, small intestine, large intestine, rectum, liver and biliary passages, pancreas, larynx, bone, connective tissue, skin, cervix uteri, corpus endornetriurn, testis, bladder, kidney and other urinary tissues, eye, brain and central nervous system, thyroid and endocrine gland. The term "cancer" also encompasses Hodgkin's disease, non-Hodgkin's lymphoinas, inultiple myeloma and hematopoietic malignancies including leukemias (Cluonlc Lymphocytic Leukeinia) and lymphomas including lymphocytic, granulocytic and monocytic.
Additional types of cancers which may be treated using the coinpounds and methods of the invention include, but are not limited to, adrenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, blastoglioma, chondrosarcoma, choriocarcinoma, chordoma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoina, endotheliosarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancers, glioblastoma multifonne, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, hepatoma, Kaposi's sarcoma, large cell carcinoma, cancer of the larynx, leiomyosarcoina, leukeinias, liposarcoma, lyinphatic system cancer, lymphomas, lyinphangiosarcoma, lymphangioendotheliosarcoma, medullary thyroid carcinoma, medulloblastoma, meningioma mesothelioma, myelomas, inyxosarcoma neuroblastoma, neurofibrosarcoina, oligodendroglioma, osteogenic sarcoma, epithelial ovarian cancer, papillary carcinoma, papillary adenocarcinomas, parathyroid tumours, pheochromocytoma, pinealoma, plasmacytomas, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancers, melanoma, small cell lung carcinoma, squainous cell carcinoma, sweat gland carcinoma, synovioma, thyroid cancer, uveal melanoma, and Wilm's tuinor.
[00581 In accordance with another aspect, methods and compositions of the invention are used for preventing neoplasias including, but not limited to, brain cancer, bone cancer, a leukemia, a lymphoma, epithelial cell-derived neoplasia (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophogeal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body. The neoplasia can be selected from gastrointestinal cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamous cell and basal cell cancers.
[0059] In accordance with another aspect, metllods and compositions of the invention are used for treating autoimmune diseases including, but not limited to:
autoimmune disease that targets the nervous system, e.g., inultiple sclerosis, myasthenia gravis, autoimmune neuropathies such as Guillain-Barre syndrome, autoimmune uveitis;
autoimmune disease that targets the gastrointestinal system, e.g., Crohn's disease, ulcerative colitis, primary biliary cirrhosis; autoimmune hepatitis; autoimmune disease that targets the blood, e.g., autoimmune heinolytic anemia, pernicious anemia, autoimmune thrombocytopenia; autoimmune disease that targets endocrine glands, e.g., Type 1 or immune-mediated diabetes mellitus, Grave's disease, Hashimoto's thyroiditis, autoimmune oophoritis and orchitis, autoimmune disease of the adrenal gland; autoimmune disease that targets blood vessels, e.g., temporal arteritis, anti-phospholipid syndrome, vasculitides such as Wegener's granulomatosis, Behcet's disease; autoimmune disease that targets multiple organs including the musculoskeletal systein, e.g., rheumatoid arthritis, scleroderma, polymyositis, dermatomyositis, spondyloarthropathies such as ankylosing spondylitis, Sjogren's syndrome; autoimmune disease that targets skin, e.g., psoriasis, dermatitis herpetiformis, pemphigus vulgaris, or vitiligo.
[0060] In accordance with another aspect, methods and compositions of the invention are used for treating disease states characterized by tissue damage, where the disease states include, but are not limited to, vascular diseases, inigraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheuinatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like.
[0061] In accordance with another aspect, methods and coinpositions of the invention are used for treating the fibrosis which occurs with radiation therapy.
[0062] In accordance with another aspect, methods and compositions of the invention are used for treating subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, the present coinpounds and methods can be used to prevent polyps from forming in patients at risk of FAP.
[0063] In accordance with another aspect, methods and compositions of the invention are used for treating anemias or thalassemias including, without limitation, sickle cell anemia.
[0064] In accordance with another aspect, methods and coinpositions of the invention are used for treating a cardiovascular condition, e.g., cardiac hypertrophy and heart failure.
[0065] In accordance with another aspect, methods and coinpositions of the invention are used for treating diseases related to an inflainmatory condition including, but not limited to, rheumatoid arthritis (RA), inflainmatory bowel disease (IBD), ulcerative colitis and psoriasis.
[0066] In accordance with another aspect, methods and compositions of the invention are used for treating certain central nervous system disorders including, but not limited to, Parkinson's disease, Alzheimer's disease, Alzheimer's dementia, and central nervous system damage resulting fiom stroke, ischeinia and trauma.
[0067] In accordance with another aspect, methods and compositions of the invention are used for treating a neurological or polyglutamine-repeat disorder including, but not limited to, Huntington's disease, Spinocerebellar ataxia 1(SCA 1), Machado-Joseph disease (MJD)/Spinocerebella ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyian atrophy (DRPLA).
[0068] In accordance with another aspect, methods and compositions of the invention are used for treating neurodegenerative disorders in which HDAC
iiihlbltlon is useful include nerve degeneration or nerve necrosis in disorders such as hypoxia, hypoglycemia, epilepsy, and in cases of central nervous system (CNS) trauma (such as spinal cord and head injury), hyperbaric oxygen convulsions and toxicity, dementia e.g. pre-senile dementia, and AIDS-related dementia, cachexia, Sydenham's chorea, Huntington's disease, Amyotrophic Lateral Sclerosis, Korsakoffs disease, imbecility relating to a cerebral vessel disorder, sleeping disorders, schizophrenia, depression, depression or other symptoins associated with Premenstrual Syndrome (PMS), anxiety and septic shock.
[0069] In accordance with another aspect, methods and compositions of the invention are used for treating bone diseases, including bone disorders involving osteoclasts and chonrocytes. Without wishing to be limited by this tlleory, it is noted that HDAC activity regulates the process of osteoclastogenesis and chondrocyte differentiation, such that inhibitors of HDAC are also useful in the treatment of all bone disorders involving osteoclasts and chondrocytes.
[0070] In accordance with another aspect, methods and coinpositions of the invention are used for treating ophthalmic diseases and other diseases in which angiogenesis plays a role in pathogeneis, such as glaucoma, retinal ganglion degeneration,occular ischemia, retinitis, retinopathies, uveitis, ocular photophobia, and of inflammation and pain associated with acute injury to the eye tissue.
[0071] Methods and compositions of the invention are used for treating human and non-huinan subjects. Methods and compositions of the invention are suitable for veterinary uses in treating companion animals, exotic animals and farm animals, including mammals, rodents, and the like. In particular embodiments, inethods and compositions of the invention are used for treating horses, dogs,and cats.
[0072] The terms "treat" or "treating" or "therapy" as used herein refer to (1) reducing the rate of progress of a disease, or, in case of cancer reducing the size of the tumor;
(2) inhibiting to some extent furtlier progress of the disease, which in case of cancer may mean slowing to some extent, or preferably stopping, tumor metastasis or tumor growth;
and/or, (3) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the disease. Thus, the term "therapeutically effective amount"
as used herein refers to that amount of the compound being administered which will provide therapy or affect treatment.
[0073J In accordance with certain aspects of the invention, the compounds of the present invention act as anti-tumor compounds and/or inhibit the growth of a tumor, i.e., they are tumor-growtll-iiiliibiting compounds. The tenns "anti-tumor" a.nd "tumor-growth-inhibiting," when modifying the term "coinpound," and the terms "inhibiting"
and "reducing", when modifying the terms "compound" and/or "tumor," mean that the presence of the subject compound is correlated with at least the slowing of the rate of growth of the tuinor. More preferably, the terms "anti-tumor," "tumor-growth-inhibiting,"
"inhibiting," and "reducing" refer to a correlation between the presence of the subject compound and at least the temporary cessation of tumor growtli. The terms "anti-tuinor," "tumor-growth-inhibiting," "inhibiting," and "reducing" also refer to, a correlation between the presence of the compound(s) of the invention and at least the temporary reduction in the mass of the tumor. It is understood that the effectiveness of compounds of the invention as anti-tumor, or tumor-inhibiting, agents may be contribute to their effectiveness in treating cancer, but that the compound of the invention may also act through other mechanisms to exert measured effects on cancer.
[0074] The term "cellular function" refers to the function of HDAC in the cell.
The term "HDAC function" is generally understood to refer to interaction of HDAC with a natural binding partner, and is particularly understood to refer to catalytic activity. The "cellular function" of HDAC is understood to refer not only to the catalyic activity of HDAC
in a cell, but also to the cellular effects of HDAC catalytic activity on the function of the cell.
The term "catalytic activity", in the context of the invention, defines the rate at wllich HDAC
deacetylates a substrate. Catalytic activity can be measured, for example, by determining the amount of a substrate converted to a product as a function of time.
Deacetylation of a substrate occurs at the active-site of HDAC. The active-site is normally a cavity in which the substrate binds to HDAC and is deacetylated.
[0075] The term "substrate" as used herein refers to a molecule deacetylated by HDAC. The substrate is preferably a peptide and more preferably a protein. In some embodiments, the protein is a histone, whereas in other embodiments, the protein is not a histone.
[0076] The term "inhibit" refers to decreasing the cellular function of HDAC.
It is understood that coarnpounds of the present invention may inhibit the cellular function of HDAC by various direct or indirect mechanisms, in particular by direct or indirect inhibition of the catalytic activityof HDAC. The term "activates" refers to increasing the cellular function of HDAC.
[0077] The tenn "modulates" refers to altering the function of HDAC by increasing or decreasing the probability that a complex forms between HDAC and a natural binding partner. A modulator may increase the probability that such a coinplex forms between HDAC and the natural binding partner, or may increase or decrease the probability that a complex forms between HDAC and the natural binding partner depending on the concentration of the compound exposed to HDAC, or may decrease the probability that a complex forms between HDAC and the natural binding partner. A modulator may activate the catalytic activity of HDAC, or may activate or inhibit the catalytic activity of HDAC
depending on the concentration of the compound exposed to HDAC, or may inhibit the catalytic activity of HDAC.
[0078] The term "complex" refers to an assembly of at least two molecules bound to one another. The term "natural binding partner" refers to polypeptides that bind to HDAC
in cells. A change in the interaction between HDAC and a natural binding partner can manifest itself as an increased or decreased probability that the interaction forms, or an increased or decreased concentration of HDAC/natural binding partner complex.
[0079] The term "contacting" as used herein refers to mixing a solution comprising a compound of the invention with a liquid medium bathing the cells of the methods. The solution comprising the compound may also comprise another component, such as dimethylsulfoxide (DMSO), which facilitates the uptake of the compound or compounds into the cells of the metllods. The solution comprising the compound of the invention may be added to the medium bathing the cells by utilizing a delivery apparatus, such as a pipet-based device or syringe-based device.
[0080] The term "monitoring" refers to observing the effect of adding the compound to the cells of the method. The effect can be manifested in a change in cell phenotype, cell proliferation, HDAC catalytic activity, substrate protein acetylation levels, gene expression changes, or in the interaction between HDAC and a natural binding partner.
[0081] The term "effect" describes a change or an absence of a change in cell phenotype or cell proliferation. "Effect" can also describe a change or an absence of a change in the catalytic activity of HDAC. "Effect" can also describe a change or an absence of a change in an interaction between HDAC and a natural binding partner.
[0082] The term "cell phenotype" refers to the outward appearance of a cell or tissue or the function of the cell or tissue. Examples of cell phenotype are cell size (reduction or enlargement), cell proliferation (increased or decreased numbers of cells), cell differentiation (a change or absence of a change in cell shape), cell survival, apoptosis (cell death), or the utilization of a metabolic nutrient (e.g., glucose uptake).
Changes or the absence of changes in cell phenotype are readily measured by techniques known in the art.
The present compounds are usefule for identifying a carbonyl coinpounds that modulates the cellular function of HDAC, comprising the steps of:
a) contacting cells expressing HDAC with the disclosed compounds of and b) measuring an effect of the coinpound or composition.
Optionally the effect is inhibition of the catalytic activity of HDAC. Further the inethods of coinprises measuring histone hyperacetylation. Additionally the effect is a change in cell phenotype and/or the effect is a change in cell proliferation.
Furtlier the disclosed compounds can be used for the manufacture of a medicainent for use in the treatment of a condition mediated by HDAC activity.
A. Pharmaceutical Compositions [0083] The present invention also relates to a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt, solvate, amide, ester, or prodrug thereof, as described herein. and a pharmaceutically acceptable carrier, diluent, or excipient, or a combination thereof.
[0084] The term "pharmaceutical coinposition" refers to a mixture of a coinpound of the invention with other chemical components, such as carriers, diluents or excipients.
The pharmaceutical composition facilitates administration of the compound to an organism.
Multiple techniques of adininistering a compound exist in the art including, but not limited to: intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
[0085] The term "carrier" refers to relatively nontoxic chemical compounds or agents. Such carriers may facilitate the incorporation of a coinpound into cells or tissues.
For exainple, hulnan serum albuinin (HSA) is a coinmonly utilized canier as it facilitates the uptake of many organic compounds into the cells or tissues of an organism.
[0086] The term "diluent" refers to chemical compounds that are used to dilute the compound of interest prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (providing pH control) are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline. It is a buffer found naturally in the blood systein, Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
[0087] The compounds described herein can be administered to a human patient per se, or in phartnaceutical coinpositions where they are mixed with other active ingredients, as in coinbination therapy, or suitable carriers or excipient(s). Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," 20th ed. Edited by Alfonso Gennaro, 2000.
1) Routes Of Administration [0088] Suitable routes of administration include local or systemic routes of administration including, but not limited to, topical, transdermal, oral, rectal, transinucosal, pulmonary, ophthalmic, intestinal, parenteral, intramuscular, subcutaneous, intravenous, intramedullary, intrathecal, direct intraventricular, iiitraperitoneal, intranasal, or intraocular delivery. In certain embodiments, compounds of the invention are adininistered topically, e,g in an ointment, patch, nasal spray, or eye drops/ointinent. In certain embodiments, compounds of the invention are delivered by intestinal, parenteral, intramuscular, subcutaneous, intravenous, intramedullary, intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
[0089] Alternately, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into an organ, often in a depot or sustained release formulation. Furthennore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with organ-specific antibody. The liposomes will be targeted to and taken up selectively by the organ.
2) Composition/Formulation [0090] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
[0091] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Phannaceutical Sciences, above.
[0092] For intravenous injections, the agents of the invention may be formulated in aqueous solutions, preferably in phannaceutically compatible buffers such as Hanlcs's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be perineated are used in the forinulation. Such penetrants are generally known in the art. For other parenteral injections, the agents of the invention may be fomlulated in aqueous or nonaqueous solutions, preferably with pharmaceutically compatible buffers or excipients. Such excipients are generally known in the art.
[0093] For oral administration, the compounds can be formulated readily by combining the active compounds with pharinaceutically acceptable carriers or excipients well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipient with one or more compound of the invention, optionally grinding the resulting mixture, and processing the niixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as: for exainple, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethyl cellulose; or others such as:
polyvinylpyrrolidone (PVP or povidone) or calciurn phosphate. If desired, disintegrating agents may be added, such as the cross-linked croscannellose sodium, polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
[0094] Dragee cores are provided witll suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or piginents may be added to the tablets or dragee coatings for identification or to characterize different combinations of active coinpound doses.
[0095] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All forinulations for oral adininistration should be in dosages suitable for such administration.
[0096] For buccal or sublingual administration, the coinpositions inay take the form of tablets, lozenges, or gels forinulated in conventional manner.
[0097] For administration by inhalation, the coinpounds for use according to the present invention are conveniently delivered in the fonn of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be fonnulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
[0098] The compounds may be forinulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage fonn, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such fonns as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain fornnulatory agents such as suspending, stabilizing and/or dispersing agents.
[0099] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble forni. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxyinethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
[00100] Alternatively, the active ingredient niay be in powder form for constitution wit11 a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[00101] The compounds may also be formulated in rectal coinpositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
[00102] In addition to the formulations described previously, the coinpounds may also be formulated as a depot preparation. Such long acting forinulations may be administered by iinplantation (for example subcutaneously or intrainuscularly) or by intrainuscular injection. Thus, for example, the coinpounds may be formulated with suitable polylneric or hydrophobic materials (for example as an einulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[00103] A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent systein may be a 10%
ethanol, 10%
polyethylene glycol 300, 10% polyethylene glycol 40 castor oil (PEG-40 castor oil) with 70%
aqueous solution. This cosolvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systeinic administration. Naturally, the proportions of a cosolvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the cosolvent components may be varied: for exainple, other low-toxicity nonpolar surfactants may be used instead of PEG-40 castor oil, the fraction size of polyethylene glycol 300 may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides maybe included in the aqueous solution.
[00104] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as N-inethylpyrrolidone also may be employed, although usually at the cost of greater toxicity.
Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
[00105] Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not liinited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free acid or base forms.
GENERAL SYNTHETIC METHODS FOR PREPARING COMPOUNDS
Molecular einbodiments of the present invention can be synthesized using standard synthetic techniques known to those of skill in the art. Compounds of the present invention can be synthesized using the general synthetic procedures set forth in Scheines I-III.
General procedure for sulfonamide (a): Scheme I
Q a ~~~~ Q
-Ir R35HN R45 0 R31 / S\ I NQ O
SI-I
b ~S\N a S~R3z ~ c Y.O~Q)r-~.-Br R31 ~ 1 ~ 0 R31 R
Reagents: (a) R31SO2CI, Et3N, THF; (b) PTT, THF; (c) KSCOR32, MeOH
General procedure for sulfonamide (b): Scheme II
Q
Rg4SO2Cl + \ ~ a R34/S\N / R~
\ ~ O
0 i b nN~ S O~~ / ~Br O
0 ( x- c /S\ \ (a R34'~ \N \ E Rs4 i ~ R35 d O
O O / ~ R3z \'e~ 0-'0y-SH e R jS~N 34 O R
I
Reagents: (a) pyridine, THF; (b) PTT, THF; (c) N-methyl 2-thiopyridone, EtOH;
(d) NaOH, water; (e) acid chloride, hunig's base, DCM
General Procedure for reverse sulfonamide :
Scheme III
a R34R33N\S ~ I Q
CI~S 0 SIII-1 O~ \O
b 0 S~R32 c Br y R34R33N YQ
\ \ \ \
$f li-3 SI I I-2 Reagents: (a) Amine (R34R33N), THF, pyr; (b) THF, PTT; (c) MeOH, KSC(O)R32 General Procedure for Ring-Fused Sulfonamides Scheme IV
pO 0 :Cr S"CI a N ~ S~ O
H
b O C
SY Br N 0 c SO f / \ O
(a) Pyridine, THF; (b) PTT, THF; (c) KSC(O)CH3, MeOH
Scheme V illustrates the general syntliesis of disulfide embodiments of the present invention.
Scheme V
Rt O R1 O
Rz /~ Br a RZ / S11 --~ I
Rs \ Re R3 ~ R 0 Ra R4 b Rl O
RZ ~ S
R3 ~ I R5 Ry Reagents: (a) KSC(O)CH3, MeOH; (b) NaOH, MeOH
Scheme VI depicts an alternative general scheme for the synthesis of thiol (mercaptan) and disulfide embodiments of the present invention Scheme VI
Ri 0 R, O
R2 a Rp / Br R3 I RS R. ~ I Rs Ry R2 = ~b ::i'ii"- c Rq d Ri 0 R3 ~ I R5 Rq Reagents: (a) PTT, THF; (b) N-methyl 2-thiopyridone, EtOH;
(c) NaOH, water; (d) MeOH, water.
EXAMPLES
[00106] The examples below are non-limiting and are merely representative of various aspects of the invention.
Example 1 o / S
\ ~s/~N \ ~ y F, CFsO I
Thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound tlliobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl}ester was synthesized according to Scheme I.
Step 1 \ ii S"N
\ H
I /
N-(4-Acetyl-phenyl)-4-trifluoromethoxy-benzenesulfonamide (SI-2): 4'-Amino acetophenone (0.375 g, 2.78 mmol) was dissolved in THF (5 ml) before pyridine (0.674 ml, 8.34 minol) was added, leaving a yellow solution. 4-trifluorometlioxy benzenesulfonylchloride (0.871 g, 3.34 minol) was then added dropwise with stirring. After strirring for 2h, THF and pyridine were removed. The desired sulfonamide (0.848 g, 2.36 minol, 85 %) was recrystallized from ethyl acetate and hexanes. 'H-NMR: (400 MHz, CDC13) 7.89 (m, 4H), 7.29 (d, IH), 7.16 (d, 2H), 6.88 (s, 1H), 2.55 (s, 3H).
LC-MS (ES+):
360 [MH]+ in/e.
Step 2 O
Br \ N
~
/ H
N-[4-(2-Bromo-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SI-3):
The ketone from stepl (0.32 g, 0.868 mmol) was dissolved in THF (9 ml), and phenyltrilnethylammonium tribromide (PTT) (0.368 g, 0.868 mmol) was added as a solid leaving an orange solution which began to deposit a white solid immediately.
Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (90% desired mono-brominated material by LC-MS, 5% starting inaterial, 5 % dibrominated) suitable for the next step. LC-MS
(ES-): 436, 43 8 m/e.
Step 3 o I
s \
v ~ \ \S~N 0 ~ H
Thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: oc-Bromoketone (SI-3) (0.3 g, 0.68 mmol) was dissolved in anliydrous THF (5 ml), and thiobenzoic acid (104 mg, 0.75 mmol) was added followed inunediately by potassium carbonate (104 rng, 0.75 mmol). The reaction was stirred for 2 hours. The THF
was evaporated and the residue was taken up in DCM and filtered. After evaporation of the DCM the product was purified by flash chromatography (7:3 EtOAC: hexanes).
Removal of the solvent afforded 57 mg product (0.11 mmols, 16%) as a white solid. 'H-NMR:
(400 MHz, DMSO): 8.00 (t, 3H), 7.98 (d, 2H), 7.61 (t, 2H), 7.50 (t, 2H), 7.32 (d, 2H), 7.22 (d, 2H), 4.52 (s, 2H); LC-MS (ES+): 496 [MH] + m/e.
Example 2 / S \ N
o Y
~N \ 0 I \
/ y Thionicotinic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Exainple 2 was synfihesized according to the procedure outlined in Example 1.
'H-NMR: (400 MHz, CDC13): 9.11 (s, 1H), 8.86 (d, 1H), 8.30 (d, 1H), 8,00 (d, 2H), 7.98 (d, 2H), 7.44 (t, 1H), 7.33 (d, 2H), 7.28 (d, 2H), 4.60 (s, 2H); LC-MS (ES+): 498 m/e.
Example 3 \V' lol / H
CF3O ~ \
Pentanethioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylainino)-phenyl]-ethyl} ester (SI-4) (0.5 g, 1.15 mmol) was dissolved in anhydrous DMF
(5 ml).
Lithium hydroxide (28 mg, 1.15 mmol) was added and the solution was sonicated until homogeneous and heated to 90 C for 4 hours, The solution was allowed to cool to room temperature and valeryl chloride (150 ing, 1.27 mmol) was added and the mixture stirred for 16 hours. The solution was partioned between 20 ml each water and EtOAc. The organic layer was washed with water, then brine and dried over Na2SO4. The solution was then filtered, stripped of solevent and the product purified by flash chromatography (100% DCM), The solvent was evaporated to afford 107 mg (0.22 mmol, 19%) product as a clear oil, 1H-NMR: (400 MHz, DMSO): 8.07 (d, 2H), 7.60 (d, 2H), 7.40 (d, 2H), 7.25 (d, 2H), 2.40 (s, 2H), 2.10 (t, 2H), 1.42 (t, 2H) 1,11 (t, 2H), 0.90 (t, 3H); LC-MS (ES+): 476 [M]+m/e.
Example 4 QLSO H
Furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester was synthesized according to Scheme II.
Step 1 \/
S~N
\ H
I
N-(4-Acetyl-phenyl)-4-trifluoromethoxy-benzenesulfonamide (SII-1): 4'-Amino acetophenone (0.375 g, 2.78 inmol) was dissolved in THF (5 ml) before pyridine (0.674 ml, 8.34 mmol) was added, leaving a yellow solution. 4-trifluoromethoxy benzenesulfonylehloride (0.871 g, 3.34 mmol) was then added dropwise with stirring. After removal of THF and pyridine, the desired sulfonamide (0.848 g, 2.36 mmol, 85 %) was recrystallized from ethyl acetate and hexanes. 1H-NMR: (400 MHz, CDCl3) 7.89 (m, 4H), 7.29 (d, 1H), 7.16 (d, 2H), 6.88 (s, 1H), 2.55 (s, 3H). LC-MS (ES+): 360 [MH]+m/e.
Sten 2 Br 0i I
S" N
I~ y N-[4-(2-Bromo-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SII-2):
The ketone from step 1(0.32 g, 0.868 nunol) was dissolved in THF (9 ml), and phenyltrimethylainmonium tribroinide (PTT) (0.368 g, 0.868 mmol) was added as a solid leaving an orange solution which began to deposit a white solid iinmediately.
Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (90% desired mono-brominated material by LC-MS, 5% starting material, 5 % dibrominated) suitable for the next step. LC-MS
(ES-): 436, 43 8 m/e.
Step 3 / s\ ~
N ~N'v/'1J
\ \S/~ H
I/ X' 1-Methyl-2-{2-oxo-2-[4-(4-trifluoromethoxybenzene- sulphonylamino) phenyl]ethylsulfanyl}-pyridinium bromide (SII-3): The bromoketone from step 2 (0.141 g crude material, 0.322 mmol) was dissolved in ethanol (2 ml) before N-methyl thiopyridone (0.040 g, 0.322 mmol) was added as a solid. The resulting yellow solution was then heated to reflux overnight. Evaporation of the volatiles leaves a residue (75 % by NMR, 0.116 g, 0.240 mmol) suitable for the next step, however, the product may be recrystallized from ethanol if desired. 'H-NMR: (400 MHz, DMSO-d6) 11.21 (s, 1H), 8.90 (d, IH), 8.18 (t, 1H), 8.03 (m, 5H), 7.90 (t, 1H), 7.80 (d, 2H), 7.15 (d, 2H), 5.33 (s, 2H), 4.24 (s, 3H). LC-MS (ES+): 483 [M]+ m/e.
Step 4 SH
\V/
I / H
S\N
N-[4-(2-Mercapto-acetyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide (SII-4):
SII-3 (4.35 g, 7,72 mmol) was suspended in water (1.7 1) before 2 M NaOH (7.25 ml) was added. Solid NaOH (1 g) was then added, and the resulting mixture was then heated to reflux overnight, producing a red solution. The solution was then acidified to a pH
of 1 and extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a red oil.
Throughout the work-up, the alpha-mercapto ketone readily oxidizes to the coiresponding disulfide, which was purified by preparative HPLC (0.582 g, 0.75 mmol, 10 %).
1H-NMR:
(400 MHz, DMSO-d6) 11.09 (bs, 2H), 7.97 (d, 4H), 7.85 (d, 4H), 7.57 (d, 4H), 7.22 (d, 4H), 4.29 (s, 4H). LC-MS (ES+): 781 [MH]+ m/e.
Step 5 I'~ y ~
H
Furan-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: To thiol SII-4 (0.5 g, 1.33 mmol) in 5 ml degassed anhydrous DCM (5 ml) was added 2-furoyl chloride (190 mg, 1.46 mmol) followed by DIEA (0.19 g, 1.46 mmol). The reaction was stirred for 4 hours and the solvent was evaporated.
The product was first purified by flash chromatography (4:6 EtOAc:hexanes), then recrystallized from EtOAc and finally triturated with DCM to afford 31 mg (0.064 mmol, 5%) product as a white solid. 'H-NMR: (400 MHz, CDC13): 8.00 (d, 2H), 7.94 (d, 2H), 7.64 (d, 1H), 7.35 (d, 2H), 7.29 (d, 1H), 7.22 (d, 2H), 6.60 (t, 1H), 4.50 (s, 2H); LC-MS (ES+): 486 [MH]+
m/e.
Example 5 o S
\ \8~N I 0 I / H
1-(4-Diethylamino-phenyl)-2-mercapto-ethanone was syntllesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13):
7.96 (d, 2H), 7.93 (d, 2H), 7.35 (d, 2H), 7.21 (d, 2H), 4.27 (s, 2H); LC-MS (ES+): 476 [MH]+ m/e, Example 6 s \
I \ S'T 0 0Y
/
/ H o Acetic acid 2-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethylsulfanylcarbonyl}-phenyl ester was synthesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13): 7.99 (d, 2H), 7.95 (d, 2H), 7.60 (t, IH), 7.30 (d, 2H), 7.12 (d, 2H), 7.09 (d, 2H), 4.47 (s, 2H), 2.37 (s, 3H); LC-MS
(ES+): 555 [MH] + m/e.
Example 7 O / ~ N\
4I~ ~ SN O
CF30 I~
4-Dimethylamino-thiobenzoic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl ester was synthesized according to the procedure described in the preparation of Example 4. 1H-NMR: (400 MHz, DMSO): 11.10 (s, 1H), 8.01 (d, 2H), 7.99 (d, 2H), 7.78 (d, 2H), 7.60 (d, 2H), 7.28 (d, 2H), 6.78 (d, 2H), 4.35 (s, 2H), 3.02 (s, 6H); LC-MS (ES+): 539 [MH]+ mle.
Example 8 sYo"
~S"N 0 Thiocarbonic acid 0-methyl ester S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedure described in the preparation of Example 4. 'H-NMR: (400 MHz, CDC13): 7.96 (d, 2H), 7,92 (d, 2H), 7.38 (d, 2H), 7.21 (d, 2H), 4.37 (s, 2H), 3.83 (s, 3H); LC-MS (ES+):
448 [MH]+ in/e.
Example 9 /I S ~N
\ \S/\N \
I H
CF3O" v Pyridine-2-carbothioic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: Picolinic acid (0.25 g, 2.04 mmol) was dissolved in anhydrous, degassed DCM (5 ml), HATU (775 mg, 2.04 mmol) was added followed by DIEA (0.53 g, 4.1 mmol). The mixture was stirred for 20 min and N-[4-(2-Mercapto-acetyl)-phenyl]-4-trifluoroinethoxy-benzenesulfonamide SII-4 (0.725 g, 1.85 mmol) was added in 5 ml anhydrous, degassed DCM and the mixture was stirred for 16 hours. The reaction was filtered and the solvent evaporated. The product was purified by flash chromatography (1:1 EtOAc:hexanes) to afford 125 mg (0.25 mmol, 14%) product as a white solid. 'H-NMR:
(400 MHz, DMSO): 11.12 (s, 1H), 8.89 (d, 1H), 8.03 (t, 1H), 8.01 (d, 2H), 8.00 (d, 2H), 7.90 (d, 1H), 7.78 (t, 1H), 7.60 (d, 2H), 7.14 (d, 2H), 4.60 (s, 2H); LC-MS (ES+):
497 [MH]} in/e.
Example 10 H
~S\N \ 0 I / H
Tert-Butoxycarbonylamino-thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester: The compound tert-Butoxycarbonylamino-thioacetic acid S- {2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylainino)-phenyl]-ethyl}ester was synthesized according to the procedures described in the preparation of Example 9. 1H-NMR: (400 MHz, CDC13): 7.94 (d, 2H), 7.88 (d, 2H), 7.31 (d, 2H), 7.21 (d, 2H), 5.24 (bs, 1H), 4.36 (s, 2H), 4.14 (s, 2H), 1.48 (s, 9H); LC-MS (ES-): 448 [MH]" - Boc m/e (major fragment, no parent ion observed).
Example 11 / H
Amino-thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylaniino)-phenyl]-ethyl} ester: N-Boc thioester from Example 12 (110 mg, 0.2 mmol) was dissolved in anhydrous DCM (1 ml) and TFA (1 ml) was added. The mixture was stirred for minutes and the volatiles removed in vacuo. Recrystallization from EtOAc-hexanes afforded 70 mg product (0.15 mmol, 75%) as an off white solid. 'H-NMR: (400 MHz, DMSO):
11.08 (bs, 1H), 8.00 (d, 2H), 7.99 (d, 2H), 7.60 (d, 2H), 7.14 (d, 2H), 4.61 (s, 2H), 4.21 (s, 2H);
LC-MS (ES+): 449 [MH]+ m/e.
Example 12 s~
\ \S\N ! / lOl Thioacetic acid S-(2-{4-[methyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]phenyl}-2-oxo-ethyl) ester: The compound thioacetic acid S-(2-{4-[methyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]phenyl}-2-oxo-ethyl) ester was synthesized according to the procedures described in the preparation of Example 1. 'H NMR: (400MHz, DMSO-d6) cS
8.00 (d, 2H), 7.63 (d, 2H), 7.60 (d, 2H), 7.38 (d, 2H), 4.50 (s, 2H), 3.10 (s, 3H), 2.40 (s, 3H);
LCMS (ES+): 448 [M]+ m/e.
Example 13 S/-~N 0 CF3 1O I / "L"
Thioacetic acid S-(2-{4-[isopropyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-phenyl}-2-oxo-ethyl) ester: The compound thioacetic acid S-(2- {4- [isopropyl-(4-trifluoromethoxy-benzenesulfonyl)-alnino]-phenyl}-2-oxo-ethyl) ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H
NMR: (400MHz, DMSO-d6) b 8.02 (d, 2H), 7.90 (d, 2H), 7.60 (d, 2H), 7.22 (d, 2H), 4.56 (s, 2H), 4.43 (m, 1H), 2.40 (s, 3H), 1.00 (d, 6H); LCMS (ES+): 476 [M]" m/e.
Example 14 \s/\ lol CF3~ - I / H
Thioacetic acid S-{2-[2-chloro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[2-chloro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H NMR: (400MHz, DMSO-d6) 611.10 (s, 1 H), 8.00 (d, 2H), 7.99 (d, 1 H), 7.60 (s, 1 H), 7.10 (d, 1 H), 4.3 5(s, 2H), 2.3 6(s, 3H); LCMS (ES+): 467 [M]+ in/e.
Example 15 s\ f \ S~\N ~o( CF3~ ~ / H F
O
Thioacetic acid S-{2-[3-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[3-fluoro-4-(4-trifluoroinethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H NMR: (400MHz, DMSO-d6) 8 10.94 (s, 1H), 7.98 (d, 2H), 7.81 (d, 2H), 7.60 (d, 2H), 7.49 (t, 1H), 4,42 (s, 2H), 2.39 (s, 3H);
LCMS (ES+): 452 [M] + m/e.
Example 16 oso \ I / s~
H
Thioacetic acid S-{2-oxo-2-[4-(toluene-4-sulfonylamino)-phenyl]-ethyl} ester:
The compound thioacetic acid S-{2-oxo-2-[4-(toluene-4-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR
(DMSO): 10.95 (s, 1H), 7.90 (d, 2H), 7.74 (d, 2H), 7.40 (d, 2H), 7.22 (d, 2H), 4.42 (s, 2H), 2.47 (s, 3H), 2.37 (s, 3H); LC-MS (ES+): 364 [MH]+ m/e.
Example 17 p/o~ s F3C \IS~N ~ I 0 H
Thioacetic acid S-{2-oxo-2-[4-(3-trifluoromethyl-benzenesulfonylamino)-phenyl]-ethyl}
ester: The compound thioacetic acid S-{2-oxo-2-[4-(3-trifluorornethyl-benzenesulfonylamino)-phenyl]-ethyl} ester was syntllesized according to the procedures described in the preparation of Exainple 1. 'H-NMR (DMSO): 11.12 (s, 1H), 8.10 (m, 3H), 7.88 (m, 3H), 7.26 (d, 2H), 4.43 (s, 2H), 2.37 (s, 3H); LC-MS (ES+): 418 [MH]+
in/e.
Example 18 S~l o N ol H
F
Thioacetic acid S-{2-[4-(4-fluoro-2-methyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester: The compound thioacetic acid S-{2-[4-(4-fluoro-2--methyl-enzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 11.16 (s, 1H), 8.08 (t, 1H), 7.90 (d, 2H), 7.31 (m, 2H), 7.19 (d, 2H), 4.42 (s, 2H), 2.62 (s, 3H), 2.37 (s, 3H); LC-MS (ES+):
382 [MH]+
m/e.
Example 19 0,I~
SrJ 0 H
\O I /
Thioacetic acid S-{2-[4-(4-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester:
The compound thioacetic acid S-{2-[4-(4-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 10.86 (s, 1H), 7.90 (d, 2H), 7.79 (d, 2H), 7.23 (d, 2H), 7.11 (d, 2H), 4.42 (s, 2H), 3.83 (s, 3H), 2.37 (s, 3H); LC-MS (ES+): 380 [MH] +
in/e.
Example 20 \ "r oSO s N
H
GI
Thioacetic acid S-{2-[4-(4-chloro-3-trifluoromethyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[4-(4-chloro-3-trifluoromethyl-benzenesulfonylarnino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. iH-NMR (DMSO):l 1.16 (s, 1H), 8.20 (s, 1H), 8.12 (t, 1H), 7.98 (m, 3H), 7.27 (d, 2H), 4.44 (s, 2H), 2.37 (s, 3H);
LC-MS (ES+):
452 [MH]+ m/e.
Example 21 o~~O
s ~N 0 y ' / H
/O
Thioacetic acid S-{2-[4-(3-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester:
The compound thioacetic acid S-{2-[4-(3-methoxy-benzenesulfonylainino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. IH-NMR (DMSO): 10.95 (s, 1H), 7.92 (d, 2H), 7.49 (t, 1H), 7.41 (d, 1H), 7.34 (s, 1H), 7.24 (m, 3H), 4.43 (s, 2H), 3.80 (s, 3H), 2.37 (s, 3H); LC-MS (ES+):
380 [MH]+ m/e.
Example 22 slir oNo , 0 N
H
Thioacetic acid S-[2-(4-ethanesulfonylamino-phenyl)-2-oxo-ethyl] ester: The compound thioacetic acid S-[2-(4-ethanesulfonylamino-phenyl)-2-oxo-ethyl] ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR
(DMSO):
10.91 (s, 1H), 8.00 (d, 2H), 7.30 (d, 2H), 4.47 (d, 2H), 3.23 (q, 2H), 2.39 (s, 3H), 1.21 (t, 3H);
LC-MS (ES+): 302 [MH]+ m/e.
Example 23 ~ / s~
~ \ ~ N 0 H
Thioacetic acid 2-[4-(3,5-dimethyl-benzenesulfonylamino)-phenyl)-2-oxo-ethyl ester:
The compound thioacetic acid 2-[4-(3,5-dimethyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 10.91 (s, 1H), 7.91 (d, 2H), 7.49 (s, 2H), 7.24 (d, 3H), 4.43 (s, 2H), 2.37 (s, 3H), 2.33 (s, 6H); LC-MS (ES+): 378 [MH]} in/e.
Example 24 s~
~~ N o ), H
I
Thioacetic acid S-{2-[4-(1,2-dimethyl-lH-imidazole-4-sulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[4-(1,2-diinethyl-lH-imidazole-sulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. iH-NMR (DMSO): 10.92 (s, 1H), 7.91 (d, 2H), 7.27 (d, 2H), 4.43 (s, 2H), 3.57 (s, 3H), 2.37 (s, 3H), 2.26, (s, 3H); LC-MS
(ES+): 368 [MH]+
m/e.
Example 25 , s ~
~s~ No H
/
Thioacetic acid S-{2-oxo-2-[4-(propane-2-sulfonylamino)-phenyl]-ethyl} ester:
The compound thioacetic acid S-{2-oxo-2-[4-(propane-2-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR
(DMSO): 10.38 (s, 1H), 8.00 (d, 2H), 7.36 (d, 2H), 4.47 (s, 2H), 2.39 (s, 3H), 1.25 (s, 7H);
LC-MS (ES+): 316 [MH]} m/e.
Example 26 slir O\ N 0 S' 'H
\0 CI qCI
N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-Dichlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-Dichlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. iH-NMR: (CDC13) 7.99(s, 1H), 7.92(d, 2H), 7.68(d, 1H), 7.56(d, IH), 4.34(s, 2H), 2.42(s, 3H); MS: (418.6) Example 27 SITr ~'iN
H
O1~
N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-bis-trifluoromethoxy-benzenesulfonamide The coinpound N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-bis-trifluoromethoxy-benzenesulfonamide was synthesized according to the procedures described in the preparation of Exaniple 1. 1H-NMR: (CDC13) 7.92(d, 2H), 7.51(d, 1 H), 7.31(s, 1 H), 7.21(d, 2H), 6.91(d, IH), 4.38(s, 2H), 2.42(s, 3H); MS: (409,8) Example 28 s"Ir o\ N \ ~ 0 I\ SoH
ci ~ ci N-[4-(2-Mercapto-acetyl)-phenyl]-2,4-Dichlorobenzene-sulfonamide The compound [4-(2-Mercapto-acetyl)-phenyl]-2,4-Dichlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. iH-NMR: (CDC13) 8.08(d, 1H), 7.91(d, 2H), 7.58(s, 1H), 7.41(d, 1H), 7.21(d, 2H), 4.32(s, 2H), 2.42(s, 3H);
MS: (418.6) Example 29 sY
SN~~ O
O
N-[4-(2-Mercapto-acetyl)-phenyl]-2-(3,5-Dimethylisoxazole)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-(3,5-Dimethylisoxazole)-sulfonainide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR:
(CDC13) 8.01(d, 2H), 7.21(d, 2H), 4.39(s, 2H), 2.63(s, 3H), 2.24(s, 3H), 2.20(s, 3H);
MS: (368.4) Example 30 s o N IQI
S S;
---X O
N-[4-(2-Mercapto-acetyl)-phenyl]-5-(2,4-Dimethyl-1,3-Thiazole)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-5-(2,4-Dimethyl-1,3-Thiazole)-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.24(d, 2H), 4.39(s, 2H), 2.68(s, 3H), 2.59(s, 3H), 2.42(s, 3H);
MS: (384.4) Example 31 sy 0, N ! / 0 N-[4-(2-Mercapto-acetyl)-phenyl]-3-(2,5-Dimethylfuran)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3-(2,5-Dimethylfuran)-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR:
(CDC13) 7.98(d, 2H), 7.41(s, 1H), 7.21(d, 2H), 4.39(s, 2H), 2.52(s, 3H), 2.44(s, 3H), 2.21(s, 3H); MS:
(368.6) Example 32 o N ~ / 0 s FF
F
N-[4-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethylbenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethylbenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. 'H-NMR: (CDC13) 8.21(d, 2H), 7.98(d, 2H), 7.78(d, 2H), 7.22(d, 2H), 4.39(s, 2H), 2.44(s, 3H);
MS: (418.5) Example 33 OS'N \ t O
I \ O
N-[4-(2-Mercapto-acetyl)-phenyl]-4-benzene-sulfonamide The coznpound N-[4-(2-Mercapto-acetyl)-phenyl]-4-benzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.88(d, 3H), 7.59(d, 2H), 7.47(d, 2H), 7.34(d, 2H), 4.29(s, 2H), 2.41(s, 3H); MS: (348.6) Example 34 o 0 s'N
F
N-[4-(2-Mercapto-acetyl)-phenyl]-4-Fluorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Fluorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exalnple 1. 1H-NMR: (CDC13) 7.91(d, 2H), 7.89(d, 2H), 7.22(d, 2H), 7.18(d, 2H), 4,38(s, (2H), 2.42(s, 3H); MS: (367.6) Example 35 s OSN \ !
\
I ~ o ~ F
N-[4-(2-Mercapto-acetyl)-phenylJ-2-Fluorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-Fluorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.98(d, 1H), 7.89(d, 2H), 7.61(t, 1H), 7.24(d, 2H), 7.22(d, 2H), 4.37(s, 2H), 2.41(s, 3H);
MS: (367.6) Example 36 s"r p 0 ' N \ I
s I ~ o Ci N-[4-(2-Mercapto-acetyl)-phenyl]-4-Chlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Chlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7,85(d, 2H), 7.78(d, 2H), 7.60(d, 2H), 7.40(d, 2H), 4.28(s, 2H), 2.41(s, 3H); MS: (384.1) Example 37 slir O O
\N pso CI
N-[4-(2-Mercapto-acetyl)-phenyl]-3-Chlorobenzene-sulfonamide The coinpound N-[4-(2-Mercapto-acetyl)-phenyl]-3-Chlorobenzene-sulfonaznide was synthesized according to the procedures described in the preparation of Example 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.90(s, 1 H), 7.78(d, 1 H), 7.60(d, 114), 7.46(t, 1 H), 7.21(d, 2H), 4.38(s, 2H), 2.41(s, 3H); MS:
(384.1) Example 38 s"r cC0 N-[4-(2-Mercapto-acetyl)-phenyl]-2-Chlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-Chlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. 1H-NMR: (CDC13) 8.18(d, 1H), 7.90(d, 2H), 7.58(d, 2H), 7.43(d, 1H), 7.22(d, 2H), 4.38(s, 2H), 2.42(s, 3H);
MS: (384.1) Example 39 os N g/\
F \~O
]F' N-[3-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide The compound N-[3-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonainide was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 7.90(d, 2H), 7.82(d, 1H), 7.65(s, 1H), 7.44(d, 2H), 7.37(d, 1H), 7.24(d, 1H), 4.39(s, 2H), 2.43(s, 3H); MS: (433.2) Example 40 0 ,N ~
~ S~ O
FF O I /
t F O~
N-[2-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide The compound N-[2-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 7.91(d, 2H), 7.82(d, 1H), 7.79(t, 1H), 7.58(dd, 1H), 7.24(d, 2H), 7,19(d, 1H), 4.39(s, 2H), 2.42(s, 3H); MS: (433.2) Example 41 sY
OS'N 0 O
O
F
F F
1V-[4-(2-Mercpto-acetyl)-phenylJ-3-Trifluoromethoxybenzene-sulfonamide The compound .N-[4-(2-Mercpto-acetyl)-phenyl]-3-Trifluoromethoxybenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.96(d, 2H), 7.81(d, 1 H), 7.72(s, 1 H), 7.59(dd, 1H), 7.43(d, 1 H), 7.21(d, 2H), 4.38(s, 2H), 2.41(s, 3H); MS: (433.2) Example 42 s4 ~
s, ~~N N
F ~ S
F~O I / O
F
Thioacetic acid-S-{2-[2-(3,4-Di-Trifluoromethoxy-benzenesulfonylamino)-4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester The compound thioacetic acid-S-{2-[2-(3,4-Di-Trifluoromethoxy-benzenesulfonylamino)-4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 8.01(d, 2H), 7.25(d, 2H), 2.60(s, 3H), 2.41(s, 3H); MS: (454.8) Example 43 s ~
Q~N N
~ S
~
CI ~
CI
Thioacetic acid-S-{2-[2-(3,4-Dichlorobenzenesulfonylamino)- 4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester The compound thioacetic acid-S-{2-[2-(3,4-Dichlorobenzenesulfonylamino)- 4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR:
(CDC13) 8.00(s, 1H), 7.79(d, 1H), 7.49(d, 1H), 4.02(s, 2H), 2.58(s, 3H), 2.41(s, 3H);
MS: (439.6) Example 45 i S 11 CF3'O O
p a~:"
N\S
Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl]-ethyl}
ester:
Step 1 H I \
// \\
~\ /
CF311 o 0 0 4-Acetyl-N-(4-trifluoromethoxy-phenyl)-benzenesulfonamide: 4-Trifluoromethoxy aniline (3.4 g, 19.21 minol)was dissolved in THF (25 ml) before pyridine (4.44 ml, 54.88 mmol) was added. 4-Acetyl-benzenesulfonyl chloride (4.0 g, 18.29 mmol) was then added as a solid, and the resulting dark solution was stirred for 10 minutes. The volatiles were then removed, and the resulting residue was suspended in THF. Excess Et3N was then added, and the mixture was stirred for several minutes before the solids were filtered.
The mother liquor was then evaporated to a solid which was purified by flash chroinatography (EtOAc/hexanes) to yield the desired compound as a white solid. (5.5 g(15.31 mmol, 84 %).
Step 2 Br CFa~O 0 0 /\ all, N\S
4-(2-Bromo-acetyl)-N-(4-trifluoromethoxy-phenyl)-benzenesulfonamide: The bromoketone intermediate was synthesized according to the procedures described in the preparation of Example 44 Step 2.
~ I \
// \\
CF3~0 ~ O O
~N\S 0 Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl)-ethyl}
ester: The desired compound was synthesized according to the procedures described in the preparation of Example 44 step 3. 1H NMR: (400MHz, DMSO): 10.74 (s, 1H), 8.08 (d, 2H), 7.92 (d, 2H), 7.23 (d, 2H), 7.20 (d, 2H), 4.57 (s, 2H), 2.38 (s, 3H); LC-MS
(ES+): 360 [MH]+
m/e.
Example 46 s"r O N \ I 0 9"s, O
F
N- [4-(2-Mercapto-acetyl)-phenyl)-3-Fluorobenzene-sulfonamide:
The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3-Fluorobenzene-sulfonainide was synthesized according to the procedures described in the preparation of Exatnple 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.68(d, 1H), 7.60(d, 1H), 7.51(dd, 1H), 7.22 (d, 2H), 4.38(s, 2H), 2.41(s, 3H); LC-MS (ES+): 367.6 [MH]+ m/e Example 47 O
/ ~ S1, I SH F O
O :
Thioacetic acid S-{2-[2-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester The coinpound thioacetic acid S-{2-[2-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. , 1H-NMR (DMSO): 11.37 (bs, 1H), 8.02 (dd, 2H), 7.79 (t, 1H), 7.61 (d, 2H), 7.06 (m, 2H), 4.33 (d, 2H), 2,35 (s, 3H). LC-MS
(ES+): 452 [MH]+ m/e.
Example 48 O
~ S
~ y N i 0-0 S
O
O
Thioacetic acid S-[2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester The compound thioacetic acid S; [2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester was synthesized according to Scheme IV.
Step 1 O
CO
S
O
1-(1-Senzenesutfonyl-2,3-dihydro-lH-indol-5-yl)-ethanone 1-(2,3-Dihydro-lH-indol-5-yl)-ethanone (0.200 g, 1.24 mmol) was dissolved in THF (2 inl) before pyridine (0.303 ml, 3.75 mmol) was added, leaving a yellow solution.
The benzenesulfonyl chloride (0.220 g, 1.24 mmol) was then added, as a solid, with stirring. The reaction mixture was stirred at 40 C for 5h. The mixture was cooled and the THF and pyridine were reinoved in vacuo. The desired sulfonamide (0.310 g, 1.02 mmol, 82 %) was recrystallized from ethyl acetate and hexanes. It had LC-MS (ES+): 302 [MH] +
in/e Step 2 O
Br N CO--'~ ~ \~ S~O
.,. O
1-(1-Benzenesulfonyl-2,3-dihydro-IH-indol-5-yl)-2-bromo-ethanone: The ketone from step 1(0.310 g, 1.02 mmol) was dissolved in THF (3 ml), and phenyltrimethylammonium tribromide (PTT) (0.386 g, 1.02 mmol) was added as a solid leaving an orange solution which began to deposit a white solid iinmediately. Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (85% desired mono-brominated material by LC-MS, 5% starting material, 10% dibrominated) suitable for the next step. LC-MS (ES+): 381, 379 m/e.
Step 3 O
Sllr N I O
~'0 Thioacetic acid S-[2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester The mono-brominated sulfonamide from step 2(0.194 g, 0.509 mmol) was was dissolved in methanol (2 ml) before potassiuin thioacetate (0.0639 g, 0.560 minol) was added as a solid.
LC-MS of the resulting yellow solution shows the reaction is coinplete in minutes.
Evaporation of the volatiles leaves a tan residue which was taken up into dichloroinethane (4 ml), during which the disulfide of the thioacetic acid was deposited and filtered. The desired thioester could then be recrystallized fioin dichloroinethane/hexanes (0.080 g, 0.214 mmol, 42%). LC-MS (ES+): 376 [MH]+ m/e. 1H-NMR (DMSO): 7.87 (d, 3H), 7.78 (s, 1H), 7.7 (m, 1H), 7.57 (m, 3H), 4.41 (s, 2H), 3.99 (t, 2H), 3.06 (t, 2H), 2.34 (s, 3H) Example 49 O
~
~N
/ \, So0 Thioacetic acid S-[2-(1-benzenesulfonyl-lH-indol-5-yl)-2-oxo-ethyl] ester The compound thioacetic acid S-[2-(1-benzenesulfonyl-lH-indol-5-yl)-2-oxo-ethyl] ester was synthesized according to the procedures described in the preparation of Example 48.
1H-NMR (CDC13): 8.22 (d, 1H), 8.07 (m, 1H), 7.98 (m, 1H), 7.90 (m, 2H), 7.66 (d, 1H), 7.57 (m, IH), 7.47 (m, 2H), 6.76 (m, 1H), 4.42 (s, 2H), 2.40 (s, 3H). LC-MS (ES+):
374 [MH]+
m/e Example 50 / sY
N
SNH
\
Thioacetic acid S-{2-[6-(3-methoxy-benzenesulfonylamino)-pyridin-3-yl]-2-oxo-ethyl}ester The compound thioacetic acid S-{2-[6-(3-methoxy-benzenesulfonylamino)-pyridin-3-yl]-2-oxo-ethyl}ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H-NMR: (CDC13) 8.91(s, 1 H), 8.21(d, IH), 7.51(d, 1 H), 7.44(d, 1H), 7.42(d, 1H), 7.38(s, 1H), 7,09(d, 1H), 4.21(s, 2H), 3.82(s, 3H), 2.41(s, 3H) ppm. MS:
(380.05) Example 51 O
s N S
~N~
~
I H
/
Thioacetic acid S-{2-oxo-2-[4-(pyridine-2-sulfonylamino)-phenyl]-ethyl} ester The coinpound Thioacetic acid S-{2-oxo-2-[4-(pyridine-2-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR (DMSO): 11.19 (bs, 1H), 8.71 (d, 1H), 8.10 (in, 2H), 7.89 (d, 2H), 7.67 (m, 1H), 7.28 (d, 2H), 4.41 (s, 2H), 2.36 (s, 3H). LC-MS (ES+): 351 [MH]+ m/e.
Example 52 O
A~y \%
a~~ SN O
H
Thioacetic acid S-{2-oxo-2-[4-(pyridine-3-sulfonylamino)-phenyl]-ethyl} ester The compound Thioacetic acid S-{2-oxo-2-[4-(pyridine-3-sulfonylainino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Exainple 1 tH-NMR (DMSO): 11.16 (bs, 1H), 8.99 (d, 1H), 8.81 (dd, 1H), 8.23 (in, 1H), 7.92 (d, 2H), 7.64 (dd, 1H), 7.26 (d, 2H), 4.42 (s, 2H), 2.36 (s, 3H). LC-MS (ES+): 351 [MH]+
m/e.
Example 53 O
y DO S
N O
N
~ S~O
Thioacetic acid S-{2-oxo-2-[1-(pyridine-2-sulfonyl)-2,3-dihydro-lH-indol-5-yl]-ethyl}
ester The coinpound thioacetic acid S-{2-oxo-2-[1-(pyridine-2-sulfonyl)-2,3-dihydro-lH-indol-5-yl]-ethyl} was synthesized according to the procedures described in the preparation of Example 48. 1H-NMR (DMSO): 8.67 (m, IH), 8.11 (m, 2H), 7.82 (m, 2H), 7.50 (m, 1H), 7.43 (d, 1H), 4.42 (s, 2H), 4.23 (t, 2H), 3.15 (t, 2H), 2.36 (s, 3H). LC-MS
(ES+): 377 [MH]+
m/e.
Example 54 O
O / S~PHOH
o .i1 I 11 ~S. ~ O
F3C\ ~ / H
O
Thiophosphoric acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester The compouiid from Example 1, Step 2 (0.200 g, 0.461 mmol) was dissolved in methyl alcohol (3 mL). Na3SPO3 (0.091 g, 0,508 mmol) was added as a solid, fornning a heterogeneous suspension. The suspension was stirred at room temperature.
After 1.5 hours a white precipitate was present. This precipitate was filtered and found to be the undesired disulfide of the starting sulfonainide. The methyl alcohol was then removed and dichloromethane was added to the crude reaction mixture. A white solid precipitated out of the dichloromethane solution which was collected by filtration. The solid was further purified by mass triggered HPLC to give the desired compound (0.050 g, 0.106 mmol, 23%). 'H-NMR (DMSO): 11.06 (s, 1H), 7.98 (in, 2H), 7.88 (in, 2H), 7.59 (d, 2H), 7.23 (m, 2H), 4.16 (d, 2H). LC-MS (ES+): 471 [MH]+ m/e.
The following compounds can be made using the methods as described above and when made should have similar activity as those made above.
G3 ~eGZ'G~S\G4 , wherein Gl is selected from the following:
H
N N
ol ~ N N s N~ N
I H NJ N
v ~ > > > > >
N1 N~ N
N" ~ N
vN N" N N~N and N
> > > > >
G2 is selected from the following:
N'U"I AN i rS.N N, R3 R3 ~ R3 and R4 G3 is selected from the following:
H
Ol NJ NJ H N N~\
> > > , I ~ > > >
N rN N
~ , N NN N~N N,NJ
and and G4 is selected from the following:
-Yk ~ .~ o\ .~
YO ~
~ o 0 ~ 0 0 / I
o' yo / \
O O A N N A \\
)r 0 0 ~ 0 0 s~s X
0~ +N\ S' X
~
~ 0 , , , , , S OH ~\g NHz ~\S NH2 S H
//~ ~ ~ "*,r N I I
OH CO2H COZMe CO2H 0 ~ ~ > >
,S\S H
S' N
CO2MeO -P(O)(OH)2 , and Additionally, the following compounds can be made using the methods as described above.
iGz, ,~is~
~3 ~~ G4, wherein GI is selected from the following:
l/ ~ I ~ I (J3 / I N\N ~ I NN
and G2 is selected from the following:
and G3 is selected from the following:
'~'J 0 0 NN S N1 N
olNJ N J O~~ H N~r N,J\ JJ N
> > > > > > > > > >
CN~ y N N
NI-~ N , N N and N.NJ
and G4 is selected from the following:
~ i~ N
.~ \
y Y**"~~ .~' \
O O O O O O
~
.~ \~ yo i Y(N o O 0~ s~ \ N / I / \~
O O O O O
~ N~ N~ ~ OH ~ OH
0 ~I ~ ~ ~1 54S-~, S / OH '\g~NH2 ,~\S~NHz S~ N
~
OH CO2H CO2Me CO2H 0 H
\S~N~ P O OH
COzMeO , aud -~ ~~ )2 The prophetic examples disclosed herein may optionally be substituted as described above.
The activity of the above mentioned compounds as HDAC inhibitors has generally been shown by the following assays. The other compounds listed above, which may not yet been made or tested, are predicted to generally have activity in these assays as well.
Inhibition Assays:
In vits o HDAC-inhibition Assay:
[00107] This assay measures a compound's ability to inhibit acetyl-lysine deacetylation in vitro and was used as both a primary screening method as well as for IC5o detenninations of confirmed inhibitors. The assay is performed in vitro using an HDAC
enzyme source (e.g. partially purified nuclear extract or iinmunopurified HDAC
complexes) and a proprietary fluorescent substrate/developer system (HDAC Quantizyine Fluor de Lys Fluorescent Activity Assay, BIOMOL). The assay is run in 1,536-well Greiner white-bottom plates using the following volumes and order of addition:
Step 1: Enzyme (2.5 ul) source added to plate (from refrigerated container) Step 2: Compounds (50 nl) added with pin transfer device Step 3: Fluor de Lys (2.5 ul) substrate added, incubate at RT, 30 minutes Step 4: Developer (5 ul) solution is added (containing TSA), to stop reaction Step 5: Plate Reader - data collection The deacetylated fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on an automated fluorometric plate reader (Aquest, Molecular Devices).
Cellular Histone Hyperacetylation Assays:
[001081 These two secondary assays evaluates a compound's ability to iiihibit HDAC in cells by ineasuring cellular histone acetylation levels. The cytoblot facilitates quantitative EC50 information for cellular HDAC inhibition. Transformed cell lines (e.g.
HeLa, A549, MCF-7) are cultured under standard inedia and culture conditions prior to plating.
For Cytoblot:
[001091 Cells (approx. 2,500/well) are allowed to adhere 10-24 hours to wells of a 384-well Greiner PS assay plate in media containing 1-5% serum. Cells are treated with appropriate cornpound and specific concentrations for 0 to 24 hours. Cells are washed once with PBS (60 ul) and then fixed (95% ethanol, 5% acetic acid or 2% PFA) for 1 ininute at RT
(30 ul). Cells are blocked with 1% BSA for 1 hour and washed and stained witll antibody (e.g. anti-Acetylated Histone H3, Upstate Biotechnology), followed by washing and incubation with an appropriate secondary antibody conjugated to HRP or fluorophore. For luminescence assays, signal is generated using Luminol substrate (Santa Cruz Biotechnology) and detected using an Aquest plate reader (Molecular Devices).
For Iinmunoblot:
[00110J Cells (4 x 105/well) are plated into Conling 6-well dish and allowed to adhere overnight. Cells are treated with compound at appropriate concentration for 12-18 hours at 37 degrees. Cells are washed with PBS on ice. Cells are dislodged with rubber policeman and lysed in buffer containing 25 mM Tris, pH7.6; 150 mM NaC1, 25 mM
MgC12, 1% Tween-20, and nuclei collected by centriguation (7500g). Nuclei are washed once in 25 mM Tris, pH7.6; 10 mM EDTA, collected by centrifugation (7500g). Supematant is removed and histones are extracted using 0.4 M HCl. Samples are centrifuged at 14000g and supernatants are precipitated in 1 ml cold acetone. The histone pellet is dissolved in water and histones are separated and analyzed by SDS-PAGE Coomassie and immunobloting (anti-acetylated histone antibodies, Upstate Biotechnology) using standard techniques.
Differential Cytotoxicity AssU:
[00111] HDAC inhibitors display differential cytotoxicity toward certain transformed cell lines. Cells are cultured according to standard ATCC
recommended conditions that are appropriate to each cell type. Compounds were tested for their ability to kill different cell types (normal and transformed) using the ATPlite luminescence ATP
detection assay system (Perkin Elmer). Assays are run in either 384-well or 1536-well Greiner PS plates. Cells (30 ul or 5 ul, respectively) are dispensed using either rnultichannel pipette for 384-well plates, or proprietary Kalypsys bulk liquid dispenser for 1536-well plates.
Compounds added using proprietary pin-transfer device (500 nL or 5 nL) and incubated 5 to 30 hours prior to analysis. Luminescence is measured using Aquest plate reader (Molecular Devices).
[00112] The activity of some of the coinpounds of the invention are shown in Table 1, below. Syntllesis of each compound is described in the Exainple listed in the left column.
Table 1 Example COMPOUND In vitro IC50 Cellular IC50 No. ( M) ( M) 02 O s 'H <1 <10 \
H
04 0 <1 % S \
, S
F3C_ 1/
06 S <1 <1 F3C- ~ H 0 07 ~ <1 <10 ~i ~~s ~ N
H
, <10 <1 09 <1 <1 .~~P
S~N O
F,C_p ~ H
00 <1 ry p FaC~~ r H
-,-S <1 \ ~5 O \ I --~-NHz F3Cy H
LC-MS (ES+): 449 [MH]+ m/e.
Example 12 s~
\ \S\N ! / lOl Thioacetic acid S-(2-{4-[methyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]phenyl}-2-oxo-ethyl) ester: The compound thioacetic acid S-(2-{4-[methyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]phenyl}-2-oxo-ethyl) ester was synthesized according to the procedures described in the preparation of Example 1. 'H NMR: (400MHz, DMSO-d6) cS
8.00 (d, 2H), 7.63 (d, 2H), 7.60 (d, 2H), 7.38 (d, 2H), 4.50 (s, 2H), 3.10 (s, 3H), 2.40 (s, 3H);
LCMS (ES+): 448 [M]+ m/e.
Example 13 S/-~N 0 CF3 1O I / "L"
Thioacetic acid S-(2-{4-[isopropyl-(4-trifluoromethoxy-benzenesulfonyl)-amino]-phenyl}-2-oxo-ethyl) ester: The compound thioacetic acid S-(2- {4- [isopropyl-(4-trifluoromethoxy-benzenesulfonyl)-alnino]-phenyl}-2-oxo-ethyl) ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H
NMR: (400MHz, DMSO-d6) b 8.02 (d, 2H), 7.90 (d, 2H), 7.60 (d, 2H), 7.22 (d, 2H), 4.56 (s, 2H), 4.43 (m, 1H), 2.40 (s, 3H), 1.00 (d, 6H); LCMS (ES+): 476 [M]" m/e.
Example 14 \s/\ lol CF3~ - I / H
Thioacetic acid S-{2-[2-chloro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[2-chloro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H NMR: (400MHz, DMSO-d6) 611.10 (s, 1 H), 8.00 (d, 2H), 7.99 (d, 1 H), 7.60 (s, 1 H), 7.10 (d, 1 H), 4.3 5(s, 2H), 2.3 6(s, 3H); LCMS (ES+): 467 [M]+ in/e.
Example 15 s\ f \ S~\N ~o( CF3~ ~ / H F
O
Thioacetic acid S-{2-[3-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[3-fluoro-4-(4-trifluoroinethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H NMR: (400MHz, DMSO-d6) 8 10.94 (s, 1H), 7.98 (d, 2H), 7.81 (d, 2H), 7.60 (d, 2H), 7.49 (t, 1H), 4,42 (s, 2H), 2.39 (s, 3H);
LCMS (ES+): 452 [M] + m/e.
Example 16 oso \ I / s~
H
Thioacetic acid S-{2-oxo-2-[4-(toluene-4-sulfonylamino)-phenyl]-ethyl} ester:
The compound thioacetic acid S-{2-oxo-2-[4-(toluene-4-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR
(DMSO): 10.95 (s, 1H), 7.90 (d, 2H), 7.74 (d, 2H), 7.40 (d, 2H), 7.22 (d, 2H), 4.42 (s, 2H), 2.47 (s, 3H), 2.37 (s, 3H); LC-MS (ES+): 364 [MH]+ m/e.
Example 17 p/o~ s F3C \IS~N ~ I 0 H
Thioacetic acid S-{2-oxo-2-[4-(3-trifluoromethyl-benzenesulfonylamino)-phenyl]-ethyl}
ester: The compound thioacetic acid S-{2-oxo-2-[4-(3-trifluorornethyl-benzenesulfonylamino)-phenyl]-ethyl} ester was syntllesized according to the procedures described in the preparation of Exainple 1. 'H-NMR (DMSO): 11.12 (s, 1H), 8.10 (m, 3H), 7.88 (m, 3H), 7.26 (d, 2H), 4.43 (s, 2H), 2.37 (s, 3H); LC-MS (ES+): 418 [MH]+
in/e.
Example 18 S~l o N ol H
F
Thioacetic acid S-{2-[4-(4-fluoro-2-methyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester: The compound thioacetic acid S-{2-[4-(4-fluoro-2--methyl-enzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 11.16 (s, 1H), 8.08 (t, 1H), 7.90 (d, 2H), 7.31 (m, 2H), 7.19 (d, 2H), 4.42 (s, 2H), 2.62 (s, 3H), 2.37 (s, 3H); LC-MS (ES+):
382 [MH]+
m/e.
Example 19 0,I~
SrJ 0 H
\O I /
Thioacetic acid S-{2-[4-(4-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester:
The compound thioacetic acid S-{2-[4-(4-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 10.86 (s, 1H), 7.90 (d, 2H), 7.79 (d, 2H), 7.23 (d, 2H), 7.11 (d, 2H), 4.42 (s, 2H), 3.83 (s, 3H), 2.37 (s, 3H); LC-MS (ES+): 380 [MH] +
in/e.
Example 20 \ "r oSO s N
H
GI
Thioacetic acid S-{2-[4-(4-chloro-3-trifluoromethyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[4-(4-chloro-3-trifluoromethyl-benzenesulfonylarnino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. iH-NMR (DMSO):l 1.16 (s, 1H), 8.20 (s, 1H), 8.12 (t, 1H), 7.98 (m, 3H), 7.27 (d, 2H), 4.44 (s, 2H), 2.37 (s, 3H);
LC-MS (ES+):
452 [MH]+ m/e.
Example 21 o~~O
s ~N 0 y ' / H
/O
Thioacetic acid S-{2-[4-(3-methoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl}
ester:
The compound thioacetic acid S-{2-[4-(3-methoxy-benzenesulfonylainino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. IH-NMR (DMSO): 10.95 (s, 1H), 7.92 (d, 2H), 7.49 (t, 1H), 7.41 (d, 1H), 7.34 (s, 1H), 7.24 (m, 3H), 4.43 (s, 2H), 3.80 (s, 3H), 2.37 (s, 3H); LC-MS (ES+):
380 [MH]+ m/e.
Example 22 slir oNo , 0 N
H
Thioacetic acid S-[2-(4-ethanesulfonylamino-phenyl)-2-oxo-ethyl] ester: The compound thioacetic acid S-[2-(4-ethanesulfonylamino-phenyl)-2-oxo-ethyl] ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR
(DMSO):
10.91 (s, 1H), 8.00 (d, 2H), 7.30 (d, 2H), 4.47 (d, 2H), 3.23 (q, 2H), 2.39 (s, 3H), 1.21 (t, 3H);
LC-MS (ES+): 302 [MH]+ m/e.
Example 23 ~ / s~
~ \ ~ N 0 H
Thioacetic acid 2-[4-(3,5-dimethyl-benzenesulfonylamino)-phenyl)-2-oxo-ethyl ester:
The compound thioacetic acid 2-[4-(3,5-dimethyl-benzenesulfonylamino)-phenyl]-2-oxo-ethyl ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR (DMSO): 10.91 (s, 1H), 7.91 (d, 2H), 7.49 (s, 2H), 7.24 (d, 3H), 4.43 (s, 2H), 2.37 (s, 3H), 2.33 (s, 6H); LC-MS (ES+): 378 [MH]} in/e.
Example 24 s~
~~ N o ), H
I
Thioacetic acid S-{2-[4-(1,2-dimethyl-lH-imidazole-4-sulfonylamino)-phenyl]-2-oxo-ethyl} ester: The compound thioacetic acid S-{2-[4-(1,2-diinethyl-lH-imidazole-sulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. iH-NMR (DMSO): 10.92 (s, 1H), 7.91 (d, 2H), 7.27 (d, 2H), 4.43 (s, 2H), 3.57 (s, 3H), 2.37 (s, 3H), 2.26, (s, 3H); LC-MS
(ES+): 368 [MH]+
m/e.
Example 25 , s ~
~s~ No H
/
Thioacetic acid S-{2-oxo-2-[4-(propane-2-sulfonylamino)-phenyl]-ethyl} ester:
The compound thioacetic acid S-{2-oxo-2-[4-(propane-2-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR
(DMSO): 10.38 (s, 1H), 8.00 (d, 2H), 7.36 (d, 2H), 4.47 (s, 2H), 2.39 (s, 3H), 1.25 (s, 7H);
LC-MS (ES+): 316 [MH]} m/e.
Example 26 slir O\ N 0 S' 'H
\0 CI qCI
N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-Dichlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-Dichlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. iH-NMR: (CDC13) 7.99(s, 1H), 7.92(d, 2H), 7.68(d, 1H), 7.56(d, IH), 4.34(s, 2H), 2.42(s, 3H); MS: (418.6) Example 27 SITr ~'iN
H
O1~
N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-bis-trifluoromethoxy-benzenesulfonamide The coinpound N-[4-(2-Mercapto-acetyl)-phenyl]-3,4-bis-trifluoromethoxy-benzenesulfonamide was synthesized according to the procedures described in the preparation of Exaniple 1. 1H-NMR: (CDC13) 7.92(d, 2H), 7.51(d, 1 H), 7.31(s, 1 H), 7.21(d, 2H), 6.91(d, IH), 4.38(s, 2H), 2.42(s, 3H); MS: (409,8) Example 28 s"Ir o\ N \ ~ 0 I\ SoH
ci ~ ci N-[4-(2-Mercapto-acetyl)-phenyl]-2,4-Dichlorobenzene-sulfonamide The compound [4-(2-Mercapto-acetyl)-phenyl]-2,4-Dichlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. iH-NMR: (CDC13) 8.08(d, 1H), 7.91(d, 2H), 7.58(s, 1H), 7.41(d, 1H), 7.21(d, 2H), 4.32(s, 2H), 2.42(s, 3H);
MS: (418.6) Example 29 sY
SN~~ O
O
N-[4-(2-Mercapto-acetyl)-phenyl]-2-(3,5-Dimethylisoxazole)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-(3,5-Dimethylisoxazole)-sulfonainide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR:
(CDC13) 8.01(d, 2H), 7.21(d, 2H), 4.39(s, 2H), 2.63(s, 3H), 2.24(s, 3H), 2.20(s, 3H);
MS: (368.4) Example 30 s o N IQI
S S;
---X O
N-[4-(2-Mercapto-acetyl)-phenyl]-5-(2,4-Dimethyl-1,3-Thiazole)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-5-(2,4-Dimethyl-1,3-Thiazole)-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.24(d, 2H), 4.39(s, 2H), 2.68(s, 3H), 2.59(s, 3H), 2.42(s, 3H);
MS: (384.4) Example 31 sy 0, N ! / 0 N-[4-(2-Mercapto-acetyl)-phenyl]-3-(2,5-Dimethylfuran)-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3-(2,5-Dimethylfuran)-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR:
(CDC13) 7.98(d, 2H), 7.41(s, 1H), 7.21(d, 2H), 4.39(s, 2H), 2.52(s, 3H), 2.44(s, 3H), 2.21(s, 3H); MS:
(368.6) Example 32 o N ~ / 0 s FF
F
N-[4-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethylbenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethylbenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. 'H-NMR: (CDC13) 8.21(d, 2H), 7.98(d, 2H), 7.78(d, 2H), 7.22(d, 2H), 4.39(s, 2H), 2.44(s, 3H);
MS: (418.5) Example 33 OS'N \ t O
I \ O
N-[4-(2-Mercapto-acetyl)-phenyl]-4-benzene-sulfonamide The coznpound N-[4-(2-Mercapto-acetyl)-phenyl]-4-benzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.88(d, 3H), 7.59(d, 2H), 7.47(d, 2H), 7.34(d, 2H), 4.29(s, 2H), 2.41(s, 3H); MS: (348.6) Example 34 o 0 s'N
F
N-[4-(2-Mercapto-acetyl)-phenyl]-4-Fluorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Fluorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exalnple 1. 1H-NMR: (CDC13) 7.91(d, 2H), 7.89(d, 2H), 7.22(d, 2H), 7.18(d, 2H), 4,38(s, (2H), 2.42(s, 3H); MS: (367.6) Example 35 s OSN \ !
\
I ~ o ~ F
N-[4-(2-Mercapto-acetyl)-phenylJ-2-Fluorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-Fluorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.98(d, 1H), 7.89(d, 2H), 7.61(t, 1H), 7.24(d, 2H), 7.22(d, 2H), 4.37(s, 2H), 2.41(s, 3H);
MS: (367.6) Example 36 s"r p 0 ' N \ I
s I ~ o Ci N-[4-(2-Mercapto-acetyl)-phenyl]-4-Chlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-4-Chlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7,85(d, 2H), 7.78(d, 2H), 7.60(d, 2H), 7.40(d, 2H), 4.28(s, 2H), 2.41(s, 3H); MS: (384.1) Example 37 slir O O
\N pso CI
N-[4-(2-Mercapto-acetyl)-phenyl]-3-Chlorobenzene-sulfonamide The coinpound N-[4-(2-Mercapto-acetyl)-phenyl]-3-Chlorobenzene-sulfonaznide was synthesized according to the procedures described in the preparation of Example 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.90(s, 1 H), 7.78(d, 1 H), 7.60(d, 114), 7.46(t, 1 H), 7.21(d, 2H), 4.38(s, 2H), 2.41(s, 3H); MS:
(384.1) Example 38 s"r cC0 N-[4-(2-Mercapto-acetyl)-phenyl]-2-Chlorobenzene-sulfonamide The compound N-[4-(2-Mercapto-acetyl)-phenyl]-2-Chlorobenzene-sulfonamide was synthesized according to the procedures described in the preparation of Exainple 1. 1H-NMR: (CDC13) 8.18(d, 1H), 7.90(d, 2H), 7.58(d, 2H), 7.43(d, 1H), 7.22(d, 2H), 4.38(s, 2H), 2.42(s, 3H);
MS: (384.1) Example 39 os N g/\
F \~O
]F' N-[3-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide The compound N-[3-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonainide was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 7.90(d, 2H), 7.82(d, 1H), 7.65(s, 1H), 7.44(d, 2H), 7.37(d, 1H), 7.24(d, 1H), 4.39(s, 2H), 2.43(s, 3H); MS: (433.2) Example 40 0 ,N ~
~ S~ O
FF O I /
t F O~
N-[2-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide The compound N-[2-(2-Mercapto-acetyl)-phenyl]-4-Trifluoromethoxybenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 7.91(d, 2H), 7.82(d, 1H), 7.79(t, 1H), 7.58(dd, 1H), 7.24(d, 2H), 7,19(d, 1H), 4.39(s, 2H), 2.42(s, 3H); MS: (433.2) Example 41 sY
OS'N 0 O
O
F
F F
1V-[4-(2-Mercpto-acetyl)-phenylJ-3-Trifluoromethoxybenzene-sulfonamide The compound .N-[4-(2-Mercpto-acetyl)-phenyl]-3-Trifluoromethoxybenzene-sulfonamide was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR: (CDC13) 7.96(d, 2H), 7.81(d, 1 H), 7.72(s, 1 H), 7.59(dd, 1H), 7.43(d, 1 H), 7.21(d, 2H), 4.38(s, 2H), 2.41(s, 3H); MS: (433.2) Example 42 s4 ~
s, ~~N N
F ~ S
F~O I / O
F
Thioacetic acid-S-{2-[2-(3,4-Di-Trifluoromethoxy-benzenesulfonylamino)-4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester The compound thioacetic acid-S-{2-[2-(3,4-Di-Trifluoromethoxy-benzenesulfonylamino)-4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR: (CDC13) 8.01(d, 2H), 7.25(d, 2H), 2.60(s, 3H), 2.41(s, 3H); MS: (454.8) Example 43 s ~
Q~N N
~ S
~
CI ~
CI
Thioacetic acid-S-{2-[2-(3,4-Dichlorobenzenesulfonylamino)- 4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester The compound thioacetic acid-S-{2-[2-(3,4-Dichlorobenzenesulfonylamino)- 4-methyl-thiazol-5-yl]-2-oxo-ethyl}-ester was synthesized according to the procedures described in the preparation of Example 1. 'H-NMR:
(CDC13) 8.00(s, 1H), 7.79(d, 1H), 7.49(d, 1H), 4.02(s, 2H), 2.58(s, 3H), 2.41(s, 3H);
MS: (439.6) Example 45 i S 11 CF3'O O
p a~:"
N\S
Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl]-ethyl}
ester:
Step 1 H I \
// \\
~\ /
CF311 o 0 0 4-Acetyl-N-(4-trifluoromethoxy-phenyl)-benzenesulfonamide: 4-Trifluoromethoxy aniline (3.4 g, 19.21 minol)was dissolved in THF (25 ml) before pyridine (4.44 ml, 54.88 mmol) was added. 4-Acetyl-benzenesulfonyl chloride (4.0 g, 18.29 mmol) was then added as a solid, and the resulting dark solution was stirred for 10 minutes. The volatiles were then removed, and the resulting residue was suspended in THF. Excess Et3N was then added, and the mixture was stirred for several minutes before the solids were filtered.
The mother liquor was then evaporated to a solid which was purified by flash chroinatography (EtOAc/hexanes) to yield the desired compound as a white solid. (5.5 g(15.31 mmol, 84 %).
Step 2 Br CFa~O 0 0 /\ all, N\S
4-(2-Bromo-acetyl)-N-(4-trifluoromethoxy-phenyl)-benzenesulfonamide: The bromoketone intermediate was synthesized according to the procedures described in the preparation of Example 44 Step 2.
~ I \
// \\
CF3~0 ~ O O
~N\S 0 Thioacetic acid S-{2-oxo-2-[4-(4-trifluoromethoxy-phenylsulfamoyl)-phenyl)-ethyl}
ester: The desired compound was synthesized according to the procedures described in the preparation of Example 44 step 3. 1H NMR: (400MHz, DMSO): 10.74 (s, 1H), 8.08 (d, 2H), 7.92 (d, 2H), 7.23 (d, 2H), 7.20 (d, 2H), 4.57 (s, 2H), 2.38 (s, 3H); LC-MS
(ES+): 360 [MH]+
m/e.
Example 46 s"r O N \ I 0 9"s, O
F
N- [4-(2-Mercapto-acetyl)-phenyl)-3-Fluorobenzene-sulfonamide:
The compound N-[4-(2-Mercapto-acetyl)-phenyl]-3-Fluorobenzene-sulfonainide was synthesized according to the procedures described in the preparation of Exatnple 1. IH-NMR: (CDC13) 7.98(d, 2H), 7.68(d, 1H), 7.60(d, 1H), 7.51(dd, 1H), 7.22 (d, 2H), 4.38(s, 2H), 2.41(s, 3H); LC-MS (ES+): 367.6 [MH]+ m/e Example 47 O
/ ~ S1, I SH F O
O :
Thioacetic acid S-{2-[2-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester The coinpound thioacetic acid S-{2-[2-fluoro-4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-2-oxo-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. , 1H-NMR (DMSO): 11.37 (bs, 1H), 8.02 (dd, 2H), 7.79 (t, 1H), 7.61 (d, 2H), 7.06 (m, 2H), 4.33 (d, 2H), 2,35 (s, 3H). LC-MS
(ES+): 452 [MH]+ m/e.
Example 48 O
~ S
~ y N i 0-0 S
O
O
Thioacetic acid S-[2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester The compound thioacetic acid S; [2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester was synthesized according to Scheme IV.
Step 1 O
CO
S
O
1-(1-Senzenesutfonyl-2,3-dihydro-lH-indol-5-yl)-ethanone 1-(2,3-Dihydro-lH-indol-5-yl)-ethanone (0.200 g, 1.24 mmol) was dissolved in THF (2 inl) before pyridine (0.303 ml, 3.75 mmol) was added, leaving a yellow solution.
The benzenesulfonyl chloride (0.220 g, 1.24 mmol) was then added, as a solid, with stirring. The reaction mixture was stirred at 40 C for 5h. The mixture was cooled and the THF and pyridine were reinoved in vacuo. The desired sulfonamide (0.310 g, 1.02 mmol, 82 %) was recrystallized from ethyl acetate and hexanes. It had LC-MS (ES+): 302 [MH] +
in/e Step 2 O
Br N CO--'~ ~ \~ S~O
.,. O
1-(1-Benzenesulfonyl-2,3-dihydro-IH-indol-5-yl)-2-bromo-ethanone: The ketone from step 1(0.310 g, 1.02 mmol) was dissolved in THF (3 ml), and phenyltrimethylammonium tribromide (PTT) (0.386 g, 1.02 mmol) was added as a solid leaving an orange solution which began to deposit a white solid iinmediately. Stirring for 1.5 hours leaves a colorless mixture to which water (5 ml) was added. THF was then evaporated and the resulting aqueous mixture was extracted with ethyl acetate. Drying over Na2SO4 and evaporation leaves a white crystalline solid (85% desired mono-brominated material by LC-MS, 5% starting material, 10% dibrominated) suitable for the next step. LC-MS (ES+): 381, 379 m/e.
Step 3 O
Sllr N I O
~'0 Thioacetic acid S-[2-(1-benzenesulfonyl-2,3-dihydro-lH-indol-5-yl)-2-oxo-ethyl] ester The mono-brominated sulfonamide from step 2(0.194 g, 0.509 mmol) was was dissolved in methanol (2 ml) before potassiuin thioacetate (0.0639 g, 0.560 minol) was added as a solid.
LC-MS of the resulting yellow solution shows the reaction is coinplete in minutes.
Evaporation of the volatiles leaves a tan residue which was taken up into dichloroinethane (4 ml), during which the disulfide of the thioacetic acid was deposited and filtered. The desired thioester could then be recrystallized fioin dichloroinethane/hexanes (0.080 g, 0.214 mmol, 42%). LC-MS (ES+): 376 [MH]+ m/e. 1H-NMR (DMSO): 7.87 (d, 3H), 7.78 (s, 1H), 7.7 (m, 1H), 7.57 (m, 3H), 4.41 (s, 2H), 3.99 (t, 2H), 3.06 (t, 2H), 2.34 (s, 3H) Example 49 O
~
~N
/ \, So0 Thioacetic acid S-[2-(1-benzenesulfonyl-lH-indol-5-yl)-2-oxo-ethyl] ester The compound thioacetic acid S-[2-(1-benzenesulfonyl-lH-indol-5-yl)-2-oxo-ethyl] ester was synthesized according to the procedures described in the preparation of Example 48.
1H-NMR (CDC13): 8.22 (d, 1H), 8.07 (m, 1H), 7.98 (m, 1H), 7.90 (m, 2H), 7.66 (d, 1H), 7.57 (m, IH), 7.47 (m, 2H), 6.76 (m, 1H), 4.42 (s, 2H), 2.40 (s, 3H). LC-MS (ES+):
374 [MH]+
m/e Example 50 / sY
N
SNH
\
Thioacetic acid S-{2-[6-(3-methoxy-benzenesulfonylamino)-pyridin-3-yl]-2-oxo-ethyl}ester The compound thioacetic acid S-{2-[6-(3-methoxy-benzenesulfonylamino)-pyridin-3-yl]-2-oxo-ethyl}ester was synthesized according to the procedures described in the preparation of Exainple 1. 1H-NMR: (CDC13) 8.91(s, 1 H), 8.21(d, IH), 7.51(d, 1 H), 7.44(d, 1H), 7.42(d, 1H), 7.38(s, 1H), 7,09(d, 1H), 4.21(s, 2H), 3.82(s, 3H), 2.41(s, 3H) ppm. MS:
(380.05) Example 51 O
s N S
~N~
~
I H
/
Thioacetic acid S-{2-oxo-2-[4-(pyridine-2-sulfonylamino)-phenyl]-ethyl} ester The coinpound Thioacetic acid S-{2-oxo-2-[4-(pyridine-2-sulfonylamino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Example 1. 1H-NMR (DMSO): 11.19 (bs, 1H), 8.71 (d, 1H), 8.10 (in, 2H), 7.89 (d, 2H), 7.67 (m, 1H), 7.28 (d, 2H), 4.41 (s, 2H), 2.36 (s, 3H). LC-MS (ES+): 351 [MH]+ m/e.
Example 52 O
A~y \%
a~~ SN O
H
Thioacetic acid S-{2-oxo-2-[4-(pyridine-3-sulfonylamino)-phenyl]-ethyl} ester The compound Thioacetic acid S-{2-oxo-2-[4-(pyridine-3-sulfonylainino)-phenyl]-ethyl} ester was synthesized according to the procedures described in the preparation of Exainple 1 tH-NMR (DMSO): 11.16 (bs, 1H), 8.99 (d, 1H), 8.81 (dd, 1H), 8.23 (in, 1H), 7.92 (d, 2H), 7.64 (dd, 1H), 7.26 (d, 2H), 4.42 (s, 2H), 2.36 (s, 3H). LC-MS (ES+): 351 [MH]+
m/e.
Example 53 O
y DO S
N O
N
~ S~O
Thioacetic acid S-{2-oxo-2-[1-(pyridine-2-sulfonyl)-2,3-dihydro-lH-indol-5-yl]-ethyl}
ester The coinpound thioacetic acid S-{2-oxo-2-[1-(pyridine-2-sulfonyl)-2,3-dihydro-lH-indol-5-yl]-ethyl} was synthesized according to the procedures described in the preparation of Example 48. 1H-NMR (DMSO): 8.67 (m, IH), 8.11 (m, 2H), 7.82 (m, 2H), 7.50 (m, 1H), 7.43 (d, 1H), 4.42 (s, 2H), 4.23 (t, 2H), 3.15 (t, 2H), 2.36 (s, 3H). LC-MS
(ES+): 377 [MH]+
m/e.
Example 54 O
O / S~PHOH
o .i1 I 11 ~S. ~ O
F3C\ ~ / H
O
Thiophosphoric acid S-{2-oxo-2-[4-(4-trifluoromethoxy-benzenesulfonylamino)-phenyl]-ethyl} ester The compouiid from Example 1, Step 2 (0.200 g, 0.461 mmol) was dissolved in methyl alcohol (3 mL). Na3SPO3 (0.091 g, 0,508 mmol) was added as a solid, fornning a heterogeneous suspension. The suspension was stirred at room temperature.
After 1.5 hours a white precipitate was present. This precipitate was filtered and found to be the undesired disulfide of the starting sulfonainide. The methyl alcohol was then removed and dichloromethane was added to the crude reaction mixture. A white solid precipitated out of the dichloromethane solution which was collected by filtration. The solid was further purified by mass triggered HPLC to give the desired compound (0.050 g, 0.106 mmol, 23%). 'H-NMR (DMSO): 11.06 (s, 1H), 7.98 (in, 2H), 7.88 (in, 2H), 7.59 (d, 2H), 7.23 (m, 2H), 4.16 (d, 2H). LC-MS (ES+): 471 [MH]+ m/e.
The following compounds can be made using the methods as described above and when made should have similar activity as those made above.
G3 ~eGZ'G~S\G4 , wherein Gl is selected from the following:
H
N N
ol ~ N N s N~ N
I H NJ N
v ~ > > > > >
N1 N~ N
N" ~ N
vN N" N N~N and N
> > > > >
G2 is selected from the following:
N'U"I AN i rS.N N, R3 R3 ~ R3 and R4 G3 is selected from the following:
H
Ol NJ NJ H N N~\
> > > , I ~ > > >
N rN N
~ , N NN N~N N,NJ
and and G4 is selected from the following:
-Yk ~ .~ o\ .~
YO ~
~ o 0 ~ 0 0 / I
o' yo / \
O O A N N A \\
)r 0 0 ~ 0 0 s~s X
0~ +N\ S' X
~
~ 0 , , , , , S OH ~\g NHz ~\S NH2 S H
//~ ~ ~ "*,r N I I
OH CO2H COZMe CO2H 0 ~ ~ > >
,S\S H
S' N
CO2MeO -P(O)(OH)2 , and Additionally, the following compounds can be made using the methods as described above.
iGz, ,~is~
~3 ~~ G4, wherein GI is selected from the following:
l/ ~ I ~ I (J3 / I N\N ~ I NN
and G2 is selected from the following:
and G3 is selected from the following:
'~'J 0 0 NN S N1 N
olNJ N J O~~ H N~r N,J\ JJ N
> > > > > > > > > >
CN~ y N N
NI-~ N , N N and N.NJ
and G4 is selected from the following:
~ i~ N
.~ \
y Y**"~~ .~' \
O O O O O O
~
.~ \~ yo i Y(N o O 0~ s~ \ N / I / \~
O O O O O
~ N~ N~ ~ OH ~ OH
0 ~I ~ ~ ~1 54S-~, S / OH '\g~NH2 ,~\S~NHz S~ N
~
OH CO2H CO2Me CO2H 0 H
\S~N~ P O OH
COzMeO , aud -~ ~~ )2 The prophetic examples disclosed herein may optionally be substituted as described above.
The activity of the above mentioned compounds as HDAC inhibitors has generally been shown by the following assays. The other compounds listed above, which may not yet been made or tested, are predicted to generally have activity in these assays as well.
Inhibition Assays:
In vits o HDAC-inhibition Assay:
[00107] This assay measures a compound's ability to inhibit acetyl-lysine deacetylation in vitro and was used as both a primary screening method as well as for IC5o detenninations of confirmed inhibitors. The assay is performed in vitro using an HDAC
enzyme source (e.g. partially purified nuclear extract or iinmunopurified HDAC
complexes) and a proprietary fluorescent substrate/developer system (HDAC Quantizyine Fluor de Lys Fluorescent Activity Assay, BIOMOL). The assay is run in 1,536-well Greiner white-bottom plates using the following volumes and order of addition:
Step 1: Enzyme (2.5 ul) source added to plate (from refrigerated container) Step 2: Compounds (50 nl) added with pin transfer device Step 3: Fluor de Lys (2.5 ul) substrate added, incubate at RT, 30 minutes Step 4: Developer (5 ul) solution is added (containing TSA), to stop reaction Step 5: Plate Reader - data collection The deacetylated fluorophore is excited with 360 nm light and the emitted light (460 nm) is detected on an automated fluorometric plate reader (Aquest, Molecular Devices).
Cellular Histone Hyperacetylation Assays:
[001081 These two secondary assays evaluates a compound's ability to iiihibit HDAC in cells by ineasuring cellular histone acetylation levels. The cytoblot facilitates quantitative EC50 information for cellular HDAC inhibition. Transformed cell lines (e.g.
HeLa, A549, MCF-7) are cultured under standard inedia and culture conditions prior to plating.
For Cytoblot:
[001091 Cells (approx. 2,500/well) are allowed to adhere 10-24 hours to wells of a 384-well Greiner PS assay plate in media containing 1-5% serum. Cells are treated with appropriate cornpound and specific concentrations for 0 to 24 hours. Cells are washed once with PBS (60 ul) and then fixed (95% ethanol, 5% acetic acid or 2% PFA) for 1 ininute at RT
(30 ul). Cells are blocked with 1% BSA for 1 hour and washed and stained witll antibody (e.g. anti-Acetylated Histone H3, Upstate Biotechnology), followed by washing and incubation with an appropriate secondary antibody conjugated to HRP or fluorophore. For luminescence assays, signal is generated using Luminol substrate (Santa Cruz Biotechnology) and detected using an Aquest plate reader (Molecular Devices).
For Iinmunoblot:
[00110J Cells (4 x 105/well) are plated into Conling 6-well dish and allowed to adhere overnight. Cells are treated with compound at appropriate concentration for 12-18 hours at 37 degrees. Cells are washed with PBS on ice. Cells are dislodged with rubber policeman and lysed in buffer containing 25 mM Tris, pH7.6; 150 mM NaC1, 25 mM
MgC12, 1% Tween-20, and nuclei collected by centriguation (7500g). Nuclei are washed once in 25 mM Tris, pH7.6; 10 mM EDTA, collected by centrifugation (7500g). Supematant is removed and histones are extracted using 0.4 M HCl. Samples are centrifuged at 14000g and supernatants are precipitated in 1 ml cold acetone. The histone pellet is dissolved in water and histones are separated and analyzed by SDS-PAGE Coomassie and immunobloting (anti-acetylated histone antibodies, Upstate Biotechnology) using standard techniques.
Differential Cytotoxicity AssU:
[00111] HDAC inhibitors display differential cytotoxicity toward certain transformed cell lines. Cells are cultured according to standard ATCC
recommended conditions that are appropriate to each cell type. Compounds were tested for their ability to kill different cell types (normal and transformed) using the ATPlite luminescence ATP
detection assay system (Perkin Elmer). Assays are run in either 384-well or 1536-well Greiner PS plates. Cells (30 ul or 5 ul, respectively) are dispensed using either rnultichannel pipette for 384-well plates, or proprietary Kalypsys bulk liquid dispenser for 1536-well plates.
Compounds added using proprietary pin-transfer device (500 nL or 5 nL) and incubated 5 to 30 hours prior to analysis. Luminescence is measured using Aquest plate reader (Molecular Devices).
[00112] The activity of some of the coinpounds of the invention are shown in Table 1, below. Syntllesis of each compound is described in the Exainple listed in the left column.
Table 1 Example COMPOUND In vitro IC50 Cellular IC50 No. ( M) ( M) 02 O s 'H <1 <10 \
H
04 0 <1 % S \
, S
F3C_ 1/
06 S <1 <1 F3C- ~ H 0 07 ~ <1 <10 ~i ~~s ~ N
H
, <10 <1 09 <1 <1 .~~P
S~N O
F,C_p ~ H
00 <1 ry p FaC~~ r H
-,-S <1 \ ~5 O \ I --~-NHz F3Cy H
12 i 5~f <1 <10 \ S\N ~ ~ I I
F~C~p I r I
F~C~p I r I
13 5~ <10 p O r r /N ~ 0 F3C, C ~ I
14 p <1 <50 ''s' F,C\ I / H \ CI
0 <1 ~~5~~ ~
N
I ~ F
F,C-16 p 5Y <1 <1 \,p Jr H
17 0 0 S <1 <10 F3C \ S~ N ~ ~ =
H
18 s <1 <1 HJ~Iy I~~s 0 F
0 <1 <1 r~ 11 F,C S~H ~ p CI
<1 <1 01\ //
N O
H
22 0 S <1 <10 H
23 0 <1 <10 N O
0p H
S
0 <1 ~~5~~ ~
N
I ~ F
F,C-16 p 5Y <1 <1 \,p Jr H
17 0 0 S <1 <10 F3C \ S~ N ~ ~ =
H
18 s <1 <1 HJ~Iy I~~s 0 F
0 <1 <1 r~ 11 F,C S~H ~ p CI
<1 <1 01\ //
N O
H
22 0 S <1 <10 H
23 0 <1 <10 N O
0p H
S
24 <10 N /~ i 5~ <1 /~S\H \ 0 N
/
O
25 \0 ~ I <1 N \ ICI
H
27 s <1 <1 O ~ ~N i 0 / H
~O
28 0 ~Sy <1 <1 S_ 0 H
29 <1 <10 H
N
30 0 <1 <1 O
S 4S/, N~I
NN H
31 0 <1 <10 O
33 S~ <1 <10 H '' 0 ~
34 s~ <1 <1 , I ~ .ON ' 0 H
F ~
35 <1 <1 H O
36 0 5~ <1 <1 ~
CI
37 5\/ <1 <1 G oNJ~ 'C' H
38 <1 <1 'i~
H' 39 N <1 <1 , I /
40 ~s <10 >50 I\"
s~
p 41 0 p 0 SY <1 <1 F3C- 5 N \ I 0 ~ , 42 oF' 0 <50 N 5 S~
or ~ -r~ I ol 43 a ci 0 <50 N~/
o~ N N~ ICI
45 ~. 0 s~ <1 <10 N ~ J~
~ N~~\~\ C
F3C'p ~ f p O
46 <1 <1 O S~
y H
F
47 0 <1 <1 0%/i / ( S
~
' S\H \
CFy 48 <1 <10 5~
r S)o 49 0 <1 <1 S' /
N ~I I{
/ \\r- so 50 <1 <1 N:P' I
\INH ~
I
/
o~
51 <1 <1 sy O
I
52 0 <1 <10 Wi / S
~
NI \ S~H \ 0 /
53 <1 <1 S' ~
N I ~IOI( N
'O 0 54 0 oH
sI,,oH
O'\ ri H
F,C~,O
~5\N \ 0 A blank cell indicates that the value was not determined.
All references cited above are incorporated herein by reference in their entirety.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
/
O
25 \0 ~ I <1 N \ ICI
H
27 s <1 <1 O ~ ~N i 0 / H
~O
28 0 ~Sy <1 <1 S_ 0 H
29 <1 <10 H
N
30 0 <1 <1 O
S 4S/, N~I
NN H
31 0 <1 <10 O
33 S~ <1 <10 H '' 0 ~
34 s~ <1 <1 , I ~ .ON ' 0 H
F ~
35 <1 <1 H O
36 0 5~ <1 <1 ~
CI
37 5\/ <1 <1 G oNJ~ 'C' H
38 <1 <1 'i~
H' 39 N <1 <1 , I /
40 ~s <10 >50 I\"
s~
p 41 0 p 0 SY <1 <1 F3C- 5 N \ I 0 ~ , 42 oF' 0 <50 N 5 S~
or ~ -r~ I ol 43 a ci 0 <50 N~/
o~ N N~ ICI
45 ~. 0 s~ <1 <10 N ~ J~
~ N~~\~\ C
F3C'p ~ f p O
46 <1 <1 O S~
y H
F
47 0 <1 <1 0%/i / ( S
~
' S\H \
CFy 48 <1 <10 5~
r S)o 49 0 <1 <1 S' /
N ~I I{
/ \\r- so 50 <1 <1 N:P' I
\INH ~
I
/
o~
51 <1 <1 sy O
I
52 0 <1 <10 Wi / S
~
NI \ S~H \ 0 /
53 <1 <1 S' ~
N I ~IOI( N
'O 0 54 0 oH
sI,,oH
O'\ ri H
F,C~,O
~5\N \ 0 A blank cell indicates that the value was not determined.
All references cited above are incorporated herein by reference in their entirety.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Claims (73)
1. A compound having structural formula (I), or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof, wherein G1 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or G1 and R3 taken together form an optionally substituted heterocycloalkyl or heteroaryl, both of which can be optionally substituted;
G2 is an N-sulfonamide moiety having structure (II), an S-sulfonamide moiety having structure (III), or an amide of the form -NR3C(O)- or -C(O)NR3-:
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, wherein alkyl is preferably C2-C7;
R1 and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen and perhaloalkyl, or R1 and R2 taken together form optionally substituted cycloalkyl;
R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl; or a structural element known to confer aqueous solubility; or R3 and R4 taken together form an optionally substituted heterocycloalkyl;
G4 is chosen from the group consisting of optionally substituted acyl, wherein taken in combination with sulfur forms a thioester, optionally substituted alkyl thiol, wherein G4 taken in combination with sulfur forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; and each R5 is independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl.
G2 is an N-sulfonamide moiety having structure (II), an S-sulfonamide moiety having structure (III), or an amide of the form -NR3C(O)- or -C(O)NR3-:
G3 is optionally substituted phenyl or optionally substituted 5 or 6 membered heteroaryl, or optionally substituted alkyl, wherein alkyl is preferably C2-C7;
R1 and R2 are each independently selected from the group consisting of hydrogen, lower alkyl, halogen and perhaloalkyl, or R1 and R2 taken together form optionally substituted cycloalkyl;
R3 and R4 are each independently selected from the group consisting of hydrogen, optionally substituted lower alkyl, optionally substituted aryl, and optionally substituted alkaryl; or a structural element known to confer aqueous solubility; or R3 and R4 taken together form an optionally substituted heterocycloalkyl;
G4 is chosen from the group consisting of optionally substituted acyl, wherein taken in combination with sulfur forms a thioester, optionally substituted alkyl thiol, wherein G4 taken in combination with sulfur forms a disulfide, and -P(O)(OR5)2 or -P(O)(OH)2, wherein G4 taken in combination with sulfur, forms a phosphorothioate diester or phosphorothioate; and each R5 is independently selected from the group consisting of hydrogen, alkyl, aryl, and arylalkyl.
2. The compounds of Claim 1 wherein G1 is an optionally substituted phenyl having structure (IV) or (V):
wherein X1 and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
wherein X1 and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
3. The compound of Claim 2, wherein G2 is N-sulfonamide moiety having structure (VI) or (VII) wherein R3 may combine with X1 or X2 to form an optionally substituted bicyclic heterocycle or heteroaryl.
4. The compound of Claim 3 wherein G3 comprises is an optionally substituted phenyl of structure (VIII) or (IX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl,, dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, aminothiocarbonylaminoalkyl.
5. The compound of Claim 4 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
6. The compound of Claim 5 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
7. The compound of Claim 6 wherein the compound has the structure selected from a group consisting of:
8. The compound of Claim 3 wherein G3 comprises an 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5, wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
9. The compound of Claim 8 wherein G3 is selected from a group consisting of:
10. The compound of Claim 9 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
11. The compound of Claim 10 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
12. The compound of Claim 11 wherein the compound has the structure selected from a group consisting of:
13. The compound of Claim 3 wherein G3 comprises an optionally substituted alkyl.
14. The compound of Claim 13 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
15. The compound of Claim 14 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
16. The compound of Claim 15 wherein the compound has the structure selected from a group consisting of:
17. The compound of Claim 2, wherein G2 is S-sulfonamide moiety having structure (X) or (XI);
18. The compound of Claim 17 wherein G3 comprises is an optionally substituted phenyl of structure (XII) or (XIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, aminothiocarbonylaminoalkyl.
19. The compound of Claim 18 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
20. The compound of Claim 19 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility
21. The compound of Claim 20 wherein the compound has the structure selected from a group consisting of:
22. The compound of Claim 17 wherein G3 comprises an 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5, wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
23. The compound of Claim 22 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
24. The compound of Claim 23 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility
25. The compound of Claim 24 wherein the compound has the structure selected from a group consisting of:
26. The compound of Claim 17 wherein G3 comprises an optionally substituted alkyl.
27. The compound of Claim 26 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
28. The compound of Claim 27 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
29. The compound of Claim 28 wherein the compound has the structure selected from a group consisting of:
30. The compound of Claim 1 wherein G1 comprises a 5 or 6 membered heteroaromatic optionally substituted by X1, X2 of structure (XIV);
wherein X1 and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
wherein X1 and X2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, optionally substituted lower alkyl, optionally substituted lower alkoxy.
31. The compound of Claim 30 wherein G2 is a sulfonamide having an N-sulfonainide moiety of structure (XV) or an S-sulfonamide moiety of structure (XVI):
32. The compound of Claim 31 wherein G3 comprises an optionally substituted phenyl of structure (XVII):
wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
33. The compound of Claim 32 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
34. The compound of Claim 33 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
35. The compound of Claim 34 wherein G1 is selected from a group consisting of;
36. The compound of Claim 35 wherein the compound has the structure selected from a group consisting of:
37. The compound of Claim 31 wherein G3 comprises an 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XVIII) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
38. The compound of Claim 37 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
39. The compound of Claim 38 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
40. The compound of Claim 39 wherein G1 and G3 is each independently selected from a group consisting of:
41. The compound of Claim 40 wherein the compound has the structure selected from a group consisting of:
42. The compound of Claim 31, structure (XV) wherein G3 comprises an optionally substituted alkyl.
43. The compound of Claim 42 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
44. The compound of Claim 43 wherein R3 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
45. The compound of Claim 44 wherein G1 is selected from a group consisting of:
46. The compound of Claim 45 wherein the compound has the structure selected from a group consisting of:
47. The compound of Claim 32 wherein G3 comprises an optionally substituted phenyl of structure (XIX):
wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
48. The compound of Claim 47 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
49. The compound of Claim 48 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
50. The compound of Claim 49 wherein G1 is selected from a group consisting of:
51. The compound of Claim 50 wherein the compound has the structure selected from a group consisting of:
52. The compound of Claim 32 wherein G3 comprises an 5 or 6 membered heteroaromatic optionally substituted by X3, X4, X5 of structure (XX) wherein X3, X4 and X5 are each independently chosen from a group consisting of hydrogen, perhaloaryloxy, alkanoylalkyl, N-aryl-N-alkylamino, heterocyclylalkoxy, heterocyclylthio, hydroxyalkoxy, carboxamidoalkoxy, alkoxycarbonylalkoxy, alkoxycarbonylalkenyloxy, aralkanoylalkoxy, aralkenoyl, N-alkylcarboxamido, N-haloalkylcarboxamido, N-cycloalkylcarboxamide, N-arylcarboxamidoalkoxy, cycloalkylcarbonyl, cyanoalkoxy, heterocyclylcarbonyl, carboxy, heteroaralkylthio, heteroaralkoxy, cycloalkylamino, acylalkyl, acylalkoxy, aroylalkoxy, heterocyclyloxy, aralkylaryl, aralkyl, aralkenyl, aralkynyl, heterocyclyl, haloalkylthio, alkanoyloxy, alkoxy, alkoxyalkyl, cycloalkoxy, cycloalkylalkoxy, hydroxyl, amino, thio, nitro, alkylamino, alkylthio, arylamino, aralkylamino, arylthio, arylthioalkyl, alkylsulfonyl, heteroarylthio, heteroarylsulfonyl, heterocyclylsulfonyl, arylsulphonyl, heteroarylsulfonyl, heterocyclylsulphonyl, heterocyclylthio, alkanoyl, alkenoyl, aroyl, heteroaroyl, aralkanoyl, heteroaralkanoyl, haloalkanoyl, alkyl, alkenyl, alkynyl, alkenyloxy, alkylenedioxy, haloalkylenedioxy, cycloalkyl, cycloalkylalkanoyl, halo, haloalkyl, haloalkoxy, hydroxyhaloalkyl, hydroxyhaloalkoxy, hydroxyalkyl, aryl, aryloxy, aralkoxy, saturated heterocyclyl, heteroaryl, heteroaryloxy, heteroaryloxyalkyl, heteroaralkyl, arylalkenyl, carboalkoxy, alkoxycarboxamido, alkylamidocarboylamido, arylamidocarboylamido, carboalkoxyalkyl, carboalkoxyalkenyl, carboamido, carboxamidoalkyl, cyanocycloalkylalkyl, cycloalkenyl, alkoxycarbonyl, aralkylthio, alkylthio, alkylsulfinyl, arylsulfinyl, dialkylamino, aminoalkyl, , dialkylaminoalkyl, aminoaryl, alkylaminoaryl, acylamino, aminocarbonylalkoxy, aminocarbonylamino, aminothiocarbonylamino, or aminothiocarbonylaminoalkyl.
53. The compound of Claim 52 wherein wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
54. The compound of Claim 53 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
55. The compound of Claim 54 wherein G1 and G3 is each independently selected from a group consisting of:
56. The compound of Claim 55 wherein the compound has the structure selected from a group consisting of:
57. The compound of Claim 31, having structure (XVI) wherein G3 comprises an optionally substituted alkyl.
58. The compound of Claim 57 wherein G4 is an optionally substituted acyl of the formula -C(O)R E, wherein R E is any pharmaceutically acceptable acid, or a phosphoryl moiety that taken together with sulfur forms a phosphorothioic acid; R1 and R2 are each independently hydrogen, lower alkyl or R1 and R2 taken together form optionally substituted cycloalkyl; and X1 and X2 are each independently selected from hydrogen, halogen, hydroxyl, lower alkyl, lower perhaloalkyl, lower alkoxy and lower perhaloalkoxy.
59. The compound of Claim 58 wherein R4 is selected from the group comprising hydrogen, optionally substituted lower alkyl, or a structural element known to confer aqueous solubility.
60. The compound of Claim 59 wherein G1 is selected from a group consisting of:
61. The compound of Claim 60 wherein the compound has the structure selected from a group consisting of:
62. The compound of Claim 1 wherein the compound has the structure consisting of:
63. The compound of Claim 1, wherein R3 is a structural element known to confer aqueous solubility.
64. The compound of Claim 63, wherein R3 is N-piperazinylethyl.
65. The compound of Claim 63, wherein R3 is N-morpholinylethyl.
66. The compound of Claim 63, wherein R3 is 1,3-dihydroxy-2N-propanoyl.
67. The compound of Claim 1, wherein R4 is a structural element known to confer aqueous solubility.
68. The compound of Claim 67, wherein R4 is N-piperazinylethyl.
69. The compound of Claim 67, wherein R4 is N-morpholinylethyl.
70. The compound of Claim 67, wherein R4 is 1,3-dihydroxy-2N-propanoyl.
71. A pharmaceutical composition comprising the compound of Claim 1 in a mixture with at least one carrier, diluent or excipient.
72. The compound of Claim 1 wherein the compound or pharmaceutically acceptable salt, amide, ester or prodrug thereof is capable of inhibiting the catalytic activity of histone deacetylase (HDAC).
73. A method of treating a HDAC related disease in a patient in need thereof by administering a compound of claim 1 to said patient.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2004/018502 WO2004110418A2 (en) | 2003-06-10 | 2004-06-10 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
US10/865,743 US7271195B2 (en) | 2003-06-10 | 2004-06-10 | Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease |
USPCT/US2004/018502 | 2004-06-10 | ||
US10/865,743 | 2004-06-10 | ||
US63501904P | 2004-12-09 | 2004-12-09 | |
US60/635,019 | 2004-12-09 | ||
PCT/US2005/020770 WO2005120515A2 (en) | 2004-06-10 | 2005-06-09 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2567835A1 true CA2567835A1 (en) | 2005-12-22 |
Family
ID=35503650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002567835A Abandoned CA2567835A1 (en) | 2004-06-10 | 2005-06-09 | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1773398A2 (en) |
JP (1) | JP2008515777A (en) |
AU (1) | AU2005251816A1 (en) |
CA (1) | CA2567835A1 (en) |
WO (1) | WO2005120515A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006028104A (en) * | 2004-07-16 | 2006-02-02 | Kyowa Hakko Kogyo Co Ltd | Histone deacetylase inhibitor |
AR050552A1 (en) * | 2004-09-02 | 2006-11-01 | Osi Pharm Inc | MERCAPTOAMIDS AS INHIBITORS OF HISTONA DEACETILASE |
TW200730485A (en) * | 2005-07-29 | 2007-08-16 | Kalypsys Inc | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
WO2008010985A2 (en) * | 2006-07-20 | 2008-01-24 | Merck & Co., Inc. | Phosphorus derivatives as histone deacetylase inhibitors |
US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2436263C2 (en) * | 1974-07-27 | 1983-02-17 | Hoechst Ag, 6000 Frankfurt | Thiazolidine derivatives and processes for their preparation |
DE2533821A1 (en) * | 1975-07-29 | 1977-02-17 | Hoechst Ag | THIAZOLIDE DERIVATIVES AND METHOD FOR THEIR PRODUCTION |
SE7700500L (en) * | 1976-01-20 | 1977-07-21 | Hoechst Ag | THIAZOLIDINE DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION |
CA2404002A1 (en) * | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
KR100462045B1 (en) * | 2001-06-21 | 2004-12-16 | 네오뷰코오롱 주식회사 | An metal cap for encapsulating an organic electro-luminescence device and a fabricating method thereof |
CA2476586C (en) * | 2002-03-13 | 2011-11-01 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
-
2005
- 2005-06-09 AU AU2005251816A patent/AU2005251816A1/en not_active Abandoned
- 2005-06-09 JP JP2007527796A patent/JP2008515777A/en active Pending
- 2005-06-09 WO PCT/US2005/020770 patent/WO2005120515A2/en not_active Application Discontinuation
- 2005-06-09 EP EP05788746A patent/EP1773398A2/en not_active Withdrawn
- 2005-06-09 CA CA002567835A patent/CA2567835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005251816A1 (en) | 2005-12-22 |
EP1773398A2 (en) | 2007-04-18 |
WO2005120515A2 (en) | 2005-12-22 |
JP2008515777A (en) | 2008-05-15 |
WO2005120515A3 (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7381749B2 (en) | Sulfonamides as inhibitors of histone deacetylase for the treatment of disease | |
US7470722B2 (en) | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease | |
ES2327269T3 (en) | N-SULFONYLPIRROLES AND ITS USE AS INHIBITORS OF HISTONE DEACETILASE. | |
JP5278983B2 (en) | New uses of amide compounds | |
RU2141478C1 (en) | Amides, pharmaceutical composition, methods of decrease of apolipoprotein b secretion, compound | |
AU2003217393B8 (en) | Ansamycins having improved pharmacological and biological properties | |
US20080194681A1 (en) | Novel Inhibitors of Histone Deacetylase for the Treatment of Disease | |
US8106051B2 (en) | Utilities of amide compounds | |
CA3030581C (en) | Apoptosis inhibitors | |
CA2600531A1 (en) | Pyrimidine compounds and methods of use | |
CA2567835A1 (en) | Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease | |
AU2008305294A1 (en) | Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | |
JP2016037467A (en) | Sulfonamide derivatives and pharmaceutical applications thereof | |
JP2008515777A5 (en) | ||
WO2007045962A2 (en) | Novel hdac inhibitors | |
MX2007002246A (en) | Processes for the preparation of isothiazole derivatives. | |
WO2012098501A1 (en) | Febuxostat co-crystals | |
Calderone et al. | Heterocyclic analogs of benzanilide derivatives as potassium channel activators. IX | |
GB2154585A (en) | Prodrugs of antiinflammatory oxicams | |
MX2015002624A (en) | Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5. | |
JP3165866B2 (en) | Sulfur-containing heterocyclic compounds | |
JPS6239583A (en) | Benzodioxazole derivative and production thereof | |
JP2566843B2 (en) | Benzothiazine derivatives, their preparation and their application as pharmaceuticals or as synthetic intermediates for pharmaceuticals | |
KR101630243B1 (en) | Novel compounds, pharmaceutically acceptable salts thereof or optical isomer thereof, preparation method thereof and pharmaceutical composition for prevention or treatment of the viral diseases containing the same as an active ingredient | |
EP0298040B1 (en) | 1,3-dithiol-2-ylidene derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20100609 |